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Sambruk av medikamenter og urtepreparater i allmennpraksis og in vitro inhibisjon av 
CYP3A4, CYP2D6 og P-glykoprotein av en hyppig brukt urt, Aloe vera. 
 
Det er en høy bruk av naturmidler og alternativ medisin sammen med ordinære medikamenter av ulike 
pasientgrupper. Det finnes per i dag få studier som har undersøkt sambruk i allmennpraksis og utsatte 
legemiddel-urt kombinasjoner. Sambruk av naturmidler og medikamenter kan føre til alt fra ingen til svært 
alvorlige bivirkninger. Det er derfor behov for grunnleggende kunnskap om mekanismene for slik interaksjoner 
og pasienters sambruk i allmennpraksis.  
 
Målsetningene med denne oppgaven er todelt; 1) Kartlegge grad av sambruk av legemidler og urter 
(plantebaserte naturmidler) i norsk allmennpraksis og pasienters kommunikasjon om slik bruk med 
helsepersonell; 2) Evaluere interaksjonspotensialet til en hyppig benyttet urt, Aloe vera (Aloe barbadensis), for 
effluksproteinet P-glykoprotein (P-gp), cytokrom P-450 (CYP) enzymene, CYP3A4 og CYP2D6. 
 
Undersøkelsen i allmennpraksis viste at blant de 381 pasientene som deltok, brukte 44 % urter. De vanligste 
urtene var blåbær (41%), grønn te (31%), hvitløk (27%), Aloe vera (26%) og rød solhatt (18%). Nesten hver 
tredje (29%) pasient benyttet urtepreparater og faste medikamenter samtidig. 255 kombinasjoner av urt og 
legemiddel-grupper ble registrert og 18 av disse var klinisk relevante med hensyn til interaksjoner. Omkring 
40% av pasienter på antikoagulasjonsbehandling benyttet urter samtidig, hvorav hvitløk og blåbær var de 
hyppigst brukte. Pasienter med økt odds for sambruk var kvinner, eldre, brukere av flere urter, hadde et ønske 
om å behandle en sykdom med sin urtebruk, brukte smertestillende eller midler mot hudsykdom og hadde 
opplevd bivirkninger av urte-bruken. Kun 23% av pasientene i allmennpraksis diskuterte bruk av urter med 
helsepersonell. 
 
Selv om Aloe vera er en populær og gammel medisinplante brukt både i kosmetisk og terapeutisk henseende, 
finnes det ingen tidligere systematiske undersøkelser av Aloe veras in vitro interaksjonspotensiale ved sambruk 
av legemidler. I all hovedsak er det tre enzymer som står for farmakokinetikken for de fleste medikamenter på 
markedet: effluksproteinet P-gp som transporterer medikamenter ut og CYP3A4 og CYP2D6, som metaboliserer 
medikamenter til mindre aktive komponenter. Disse enzymene kan påvirkes (inhiberes eller induseres) og er 
derfor viktige med tanke på naturmiddel-legemiddel interaksjoner.  
  
Det ble funnet at Aloe vera juice (AVJ) ikke inhiberte P-gp mediert digoxin efflux for de undersøkte AVJ 
konsentrasjonene in vitro. Derimot ble det vist at både AVJ (10.0 mg/ml) og digoxin (≥3μM) var cytotoksiske i 
høye konsentrasjoner. For CYP3A4 og CYP2D6 ble to ulike juice-produkter undersøkt. Begge typene AVJ 
inhiberte CYP3A4 og CYP2D6 irreversibelt in vitro, med signifikant ulike IC50 verdier. Dette kan skyldes ulikt 
innhold av aktive stoffer i juicen. Begge IC50 verdiene vurderes til å være for høye til å være klinisk relevante 
alene. Forsiktighet bør allikevel utvise ved store inntak av AVJ, ved lav CYP2D6 aktivitet (”poor metabolisers”) 
eller ved bruk av medikamenter med smalt terapeutisk vindu.  
 
Det kan konkluderes med at pasienter i allmennpraksis benytter urter og medisiner samtidig og denne sambruken 
kan føre til klinisk relevante bivirkninger (eks økt blødningsfare ved sambruk av hvitløk og warfarin). Eldre 
pasienter er mest utsatt. En av de hyppig brukte urtene i allmennpraksis, Aloe vera, ble undersøkt for in vitro 
farmakokinetiske interaksjons for P-gp, CYP3A4 og CYP2D6.  En konkluderte med liten fare for klinisk 
relevante farmakokinetiske interaksjoner ved sambruk av Aloe vera og medikamenter, selv om det er en 
mulighet for klinisk relevant CYP2D6 inhibisjon ved store Aloe vera inntak for pasienter med lav CYP2D6 
aktivitet samtidig med medikamenter som kodein (metaboliseres over CYP2D6). Det er behov for kliniske in 
vivo studier for å avdekke eventuelle interaksjoner hos mennesker mellom Aloe vera og medikamenter, samt for 
andre urter som har vist potensiale for urte-medikament interaksjoner in vitro. Inntil videre oppfordres leger og 
annet helsepersonell til å spørre alle pasienter om bruk av urter.  
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Summary in English 
Co-use of drugs and herbal remedies in general practice and in vitro 
inhibition of CYP3A4, CYP2D6 and P-glycoprotein by the common herb 
Aloe vera.  
 
There is a widespread use of complementary and alternative medicine (CAM) and herbal 
remedies in particular in different patients groups, but very few are published about co-use 
among patients in general practice (GP) and herb-drug combinations at risk. Co-use of herbal 
remedies and drugs can result in none or server adverse effects. Of this reason, knowledge 
about the GP patients co-use and research on mechanisms of such interactions is needed.  
 
The aims of this thesis were divided; 1) To register the co-use of drugs and herbs among GP 
patients in Norway and the patients communication of such use with health care professionals; 
2) To evaluate the interaction potential of one of the commonly used herbs in GPs office, 
Aloe vera (Aloe barbadensis), on the P-glycoprotein (P-gp) and the cytochrome P-450 (CYP) 
enzymes, CYP3A4 and CYP2D6. 
 
Among the 381 patients answering the questionnaire in the GP office, 44% used herbs. The 
most common herbs were bilberry (41%), green tea (31%), garlic (27%), Aloe vera (26%) and 
purple coneflower (18%). Almost every third (29%) patient co-used drugs and herbs. They 
combined 255 different drug-groups and herbs whereas 18 of these were considered to have a 
clinically relevant interaction potential. Close to 40% of patients on anticoagulants co-used 
herbs, reporting garlic and bilberry most frequently. Co-users had significantly (p<0.05) 
increased odds to be female, elderly, use herbs to treat an illness, use two or more herbs and 
experienced adverse effects of herbal use compared to other GP patients. Co-use was also 
associated with use of analgesics or dermatological drugs. Only 23% of the GP patients 
discussed their herb use with a health care professional.  
 
Even though Aloe vera is a well-known, old medicine plant used both in cosmetics and as 
therapeutics, few or no earlier systematic research on its interaction potential has been 
investigated when co-used with drugs in vitro. Overall three enzymes accounts for the 
majority of the pharmacokinetics on the drugs in the market: the efflux-protein P-gp 
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transporting the medicinal drug out of the cell and CYP3A4 and CYP2D6, metabolizing the 
medicinal drugs to less active components. These enzymes can be influenced by other 
substances (inhibited or induced) and is therefore important regarding herb-drug interactions.   
 
Aloe vera juice (AVJ) did not inhibit P-gp mediated digoxin efflux for the investigated AVJ 
concentrations in vitro. However, it was shown that both AVJ (10.0 mg/ml) and digoxin 
(≥3μM) was cytotoxic in large concentrations. Two different AVJs were used in the CYP3A4 
and CYP2D6 assays. Both juices inhibited CYP3A4 and CYP2D6 irreversible in vitro, having 
significant different IC50 values. This can come from different concentrations of active 
components in the juices. Both IC50 values seems, however, to be too high to be clinical 
relevant alone. Precautions should although, be made with excessive consumption of AVJ, 
with poor CYP2D6 activity (”poor metabolisers”) or with use of drugs having a narrow 
therapeutic window.  
 
It can be concluded that GP patients co-using drugs and herbs and that this use can give 
clinical relevant interactions (e.g. excessive haemorrhage when co-using garlic and warfarin). 
Elderly patients are most vulnerable for co-use. One of the common used herbs among GP 
patients, Aloe vera, was investigated for in vitro pharmacokinetic interactions on the enzymes 
P-gp, CYP3A4, CYP2D6. Although it was concluded with low possibility of clinical relevant 
pharmacokinetic interactions co-using Aloe vera and drugs, patients with poor CYP2D6 
activity might risk interactions when co-using large quantities of Aloe vera with conventional 
drugs which is metabolized of CYP2D6 (e.g. codeine). Clinical in vivo studies are needed to 
reveal any interactions in humans for Aloe vera and other herbs at risk of herb-drug 
interactions. Until then, the GPs and other health care professionals are advised to ask all 
patients about herbal use.
13 
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Summary of papers 
Paper I 
 
The co-use of conventional drugs and herbs in Norwegian general practice: a cross-
sectional study. 
 
The primary aim of this study was to compare patients in a general practice general 
practitioner’s (GP) office in Norway that co-use herbal remedies and conventional drugs with 
those who do not, with regards to demographics, types of drugs and herbs used, reason for use 
and communication with health care professionals about this use. The second aim was to 
register the herb-drug combinations with potential clinical relevant interactions among the co-
users. 
 
A questionnaire based cross-sectional study was performed in a GP office with four GPs and 
one intern, situated in a middle large town in Norway. Adults >18 years who came for an 
office visit were invited. The questionnaire consisted of three parts; Demographics and 
conventional drug use, herbal use and communication about herbal use. The data was 
analysed with multivariable logistic regression with co-use as the dependent variable. 
 
A total of 402 patients received and 381 completed the questionnaire. The prevalence of 
herbal use was 44%, with bilberry (41%), green tea (31%), garlic (27%), Aloe vera (26%) and 
Echinacea (18%) being the most commonly used herbs. Almost every third (29%) patient co-
used drugs and herbs. They combined 255 different drug-groups and herbs whereas 18 of 
these were considered to have a clinically relevant interaction potential.  Close to 40% of 
patients on anticoagulants co-used herbs. Co-users were significantly (p<0.05) different from 
other GP patients by being female (adjOR 2.0), increasing age above 50 years (adjOR 1.3 -
3.3), using herbs to defeat an illness (adjOR 4.2), using two or more herbal remedies 
(polyherbacy, adjOR 12.1) and having experienced adverse effects of herb use (adjOR 37.5). 
Co-use was also associated with use of analgesics or dermatological drugs (adjOR 5.1 and 
7.9). Three out of four patients did not discuss herbal use with any health care professional.  
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A sizable proportion of the GP patients co-used herbs with conventional drugs, also 
combinations with reported interaction potential or additive effects like anticoagulants and 
garlic. The low disclosure of herbal use to their GP, polyherbacy and the risk of interactions 
in vulnerable groups like elderly and chronically ill patients, warrant increased awareness 
among GPs.  
 
Paper II 
 
Aloe vera juice; mechanistic and non-mechanistic CYP3A4 and CYP2D6 inhibition. 
 
The main objective was to evaluate the Aloe vera juice`s (AVJ) inhibition potential towards 
cytochrome P-450 (CYP) enzymes 3A4 or 2D6 metabolism of testosterone or 
dextromethorphan in vitro. 
 
A range of seven AVJ concentrations (0.01- 60.0 mg/ml) were incubated with recombinant 
CYP3A4 or CYP2D6 for 10 or 25 min, respectively. To assess the problem of inter-herbal 
differences two juice products, ‘A’ and ‘B’, were investigated. Testosterone (0.10 mM) or 
dextromethorphan (8 μM) were used as substrates, and ketoconazole (KTZ) (0.16 μM) or 
quinidine (0.24 μM) were used as positive control inhibitors. Amount of metabolites were 
detected by HPLC (High-performance liquid chromatography). IC50 values were estimated for 
AVJ ‘A’ or ‘B’ inhibition by non-linear regression. Time- and NADPH dependent inhibition 
assays were performed to investigate if the inhibition of CYP3A4 or CYP2D6 were 
mechanism-based. 
 
Both AVJs showed mechanism-based inhibition on CYP3A4 and CYP2D6 in vitro. AVJ ’A’ 
and AVJ ’B’ had significant dissimilar IC50 values and this may be explained from their 
different concentration of juice components. These results are not considered clinical relevant, 
because of the high IC50 values. However, precautions should be made with high AVJ intake 
in humans presumed an additive effect of both the CYP3A4 and CYP2D6 irreversible 
inhibition when co-administrated with drugs metabolised by these enzymes. In addition, AVJ 
compounds might accumulate in the hepatocytes. Furthermore, co-administration with drugs 
with a narrow therapeutic window (e.g. tricyclic antidepressants) and patients with poor 
CYP2D6 activity (”poor metabolisers”) are exposed to small changes in the drug 
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bioavailability. Further in vitro investigation of AVJ ‘A’ inhibition of CYP2D6 metabolism is 
required because of inconclusive results.  
 
Paper III 
 
Caco-2 Cell Methodology and Inhibition of the P-glycoprotein Transport of Digoxin by 
Aloe vera Juice.  
 
The aim was to explore the Aloe vera juice`s (AVJ) inhibition potential towards P-
glycoprotein (P-gp) efflux of digoxin in human colon carcinoma cells (Caco-2 cells).  
 
Bidirectional digoxin (30 nM) fluxes across monolayers of Caco-2 cells, were determined for 
digoxin alone (control), in the presence of a positive inhibitor control, verapamil (100 μM), or 
seven AVJ concentrations (0.00001-1.0 mg/ml). The AVJ range was anticipated to cover 
physiological relevant concentrations. AVJ and substrate toxicity was evaluated by the 
tetrazolium bromide (MTT) assay, based on intracellular lactatedehydrogenase (LDH) 
activity. Transport linearity, transepithelial electrical resistance (TEER) and mannitol (55 μM) 
transport were measured to secure cell integrity and quality. Only monolayers with TEER 
values > 200 Ω/cm2 and mannitol <1.0 x 10 6  cm/s were included. The apparent permeability 
coefficient (Papp (cm/s)), net Papp (PappNet (cm/s)) and the net flux (JNet (nmol/h/cm2)) were 
determined for the digoxin transport. 
 
AVJ did not inhibit the P-gp efflux of digoxin in the investigated AVJ concentration range, 
and an in vivo inhibition of P-gp mediated digoxin flux by AVJ might seem unlikely. 
The quality and integrity (transport linearity, TEER and mannitol) of the Caco-2 cell system 
was satisfactory during the AVJ inhibition studies. Surprisingly, digoxin caused a linear 
statistically significant concentration-dependent reduction of lactatdehydrogenase (LDH) 
activity at concentrations ≥3 μM. Precautions should thus be made when concentrations of 
digoxin ≥3 μM are used in Caco-2 cell studies. AVJ showed cytotoxicity at the highest 
concentration applied (10.0 mg/ml).  
18 
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1 Introduction  
Modern medicine has evolved from the traditional folk medicine with herbs as the treatment 
basis. The oldest known written records are from the Sumarians 2600 BC listing hundreds of 
medicinal plants, although the history of herbal medicine is probably as long as the human 
history (Mohammad, 2006). In the work “De Materia Medica” a Greek physician known as 
Dioscorides (100 A.D.), described more than 600 medicinal plants recognised as an important 
contribution to the modern phytomedicine (Mohammad, 2006). Today, some of the well-
known conventional drugs in modern medicine can still be purified from herbs i.e. digoxin 
from the Foxglow plant (Digitalis purpurea) or morphine from the opium poppy (Papaver 
somniferum).  
 
Herbal remedies (plant derived remedies) have gained increased popularity the last decades 
together with other types of complementary and alternative medicine (CAM) (Eisenberg et 
al., 2001; Barnes et al., 2008). CAM covers a heterogeneous group of traditional to more 
experimental approaches that purport to prevent or treat disease and includes herbal remedies 
as well as treatments like homeopathy, high dose vitamins, fish oils, yoga, chiropractic care or 
acupuncture (Eisenberg et al., 1998; Barnes et al., 2008). In USA reported 40% of the 
population to use CAM and 18% reported use of herbal remedies in particular (Barnes et al., 
2008). This thesis will focus on herbal remedies and preparations or products of such.   
 
In parallel to the growth in the herbal use, case-reports and studies of possible herb-drug 
interactions reveal a new problem: herb-drug interactions (Williamson, 2005; Ulbricht et al., 
2008; Izzo and Ernst, 2009). Drug-drug interactions are well-known in medical treatment 
(Cascorbi, 2012). Lately it has become more evident that the increasing consumption of herbs 
and dietary supplements also contains substances capable of interacting with drugs and 
changing the effect (e.g. co-use of sildenafil and grapefruit juice, cyclosporine and St.Johns 
wort) (Flanagan, 2005; Gouws et al., 2012). A number of undesired effects can appear e.g. 
altered drug pharmacokinetics, pharmacodynamics or bioactivation of drugs to reactive or 
toxic intermediates (Rodeiro et al., 2009).  
 
Herbs and drugs may interact either pharmacokinetically or pharmacodynamically. 
Pharmacokinetic interactions occur at the levels of absorption, elimination, and metabolism 
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and determine how rapidly and for how long the drug will appear at the target organ. The 
main group of proteins metabolizing or transporting drugs in humans consist of cytochrome 
P450 (CYP) enzymes and P-glycoprotein (P-gp). Inhibition or induction of these proteins by 
herbal remedies increase or decrease the drugs bioavailability causing unwanted adverse 
effects or treatment failure (e.g. grapefruit juice inhibiting CYP3A4 and P-gp increasing 
sildenafil concentration). Pharmacodynamic interactions arise when the drug and herbal 
remedy have additive (e.g. garlic and warfarin) or antagonistic (e.g. ginseng and warfarin) 
effects on the body and are not so easy to detected systematically as pharmacokinetic 
interactions (Izzo, 2005; Cascorbi, 2012).  
 
1.1 Use of herbal remedies 
The traditional folk medicine, herbal remedies and alternative medicinal systems (e.g. Chines 
medicine, Ayurvedic medicine) have roots in local traditions based on available natural 
resources and plants (Mohammad, 2006). Through the last century and especially the last 
decades, increase in travelling, commercials, advertising and  internet have shirked the 
distances between people, exchanging information and products in a faster pace. Nowadays 
one can order herbal remedies from all over the world and receive them by mail few days 
later. Thus, some of the most common herbs used by US adults like Ginkgo biloba (Ginkgo 
biloba), Garlic (Allium sativum), psyllium seed husks (Plantago ovate) does not originate 
from the US fauna and new herbs are continuously introduced to the growing market 
(Eisenberg et al., 2001; Barnes et al., 2008).  
 
According to sale statistics for Norway in 2005, the most consumed herbs were  golden root 
(Rhodiola rosea), cranberry (Vaccinium Oxycoccus), exstracts of soya bean (Glycine max), 
evening primrose oil /GLA (Oenothera Biennis) and garlic (Allium sativum) (Bransjerådet, 
2009) while the most frequently used herbs among Norwegian cancer patients were green tea 
(Camelia sinensis), garlic, ginger (Zingiber officinale), noni juice (Morinda citrifolia) and 
Aloe vera (Aloe barbadensis)  (Engdal et al., 2008). The five most popular herbs among 
people in Jamaica were bitter melon (Momordica charantia L.), life plant (Bryophyllum 
pinnatum (Lam.)/ Kalanchoe pinnata), Aloe vera, common floss flower (Eupatorium 
odoratum L.), soursop (Annona muricata L.) and ginger (Picking et al., 2011). In comparison, 
pregnant women in Great Britain used ginger, cranberry and red raspberry leaf tea (Rubus 
idaeus)  (Nordeng and Havnen, 2005) while older adults in USA bought Echinacea 
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(Echinacea purpurea), garlic supplements and Ginkgo biloba (Bruno and Ellis, 2005). Thus, 
although the intercultural influence is increasing, still the herb used by people varies between 
countries, patients groups and age groups. 
 
Studies from USA have reported extensive use (20-36%) of herbs in the general population 
(Martin et al., 2002; Kuo et al., 2004). Wide variability of herbal use has, however, been 
shown for different ethnic groups in the US were 50% of Hispanics, 50% of Asians, 41% of 
Whites, and 22% of African-Americans reported herbal use (Kuo et al., 2004; Feldmann et al., 
2008). In comparison, an UK telephone survey from 1999 reveals, a herbal medicine use of 
7% in the general population (Ernst and White, 2000). An Australian report shows an increase 
in herbal remedy use from nearly 10% in 1993 to above 20% in 2004 (MacLennan et al., 
2006). Few up to date herbal prevalence numbers are found for the Nordic countries. 
Denmark had a prevalence of herbal remedies at 8% in 2000 (ViFAB, 2000) and Sweden 
reported CAM remedy use of 19% in 1999 (Nilsson et al., 2001). However, a recent telephone 
survey reported by The National Research Centre in Complementary and Alternative 
Medicine (NAFKAM) in Norway found a herbal use of 11% among the adult population 
(Fønnebø, 2012). The prevalence of herbal use has increased the latest decades and it varies 
between ethnic groups and cultures.  
 
A cross-sectional study among the adult population in the USA showed that 41% used an 
herbal remedy sometimes or always to self-treat before seeking medical care from a physician 
(Martin et al., 2002). The typical herb user in the USA population (The 2002 National Health 
Interview Survey) were female, aged 45 to 64 years with higher education (Kennedy, 2005). 
About 40% of survey respondents from USA believed that taking prescription medications 
and herbal remedies together was more effective than taking either alone (Kuo et al., 2004)). 
Fifteen per cent of adults treated their children with herbs and nearly all (86%) respondents 
reported that they found it to be helpful or very helpful (Martin et al., 2002).  
 
In parallel to the growing herb and supplement market, efforts has been made from the World 
Health Organization (WHO), European Medicines Agency (EMA) and other national and 
international health authorities to secure the patients safety, produce guidelines, establish rules 
and legislations as well as making herbal monographs on the available literature (EMA, 
2012). In Norway and the other European countries herbal remedies and natural products are 
now regulated by quiet similar regulations (EMA, 2012). Most of the herbal remedies used in 
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Norway are considered as food, food supplements or cosmetics and is controlled by the 
Norwegian Food Safety Authority (HOD, 2003; HOD, 2004). They are bought for self-
treatment without prescription in the pharmacy, shops, by mail order or collected in the nature 
(AESGP, 1998). For the manufacture and control of these products, the rules of Good 
Manufacturing Practice (GMP) are applicable (AESGP, 1998). Herbal medicine needs, 
however, authorization from the national health authorities on the same basis and regulations 
as conventional medicinal drugs (NoMA, 1999).  
 
1.2 Co-use of herbs with conventional drugs 
Herbs are perceived as safe and “natural” and are often marketed without mentioning any 
potential for harm (van den Berg et al., 2011). This myth has been falsified by numerous 
reports and papers from minor to lethal side effects or interactions with drugs (Izzat et al., 
1998; Cott, 2001; Ioannides, 2002; Greenblatt and von Moltke, 2005). One of the well-known 
cases is transplanted patients treated with cyclosporine, an immunosuppressive drug, taking St 
John's wort (Hypericum perforatum) leading to a drop in plasma levels of cyclosporine, 
causing tissue rejection (Ruschitzka et al., 2000; Ioannides, 2002; Zhou et al., 2003).  
 
It is reported a co-use of herbal remedies and drugs up to 50% in different patients groups 
(Smith et al., 2010; Nordeng et al., 2011; Zhang et al., 2011). An US study identified that 
40% of potential adverse herb-drug interactions among the herbal users in outpatient clinics 
(Bush et al., 2007). Pregnant women reports to use herbal remedies (9-40%) and about 86% 
of these used conventional drugs concomitantly (Moussally et al., 2009; Nordeng et al., 
2011). The use of herbal remedies among adults with cancer is reported to be in the interval 
between 30-55% (Molassiotis et al., 2005; Johansen and Toverud, 2006) and one study found 
that almost 40% co-use herbal remedies and chemotherapy (Engdal et al., 2008). Elderly are 
another group at risk and in a study were 32% of the participants defined to be at risk of 
having at least one possible herbal drug interaction (Loya et al., 2009). Smith and co-workers 
reported of warfarin interactions with herbs or vitamins for 7% of the patients (Smith et al., 
2010). The American Society of Anaesthesiologists recommends to stop all herbal 
supplement use 2-3 weeks prior any surgery to minimize risk of increased bleedings or 
interactions with anaesthesia (Leak, 2000; Sabar et al., 2001). Thus, adverse effects and 
interactions between drugs and common herbs are a challenge today (Zhou et al., 2003). 
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Herbal preparations consist of multiple, often unidentified, biological active or inactive 
constituents (van den Berg et al., 2011). It is therefore more likely that an interaction between 
a single drug and a complex herbal product takes place, than towards another single drug. 
Furthermore, the combined effect of all constituents together in an herb may be different from 
the anticipated sum effect evaluated from single isolated constituents (van den Berg et al., 
2011). This emphasizes the importance of performing interaction studies with crude herbal 
extracts as an important supplement to studies on isolated herbal fractions. 
 
1.3 Herb use and co-use among general practice patients 
Despite the large reported use of herbs and co-use of herbs and regular drugs in patients 
groups, few studies have been performed in primary care and general practice in particular. 
General practitioners (GPs, family doctors) provide the main health care to the general 
population in the society (Allen et al., 2005). They have the long term follow up on regular 
medication/chronic disease and common illnesses (i.e. diabetes, hypertension, arthritis) with a 
large degree of variety in the patient population (age, gender, illnesses, socioeconomic status 
etc.) (Gillam et al., 1989). Thus the GP is the physician to whom the patients are expected to 
disclose their herb use and the GP is on the other hand, expected to ask for this information in 
the medical history taking.  
 
A study from Israel reported a prevalence of herbal use in family medicine practices of 36% 
and nearly 50 % of these co-used natural and conventional drugs usually or sometimes 
(Giveon et al., 2004). Another study showed herb use of 35% and a concomitantly use of 
CAM and conventional drugs of nearly 80% among the CAM users in Scotland (Featherstone 
et al., 2003). Due to the low number of studies from general practice as such, it is relevant to 
look at use among typical patient groups in general practice, elderly patients and patients with 
chronic diseases.  
 
The elderly patients tend to go more often to their GP, have more polypharmacy problems and 
they are more vulnerable to interactions because of decreased health in general (hearth failure, 
liver failure, kidney failure etc.) (Loya et al., 2009). Considering 13-47% of elderly patients 
reports to consume herbs in the general population (Bruno and Ellis, 2005; Raji et al., 2005) 
and as many as 31- 75% of the elderly co-using herbs and prescribed drugs (Loya et al., 2009; 
Gonzalez-Stuart, 2011) , the risk of server interactions are high. For instance, it is reported 
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herbal interaction with a variety of cardiovascular drugs, which may lead to adverse 
alterations in drug efficacy and/or toxicity (Gurley et al., 2005; Cohen and Ernst, 2010). In 
addition, about 50% of the population has one or more chronic conditions and have, as the 
elderly, a high care rate and polypharmacy (50%) (Schoen et al., 2007). They also tend to use 
more herbal remedies, which increase the possibility of herb-drug interactions (Ravven et al., 
2011). Thus, the risk of harmful co-use in the GP practice is present and needs to be 
addressed.  
 
Only 20-45% of the population inform their physician of herb use (Giveon et al., 2003; 
Wheaton et al., 2005; Davis et al., 2012). In addition, the health care professionals rarely 
asked the patients about the use of herb or other types of use of complementary and 
alternative medicine (Giveon et al., 2003). ”The doctor did not ask” is the common phrase 
explaining the lack of communication (Saw et al., 2006). The physicians also tended to 
underestimate the use (Giveon et al., 2003). Thus, a lack of disclosure from the patient about 
herbal use is to some degree documented, particularly so among GP patients. 
 
1.4 Aloe vera 
Aloe vera (AV), Aloe Barbadensis, is a widely used and old medicine plant and a perennial 
succulent (Liliaceal) (Boudreau and Beland, 2006). It has been used traditionally for 
thousands of years as topical or oral therapeutic against different skin diseases and a wide 
range of illnesses (skin burns, antiviral, antibacterial, inflammatory bowel disease (IBD), 
hyperlipidaemia, diabetes, HIV etc.), as well as in cosmetic products (Reynolds and Dweck; 
Turner et al., 2004; Boudreau and Beland, 2006; Ahlawat and Khatkar, 2011).  
 
The National Centre for Toxicological Research (NCTR), U.S. Food and Drug Administration 
(FDA), have in their report (FY 2006/2007) aimed on AVs increasing usage in both 
cosmetics, dietary supplement and natural medicine (Slikker, 2007). AV supplements were 
the top-selling botanical supplements within the natural and health foods channel in USA in 
2009 (Cavaliere, 2010). The International Aloe Science Council (IASC) estimated sale of AV 
products for over 125 million dollars per year in 2004 (Rodriguez, 2004), and the potential 
market is estimated to be around 10 billion dollars. Forever Living Products sold AV products 
for 1.7 billion dollars in 2010 (Januszewski, 2011).  
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1.4.1 Pharmacological and toxicological properties of Aloe vera 
 
The constituents of AV have biological and toxicological properties, yet the active 
components elude definition (Williamson et al., 2011). The AV products are made from its 
fleshy leaves containing aloe latex and aloe gel. The latex contains laxative anthraquinone and 
oral AV is documented used as a stimulant laxative (Werner C., 2007; Williamson et al., 
2011). In addition, other constituents with known therapeutic activity (laxative) are barbaloin 
(aloin A (10S) and B (10R)) and 5-hydroxyaloin A (10S) (Farnsworth NR, 1999; Patel et al., 
2012). Because of the empirically documented laxative effect, Aloe vera is defined as a 
medicinal herb by the Norwegian Medicines Agency (NoMA, 1999). The FDA reclassified, 
however, the stimulant laxative ingredient aloe from category I (monograph) to category III 
(more data needed) in 2002, because of lack updated safety and toxicology data (FDA, 2002; 
Ulbricht et al., 2008). 
 
The aloe gel is processed to purified gels, juices or dried powder to make tablets (Ahlawat and 
Khatkar, 2011). The water content in AV gel is ranging from 99-99.5% (Boudreau and 
Beland, 2006). The remaining solid material consists mostly of polysaccharides, vitamins and 
minerals (Atherton, 1998; Vogler and Ernst, 1999; Ni et al., 2004; Boudreau and Beland, 
2006), though its composition varies between harvest seasons and growth location (van Wyk 
et al., 1995). Acemannan is one of the most abundant (> 60 % of solid matter) and well-
known of the polysaccharides and is believed to be important for the immunostimulating and 
anticancer activity attributed to AV (Zhang and Tizard, 1996; Harlev et al., 2012). A recent 
paper concludes of possible induction of bone formation by influence of acemannan in rats 
(Boonyagul et al., 2013). Other components isolated from AV are also attributed 
pharmacological effects in the literature, like emodin to be anti-angiogenic (Cardenas et al., 
2006) and phytosterols to have hypoglycaemic activity (Tanaka et al., 2006). In addition, anti-
inflammatory and thrombolytic (Vazquez et al., 1996) , anti-arthritic and antibacterial 
activities are reported for AV (Vogler and Ernst, 1999). This makes AV an interesting herb in 
regard to evaluate for in vitro interactions on drug metabolism and transport.  
 
It is shown that crude AV juice (AVJ) (200 μg/ml) enhances NF-kappa B activation from 
human macrophages in vitro with 7 % (Pugh et al., 2001) and AV leave extract (1.0 ml/kg) 
significantly decreased high liver markers induced by lindane (Etim et al., 2006). In addition, 
a mixture of AV and milk thistle (Silybum marianum) is reported to increase the mRNA 
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expressions for tumor necrosis factor-alpha (TNF-alpha), inducible nitric oxide synthase 
(iNOS), and cyclooxygenase-2 (COX-2) in acute hepatotoxicity in mice (Kim et al., 2009).  
 
Human in vivo studies are, however, weak in study methods and inconsistency of data do not 
currently warrant the recommendation of oral AV for the management of diabetes mellitus, 
dyslipidaemia, inflammatory bowel disease, cancer, osteoarthritis, hypertension or other 
diseases (Williamson et al., 2011; Harlev et al., 2012). Ingestion of oral AV may give 
diarrhea, electrolyte imbalance or kidney dysfunction and is considered unsafe for multiple 
medical conditions as well as for pregnant or breastfeeding women (Ulbricht et al., 2008). 
Although topical application is considered more safe, episodes of contact dermatitis, erythema 
and phototoxicity have been reported (Farnsworth NR, 1999; Williamson et al., 2011). 
 
1.4.2 Co-use of Aloe vera 
Aloe vera is reported to be the most frequently used herb (25%) among the HIV patients using 
herbs in addition to be on anti-retroviral therapy in Uganda (Lubinga et al., 2012). Among 
osteoarthritis patients in Nigeria, 30% of the patients used herbal products and of these used 
nearly 30% AV concomitantly with conventional drug treatment (Obalum and Ogo, 2011). 
Cancer patients in Norway reported of co-use of AV and chemotherapy of 5% (Engdal et al., 
2008).  
 
Little has been known, however, about AVJs interaction potential when co-administrated with 
drugs. Apart from a publication (Brandin et al., 2007) indicating a minor induction of 
CYP1A2, CYP3A4 and MDR1 in vitro and a study on one single component in AV, rhein, 
inhibiting both CYP3A4 and CYP2D6 in vitro (Tang et al., 2009), no interaction data of AVJ 
on P-gp, CYP3A4 or CYP2D6 have been published previously to our knowledge. 
 
1.5 Levels of interaction 
The herb-drug pharmacokinetic interactions might take place on different pharmacokinetic 
enzymes. The cytochrome P450 enzymes (CYP) accounts for a significant part of the first 
pass metabolism together with the efflux protein, P-glycoprotein (P-gp) in humans (Liu et al., 
2007).  
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1.5.1 Cytochrome P-450 (CYP) enzymes 
Cytochrome P450 enzymes (CYP) are large groups 
of haeme-containing metabolic enzymes of great 
importance in xenobiotic metabolism. CYP 
enzymes are essential for the production of steroids, 
prostacyclins, cholesterol and thromboxane A2 
(Guengerich, 2008). They also are necessary for the 
detoxification of foreign chemicals and the 
metabolism of drugs. Figure 1 show the CYP 
catalytic cycle for substrate hydroxylation. CYP 
enzymes are so named because they are bound to 
membranes within a cell (cyto) and contain a haeme 
pigment (chrome and P) that absorbs light at a 
wavelength of 450 nm when exposed to carbon 
monoxide. Human drug metabolism are mostly 
performed by five of the 57 known human CYPs 
(Guengerich, 2008). These are CYP1A2, 
CYP2C9/CYP2C19, CYP2E1, CYP2D6 and 
CYP3A4 which metabolise 90% of drugs, with the 
two most significant enzymes being CYP3A4 and 
CYP2D6 (Lynch and Price, 
2007). They are predominantly 
expressed in the liver, but they 
also occur in the small intestine 
(reducing drug bioavailability), 
lungs, placenta, and kidneys 
(Rendic and Di Carlo, 1997).  
1.5.1.1 CYP3A4 
Isoenzyme CYP3A4 is an 
important metabolic enzyme 
and the most abounded in the 
intestine and liver (Liu et al., 
2007; Lynch and Price, 2007). 
 
Figure 1. The substrate (R-H) binds to the CYP 
enzyme (1) close to the haeme-group. Depending 
on the substrate and enzyme involved, P450 
enzymes can catalyze any of a wide variety of 
reactions like hydroxylation shown in this figure. 
In the presence of NADPH+ (2 and 4) and oxygen 
(3), the CYP enzyme catalyzes the metabolic 
reaction forming a product (R-OH) and a water 
molecule. After the product has been released 
from the active site, the enzyme returns to its 
original state, with a water molecule returning to 
occupy the distal coordination position of the iron 
nucleus (Figure modified from Guengerich, 2008). 
 
Figure 2. CYP isoenzymes and their relative hepatic expression levels 
(upper pie chart and table) and contributions to Phase-I drug reactions 
(lower pie chart and table). A high hepatic expression level does not 
necessarily correspond to a large part of the drug metabolism eg. 
CYP1A2 and vice versa (Figure from Kramer and Testa, 2008). 
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The CYP3A subfamily, CYP3A4 and CYP3A5 mainly, metabolizes approximately 50% of all 
CYP metabolized drugs, thus a heavy contributor in the drug metabolism (Rendic and Di 
Carlo, 1997). Furthermore, P-gp and CYP3A are frequently co-expressed in the same cells 
and share a large number of substrates and modulators. The disposition of such drugs is thus 
affected by both metabolism and transport (Liu et al., 2007).  
 
CYP3A4 has a low degree of substrate specificity which makes it susceptible for inhibition of 
a variety of structurally unrelated substances e.g. antifungal agents (ketoconazole and 
itraconazole), antimicrobials (clarithromycin, erythromycin and ritonavir), antihypertensives 
(verapamil and diltiazem) and several herbal and food constituents, e.g. grapefruit juice and 
bergamottin (Kent et al., 2002; Liu et al., 2007; Pelkonen et al., 2008). Thus inhibition of 
CYP3A4 activity by AVJ seems not unlikely. 
 
1.5.1.2 CYP2D6 
Approximately 20-30% of the CYP drug metabolism is carried out by CYP2D6 enzymes 
(Figure 2) (Rendic and Di Carlo, 1997; Ingelman-Sundberg, 2005). Some of these drugs are 
commonly used and consumed in large scale as for instance cardiovascular drugs (e.g. β-
adrenergic blocking agents), antidepressants and analgesics, and an interaction would 
therefore have large implications for the patients.  
 
Furthermore, CYP2D6 has been studied extensively because it exhibits genetic 
polymorphism, meaning that distinct population differences are apparent in its expression or 
activity. Approximately 7 to 10 per cent of Caucasians are poor metabolisers of drugs 
metabolised by CYP2D6 (Cupp and Tracy, 1998). Adverse effects due to elevated drug 
plasma levels occur more frequently in poor metabolisers in cases where the drug clearance is 
dependent on CYP2D6. A lack of or inhibition of CYP2D6 enzymes reduce the effectiveness 
of drug therapy in cases where pro-drugs requiring activation by CYP2D6 metabolism as for 
tramadol and codeine (Ingelman-Sundberg, 2005). An inhibition in CYP2D6 in poor 
metabolisers may thus have great impact on the drugs bioavailability.  
 
In vitro investigations have shown that extracts of Heliopsis longipes (A.Gray) (Rodeiro et al., 
2009), isolated constituents from grapefruit juice (e.g. bergamottin) (Tassaneeyakul et al., 
2000), Ginkgo biloba (ginkgolic acids I and II) (Zou et al., 2002) and ginseng (ginsenoside 
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Rd) (Henderson et al., 1999), can inhibit CYP2D6 metabolism. A in vivo study performed by 
Gurley et al. revealed a significant inhibition (approximately 50%) of CYP2D6 activity by 
goldenseal in humans, while Ginseng and black cohosh demonstrated a weak inhibitory effect 
on CYP2D6 metabolism of debrisoquine in the same study (Gurley, 2008). Thus, CYP2D6 
metabolism seems to be vulnerable for inhibition by herbal products. 
 
1.5.1.3 Patterns of inhibition 
Inhibition of CYP3A4 and CYP2D6 can be both reversible (Figure 3a) or irreversible 
(mechanism-based, Figure 3b) in nature. The latter have the highest impact on the drug 
bioavailability (Zhou et al., 2005). A mechanism-based inactivation is anticipated to be due to 
a chemical modification of the haeme or protein part of the enzyme, or both, leading to the 
formation of reactive metabolites that bind covalently to the enzyme causing CYP 
inactivation (Zhou et al., 2005). A number of clinically important drugs have been identified 
to be mechanism-based CYP3A4 inhibitors as erythromycin, tamoxifen, midazolam and 
verapamil (Guengerich, 2008). In addition to some herbs as grapefruit juice, common valerian 
(Zhou et al., 2004; Hellum and Nilsen, 2007) and a few isolated herb constituents as 
bergamottin and glabridin (Kent et al., 2002). The herbs black pepper (Piper nigrum) 
(Subehan et al., 2006) and Madagascar Periwinkle (Catharanthus roseus) (Usia et al., 2005) 
have been identified as potent mechanism-based inhibitors of CYP2D6. CYP3A4 and 
CYP2D6 metabolism seems thus to be vulnerable for irreversible inhibition by herbal 
products.  
 
 
 
 
Figure 3a. Reversible inhibition of CYP enzyme 
binding a substrate to its active site, forming an 
enzyme-substrate (ES) complex. The metabolite is 
released and the enzyme is free to receive a new 
substrate. 
 
Figure 3b. Irreversible inhibition of CYP enzyme 
binding a substrate to its active site, forming an 
enzyme- inhibitor (EI) complex. The reactive 
metabolite binds irreversible to the enzyme using 
NADPH.  
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1.5.2 Efflux proteins 
Since the discovery of the permeability-
glycoprotein (P-glycoprotein/P-gp) 40 years 
ago the research on  ATP-binding cassette 
proteins (ABC-proteins) have shed light on 
their roles in cytotoxic drug efflux in human 
cells and drug resistance in cancer cells 
(Szakacs et al., 2006). The ABC-transporters 
are situated in the cell-membrane and contains 
typically two transmembrane domains (TMDs) 
and two nucleotide (ATP)-binding domains 
(NBDs) (Taipalensuu et al., 2001; Szakacs et 
al., 2006). They protect the body against toxic 
substances including drugs, and have in general 
a low substrate affinity, effluxing both 
chemotherapeutics and naturally occurring 
biological compounds (Szakacs et al., 2006). In 
addition, the ABC-transporters are highly 
expressed in important pharmacological 
barriers as in the intestines, liver, kidneys and 
in the blood–brain barrier (BBB) affecting the absorption and elimination of drugs (Szakacs et 
al., 2006).   
 
The human genome contains 48 genes encoding ABC-transporters divided into seven 
subfamilies given symbols from A to G (NCBI, 2008). P-gp is sorted as ATP-binding cassette 
sub-family B member 1 (ABCB1) and are the most well-known of the ABC-transporters 
together with the breast cancer resistance protein (BCRP, ABCG2), multidrug resistant 
protein 2 (MRP2, ABCC2) and the bile salt exporting pump (BSEP, ABCB11) (Taipalensuu 
et al., 2001).  
 
 
Figure 4. The distribution of P-gp in different 
human tissue. The bold solid arrows indicate the 
known direction of transport, whereas the broken-
line arrow indicates unclear direction of transport. 
P-gp is located in the lipid bilayer (thick black 
line) that forms a barrier between various organs; 
red indicates vasculature, blue represents tissue, 
and white indicates excreta. CSF, cerebrospinal 
fluid; MDR, multidrug resistance (Figure from 
Kannan et al., 2009).  
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1.5.2.1 P-glycoprotein 
P-gp is located in epithelial cells in organs of excretion (Figure 4) like intestines, placenta, 
liver and kidneys to facilitate directed drug efflux and thus counteracting systemic 
accumulation of potentially toxic compounds (Zhou, 2008). Like other ABC-transporters, P-
gp holds a polyspecific drug-binding site which effluxes a vast selection of different drugs 
(Aller et al., 2009) and is also widely expressed in cancer cells (Hochman et al., 2002). An 
interacting effect of AV on the P-gp transporter will influence drug pharmacokinetics and 
efficacies (Doherty and Charman, 2002; Lin and Yamazaki, 2003; Zhou, 2008). P-gp 
contributes significantly to the first pass metabolism as about 50% of all marketed drugs are 
reported to be P-gp substrates such as statins, antibiotics, human immunodeficiency virus 
(HIV) protease inhibitors, immunosuppressants, anticancer, and cardiac drugs (Endres et al., 
2006; Keogh and Kunta, 2006). An alteration (inhibition or induction) of P-gp efflux by AV 
could therefore change the pharmacokinetics of several drugs and be of importance for patient 
safety in general (Lin and Yamazaki; Zhou et al., 2004).  
 
Caco-2 cells derived from human colon carcinoma 
cells, constitute a well-established model for bi-
directional P-gp transport (Figure 5) and interaction 
studies (Hidalgo et al., 1989; Artursson, 1991; Sun et 
al., 2008). This model is well tested for its suitability 
as an in vitro assay, and correlates well with in vivo 
controls (Artursson and Karlsson, 1991; Adachi et 
al., 2001; Collett et al., 2004). Despite this, the Caco-
2 cells are a heterogeneous cell population that is 
exposed to different growth conditions which causes 
interlaboratory variabilities (Shah et al., 2006). A thorough quality control for Caco-2 cells 
can, however, facilitate the possibility to compare data between laboratories. Characteristics 
as assay linearity, transepithelial electrical resistance (TEER), mannitol transport and general 
cell toxicity should be obligatory (Artursson, 1991; Hidalgo, 2001; Markowska et al., 2001).  
 
Even though a weak induction of the P-gp gene (ABCB1 gene) is reported, a P-gp inhibition 
by AVJ can occur at higher concentrations as reported for Echinacea purpurea (Hansen and 
Nilsen, 2008) or when given as a single dose compared with repeated dosing as shown for St. 
 
Figure 5. A schematic model of the 
Caco-2 and P-glycoprotein system. 
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Johns wort, grapefruit juice or garlic (Allium sativum) (Zhou et al., 2004). It can also be an 
allosteric induction or inhibition of the P-gp transport. 
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2 Aims 
The aims of this thesis were divided; 1) To register the co-use of drugs and herbs among GP 
patients in Norway and the patient’s communication of such use with health care 
professionals; 2) To evaluate the interaction potential of one of the commonly used herbs in 
GPs office, Aloe vera, on the P-glycoprotein (P-gp), CYP3A4 and CYP2D6 enzymes. 
 
2.1 Co-use among GP patients 
The primary aim of this study was to compare patients in a general practice in Norway that 
co-use herbal remedies and drugs with those who do not, with regards to demographics, types 
of drugs and herbs used, reason for use and communication with health care professionals 
about this use. The second aim was to register the herb-drug combinations and identify those 
with interaction potential.  
 
To address the aims, the following questions were asked:  
1. Do Norwegian GP patients use herbal remedies and if so, to what extent? 
2. Are some herbs more commonly used than others? 
3. Which motives do they have for use? 
4. Do the patients disclose their herbal use to the GP or other health care providers? 
5. Do any of the herb users also use conventional drugs on a regular basis; if so was there 
any difference between the drugs?  
6. Which herbs and conventional drug combination can be identified, and are any of 
them at risk of being harmful to the patient? 
7. Do they experience any adverse effects of herbal use? 
8. Is there any common characteristics of those who co-use herbs and conventional, 
regular drugs and can the GP use them to pin-point those at risk?  
 
2.2 Aloe vera juice in vitro studies 
The aims of Paper II and Paper III were to evaluate the inhibitory potency of two different 
Aloe vera juice (AVJ) products on CYP3A4 or CYP2D6 activities in vitro, compare the IC50 
inhibition values and determine if a possible AVJ inhibition of these two CYP enzymes could 
be mechanism-based.  
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The aims of Paper III were to carry out a thorough quality control setup for essential Caco-2 
cell characteristics in P-gp inhibition studies and to explore whether Aloe vera juice (AVJ) 
possesses any inhibitory effect on the bidirectional transport of the P-gp substrate digoxin. 
 
To address the objectives of these studies following questions were asked:  
1. Does Aloe vera inhibit CYP3A4, if so to what extent? 
2. Does Aloe vera inhibit CYP2D6, if so to what extent? 
3. Does Aloe vera inhibit CYP3A4 and CYP2D6 by mechanistic inhibition? 
4. Is there a difference between different commercial Aloe vera juice products in their 
ability to inhibit CYP3A4 and CYP2D6 mediated metabolism?  
5. Is the Caco-2 cell model functioning in our laboratory as a reliable and reproducible 
system for evaluating P-gp transport and interactions? 
6. Is Aloe vera toxic to the Caco-2 cells? 
7. Does Aloe vera inhibit P-gp, if so to what extent? 
8. Does Aloe vera possess a clinical relevant interaction potential towards other drugs? 
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3 Materials and methods 
The thesis is a product of the several methods and procedures that have been used and a 
thoroughly described in the respective papers. An overview is given here.  
 
3.1 Cross-sectional study 
This was a questionnaire based cross-sectional study (Paper I) conducted in a GP office in a 
middle large town on the west coast of Norway with nearly 70 000 inhabitants (Sandnes). The 
demographic of the city is quiet similar to other middle large towns in Norway (Aalandslid 
and Østby, 2007). At the time of the data collection (2011.07.11-2011.12.15) the GP office 
had 6000 patients on the practice list, four GPs and one intern (me). The study was approved 
by the Regional Committee for Research Ethics in South-eastern Norway.  
 
The inclusion criteria were patients 18 years old or older, having an office consultation with a 
GP and who were able to read and understand the questionnaire. The patients were asked if 
they wanted to participate by the staff when the patients contacted the reception. It was not 
systematically registered how many said no, but according to the staff this was about half of 
the patients.  
 
The questionnaire was based on a previously questionnaire used among cancer patients in an 
outpatient clinic in Central Norway and adapted to fit patients in a GP office (Engdal et al., 
2008). It was divided into three parts (Appendix 1). The first part contained questions about 
demographic data and conventional drug used. The second part asked about herbal use from a 
predefined list of the 24 most common herbs sold in Norway and the frequency of use 
(Moussally et al., 2009). Only those products defined as herbs (herbal substances, herbal 
preparations or herbal medicinal products) were included in the analysis (EMA, 2012). Herb 
users were defined as those answering that they used herbs daily, weekly, monthly, less than 
monthly or periodically. Non-users were defined as those answering that they used herbs 
earlier or never used.  
 
In the last part of the questionnaire the communication between the patient and health care 
professionals, motives for use or no use, and who recommended use of herbs were obtained 
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(Paper I, Tables 1 and 5). In addition, they were asked about any side effects of their herbal 
use and approximately monthly costs.  
 
3.1.1 Calculations and statistics 
Pearson’s Chi-square was used for bivariable analyses of categorical data. Multivariable 
analysis was conducted to disclose any associations between co-users and other variables, 
using binary logistic regression analysis (adjusted odds ratio, adjOR). All variables with p-
values <0.2 in bivariable analysis were included in the regression analysis. P-values < 0.05 
were considered as statistically significant. Tendencies were ascribed for p-values between 
0.05 and 0.10. The statistics analysis was done using SPSS 19.0 (SPSS, Chicago, IL, USA).  
 
To find the total number of consultations in the GP practice during the 5 weeks data collection 
period, and the age and gender distribution of these patients, a report module of the electronic 
health record system was used (WinMed 2.12r Statistics, CompuGroup Medical Norway AS, 
Lysaker, Norway). 
 
3.2 Aloe vera juice in vitro studies 
3.2.1 Preparation of Aloe vera juice 
An estimated daily dose (30 ml) of AVJ was centrifuged (3000 rpm for 10 min) and the 
supernatant was freeze-dried (-70 ºC). The dried AVJ was resuspended in 0.8% DMSO (P-gp 
assays) or 1.9% ethanol (CYP assays) to make a stock solution (SS) of 270 mg/ml. The 
amount of DMSO or ethanol was kept to a minimum needed to dissolve the AVJ. A dilution 
sequence was made of the SS with HBSS or KPO buffer to make seven or eight working 
solutions (WS) from the AVJ. All solutions included in the assays contained the same amount 
of diluting reagents (ethanol or DMSO). To minimize a potential source of error from the low 
juice pH, each WS was pH adjusted to be >5.0. 
 
3.2.2 P-glycoprotein in vitro assay 
The human colon carcinoma cell line, Caco-2, express P-gp on the apical side when cultivated 
as monolayers. The Caco-2 cells were cultured (37 ºC, pH 7.4) in growth medium (DMEM) 
prior to seeding. To prevent phenotypic drift only passage 35-40 were used. The cells were 
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seeded onto 24-well 6.5 mm Transwell® plates with 0.4 μm Pore Polycarbonate Membrane 
Inserts at a density of 0.4-0.5 mill/cm2 for transport studies. The culture medium was replaced 
every 2nd day. In addition, the growth medium was always replaced the day prior to the 
transport experiment. The seven different AVJ concentrations were pH adjusted > 5.0 pre-
incubation, to minimize the confounding effects of the low juice pH on the cells (Neuhoff et 
al., 2005).  
 
3.2.2.1 Cell viability  
In vitro cytotoxicity of AVJ and digoxin, the P-gp substrate, were determined by the 
tetrasodiumsalt colorimetric assay (MTT). MTT is converted to formazan crystals by 
mitochondrial lactate dehydrogenases (LDH) in living cells (Figure 6). The measured 
absorbance of formazan at 570 nm, is thus proportional to the number of living cells 
(Mosmann, 1983). 
 
Caco-2 cells were cultivated for 3 days directly in the wells. The culture medium was 
exchanged by the final study solutions and the cells were incubated for 90 minutes. 
Afterwards, the final study solutions were replaced by MTT (5 mg/ml), and incubated for 40 
min. After removal of the MTT solution, the cells were washed with cold PBS buffer. DMSO 
was added to each well for extraction of the formazan product. The amount of crystals was 
analysed by spectrophotometric measurement of optical density at 570 nm.  
 
3.2.2.2 Bidirectional transport studies of digoxin 
The cells were cultured for 21-22 days before the growth medium was replaced with 
HBSS/HEPES buffer. The monolayer integrity was monitored by measuring TEER 
(transepithelial electrical 
resistance) before and after the 
transport assay, in addition to 
mannitol transport during the 
assay. The TEER values should 
be ≥ 200 Ω/cm2 and mannitol 
PappA-B values < 1.0 x 10-6 
cm/s to be included in the 
results (Artursson, 1991). 
Apical
Basolateral
Aloe vera
Caco-2 cells
Membrane
Figure 7. Caco-2 cell well with insert containing inhibitor (AVJ or 
verapamil) on both apical and basolateral side i.e. sink conditions. P-
gp is expressed on the apical side of the Caco-2 monolayer.  
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The substrate, 3H–digoxin, was dissolved in HBSS/HEPES buffer (30 nM, 23.5 Ci/mmol) and 
added to the donor side (250 μl on apical side and 500 μl on basolateral side) of the Caco-2 
cell monolayer in the presence of test compounds under sink conditions (Figure 7). The 
digoxin transport was measured for 90 minutes in apical to basolateral (A-B) and basolateral 
to apical (B-A) directions. All inhibitors were added both on the donor sides and the receiver 
sides (sink conditions). Verapamil (100 μM) was used as a positive inhibitor control (Lin, 
2003). Seven different AVJ concentrations (1.0 x 10-5 mg/ml to 1.0 x 10-5 mg/ml) were used 
in the AVJ inhibition assay. A 55 μM 14C-mannitol solution (1.20 μCi/ml) was added to the 
apical side as an indicator of the monolayer integrity during the transport assay i.e. sustainable 
tight junctions (Artursson et al., 1994). None of the Papp A-B values were above 1.0 x 10-6 
cm/s. 
 
The transported amount of 3H–digoxin or 14C-mannitol was measured by a scintillation 
counter. For more detailed information see Paper III.  
 
3.2.3 CYP enzyme in vitro assays  
The CYP3A4 or CYP2D6 enzymes were in general incubated in KPO-buffer (pH 7.4) on a 
shaking water bath (37ºC) for 10 or 25 min., respectively. The incubation solutions contained 
the substrate with AVJ or without AVJ (control). Testosterone or dextrormethorphan were 
used as substrates for CYP3A4 or CYP2D6, respectively. Seven AVJ concentrations in the 
range from 0.01 mg/ml – 60.0 mg/ml were investigated. Ketoconazole (KTZ) was used as 
positive inhibitor control for CYP3A4 and or quinidine for CYP2D6. The final incubation 
concentration of ethanol was 0.04 % in all solutions to avoid ethanol influence (biphasic 
effect) on the CYP enzymes (Hellum and Nilsen, 2007). The CYP catalytic reactions were 
initiated by addition of 20 μl solution A from the NADPH-regenerating system completing a 
total incubation volume of 400 μl. The NADPH-regenerating system consist of two reagents, 
Solution A [NADP+ and glucose-6-phosphate (Glc-6-PO4)] and Solution B [glucose-6-
phosphate dehydrogenase (G6PDH)]. Combined, these two reagents form an NADPH 
regenerating system that can be used for all NADPH requiring oxidase assays (cDNA-
expressed enzymes and liver fractions). 
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The CYP3A4 or CYP2D6 enzyme activity was terminated after 10 or 25 min. by the addition 
of 200 μl ice cold methanol or ice cold acetonitrile, respectively. After centrifugation was the 
supernatants directly transferred to HPLC vials and the formation of metabolite (6-OH-
testosterone or dextrorphan) was analysed by HPLC. For more details see Paper II.  
 
3.2.3.1 Enzyme inhibition assays 
The incubations were performed as described above. Test solutions of AVJ, KTZ or quinidine 
in volumes of 100 μl were added to the CYP3A4 or CYP2D6 incubations in final 
concentration ranges of 0.01- 60 mg/ml, 0.0064 – 2.0 μM or 0.001- 1 μM, respectively. IC50 
values were estimated by linear regression for the CYP activity.  
 
3.2.3.2 Time and NADPH dependent assays 
The incubations were performed as described in section 3.2.3. The IC50 value of AVJ for 
CYP3A4 or CYP2D6 enzyme activity was used. In the time dependent assay was the test 
solutions added AVJ and preincubated for 0, 15, 30 or 45 min at 37ºC before initiation of the 
CYP activity (addition of solution A). To analyse whether the AVJ inhibition of the CYP3A4 
or CYP2D6 enzyme was NADPH dependent, solutions with or without NADPH were pre-
incubated for 45 or 30 min.  
 
3.2.3.3 High-performance liquid chromatography (HPLC) 
In general high-performance liquid chromatography (HPLC) utilizes a column that holds 
chromatographic packing material (stationary phase), a pump that moves the mobile phase(s) 
through the column, and a detector that shows the retention times of the molecules (Figure 8). 
Retention time varies depending on the interactions between the stationary phase, the 
molecules being analysed, and the solvent(s) used  (Connections, 2004). The mobile phase 
refers to the solvent being continuously applied to the column, or stationary phase, and acts as 
a carrier for the sample solution. A component in the sample solution migrates according to 
non-covalent interactions with the column compound. This determines the degree of 
separation and i.e. the specific retention time to each compound.  
The 6-OH-testosterone was detected by UV detector at retention time of about 20 min. with 
mobile phase 40 % CH3OH/water, pH 7.4, flow rate 1 ml/min., total run time 35 min. and 
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injection volume 40 μl. UV detector is the most common detector and relies on the 
absorbance of the light by the analytes of interest which requires that the compound contain a 
chromophore group.  
Fluorescent detectors (FLD) measure the ability of a compound to absorb and re-emit light at 
given wavelengths. Each compound has a characteristic fluorescence. The excitation source 
passes through the flow-cell to a photodetector while a monochromator measures the emission 
wavelengths (Lodder, 2009). Since only a few organic compounds are able to emit light at a 
different wavelength than they absorbed, is HPLC-FLD not only a highly selective detector 
but also a very sensitive detector, because background noise from the mobile phase is 
practically eliminated (Connections, 2004). 
Figure 8: Schematic representation of an HPLC unit. (1) Solvent reservoirs, (2) Solvent degasser, (3) 
Gradient valve, (4) Mixing vessel for delivery of the mobile phase, (5) High-pressure pump, (6) Switching 
valve in "inject position", (6') Switching valve in "load position", (7) Sample injection loop, (8) Pre-
column, (9) Analytical column, (10) Detector (i.e. IR, UV, FLD), (11) Data acquisition, (12) Waste or 
fraction collector (From Wikipedia, 2009). 
The chromatographic analysis of dextromethorphan and its metabolite was performed using a 
FLD at excitation and emission wavelengths of 230 and 330 nm, respectively. Mobile phase: 
20 % CH3CN and 80 % 0.01 M KPO-buffer, pH 3.4. Flow rate: 1 ml/min., total run time 
25 min. and injection volume 30 μl. The registered emitted fluorescents were detected and 
chromatograms were printed. The retention time for the metabolite, dextrorphan, was 
approximately 4.3 min. and for the substrate, dextromethorphan, 21 min. Each peak in the 
chromatograms reflects one of the separated substances, and the area of each peak was used to 
estimate the amount of each substance. 
 
41 
 
3.2.3.3.1 Validation of HPLC methodologies 
A seven point calibration curve of the metabolite was used to quantify the CYP3A4 or 
CYP2D6 activity. The standard curves were fitted to the measured peak responses. The linear 
correlation coefficient (r2) had to be ≥ 0.99 for the calibration curve to be accepted. The 
lowest accepted concentration in the calibration curve, LLOQ, should be >5 times blank 
response, the peaks need to be identifiable, discrete, and reproducible with a precision < 20% 
and accuracy of 80-120%. Quality controls (QC) were constituted at three concentrations 
(low, medium and high) in three or two parallels for pre-run or in-run validation, respectively. 
The standards WS and QCs WS were made by two different laboratory assistants. The QCs 
were accepted if at least 4 of 6 QCs had a precision <15% and minimum one concentration on 
each level had to be accepted. In addition, the linear correlation coefficient (r2) had to be ≥ 
0.99. 
 
The analytes precision i.e. the closeness of individual measures of an analyte when the 
procedure is applied repeatedly to multiple aliquots of a single homogeneous volume of test 
solutions, at each concentration level should not exceed 15% of the coefficient of variation 
(CV) except for the LLOQ, where it should not exceed 20% of the CV. In addition, the 
analysis` accuracy i.e. the degree of closeness of measurements of a quantity to its actual 
(true) value, should be <15% of the actual value except for the LLOQ where it should not 
deviate >20% (FDA, 2001).  
 
3.2.4 Calculations and statistics 
The P-gp efflux was measured by digoxin transport across the cell monolayer and expressed 
as the apparent permeability coefficients (Papp (cm/s)), Papp ratio (RB-A/A-B), net digoxin 
Papp (PappNet) and net digoxin flux (JNet). Papp ratio is the Papp in basolateral to apical (B-A) 
direction divided with Papp in apical to basolateral (A-B) direction. The net flux (JNet) 
expressed the net transport in B-A direction i.e. the J A-B subtracted from JB-A (nmol/h/cm2). 
 
The CYP3A4 or CYP2D6 activity were determined from the amount metabolite (pmol) 
formed during incubation divided on the total CYP amount in the incubation solution (pmol) 
and the incubation time (min). Enzyme activity is expressed as percentage of reference 
control. The IC50 (concentration of herb that inhibits CYP3A4 or 2D6 activity with 50%) of 
the investigated inhibitor (KTZ or quinidine) and herbs is estimated from non-linear 
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regression of inhibition plots where CYP activity is plotted against increasing inhibitor or 
AVJ concentrations using Sigmaplot (Sigmaplot 2008 for Windows, Version 11.0; Systat 
Software Inc., Point Richmond, CA, USA). 
 
Statistical analysis was done using Microsoft Office Excel 2003 and Sigmaplot (Sigmaplot 
2008 for Windows, Version 11.0; Systat Software Inc., Point Richmond, CA, USA). 
Differences between groups were analysed by a two-sample student’s t-test. All data are given 
as means ± standard deviation (SD). P-values < 0.05 were considered statistically significant. 
Least square regression lines were considered to fit linearity at p-values < 0.05. 
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4 Methodological considerations 
4.1 Cross-sectional study in GP office 
One of the limitations of this study was that it is a cross sectional study, meaning that no 
causal relationship can be identified. In addition, the study took place in one GP clinic in a 
middle large town on the west coast of Norway. It thus might not be representative for other 
populations, but the patients visiting the practice are similar to other GP patients in Norway 
(NDH, 2012).  
 
Although those taking part in this study were representative for all patients visiting the GP 
practice during the period of the survey, those using herbs might also be more positive to 
contribute to such a study than non-herb users. This would give an overestimation in the 
prevalence of herb users (selection bias). However, this would also be the same for other 
studies investigating herbal use, and would not hamper the comparison with these.  
 
The patients responding had to understand the questionnaire in order to answer it correctly 
(information bias). To limit this bias, the patients were invited to ask the reception staff or me 
for help in case of questions. All data are self-reported and inaccuracies in the reported use of 
herbs and drugs must be taken into consideration. Still, the latter was minimized by handing 
out lists of the most common drugs in familiar groups with examples of the most common 
sales name of the different drugs (e.g. anticoagulants (Marevan™, Albyl-E ™).  
 
The number of patients included was too low to draw any firm conclusion about herb-drug 
combinations at risk of giving server adverse effects among the GP patients. However, some 
combinations were more frequent than others and this information gives an important 
contribution with regard to risk of harmful adverse effects.  
 
Although herbs were listed, patients could put other herb in the optional space in the 
questionnaire. However, it was not made clear in the patient information that only herbs (plant 
derived substances) should be included, thus, some had written fish oil or probiotics. In 
addition, Q10 (proteins), multivitamins and minerals were already on the list, but were 
excluded in the further analysis to focus on herb users. This may have influenced their 
response later in the questionnaire, although it did not influence the data in a significant way.  
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The duration or amount of herb use and the way of administration of the herb (i.e. oral, 
topical) was not covered in Paper I and would have given us more information whether the 
herb-drug interaction was clinically relevant. Aloe vera used as juice ingested orally in large 
daily doses has a much higher interaction potential contra Aloe vera used topically against 
skin burns, although dermal absorption cannot be excluded. Some of the herbs are ingested as 
foods like garlic and grapefruit and will in general not be a problem, unless used in excessive 
amounts.  
 
During the analysis of the questionnaire some of the questions had to be merged because of 
quite similar options/responses were given (e.g. question 7 and 8, Appendix 1). This might 
have been avoided if a proper pilot-study was performed, but this seemed unnecessary since 
the questionnaire already had been used in an outpatient clinic in Ålesund (Engdal et al., 
2008).  
 
Working as an intern on the GP office during the data collection, my presence might have 
influenced some of the patients to answer or not answer the questionnaire. However, the 
advantages of being present (able to answer questions, give practical information or tasks) 
were assumed to give more value than the bias-disadvantage.  
 
4.2 In vitro studies 
4.2.1 The Caco-2 cell model 
The P-gp inhibition assay was performed on polarized Caco-2 cell monolayers with an apical 
(A) and a basolateral (B) side. Alternatively one could have utilized LS-180 cells as an 
intestinal cell line model. LS-180 cells are a colorectal adenocarcinoma cell line and express 
human Pregnane-X-Receptor (PXR) to a higher degree than Caco-2 cells, thus making a more 
suitable model to show both inhibition and induction of P-gp transport (Sun et al., 2008; Fan 
et al., 2011). However, the experience with this cell line in P-gp studies is limited. Caco-2 
cells on the contrary, are a well-known cell line and reported as a good P-gp screening model 
for drug-drug inhibition interactions (Markowska et al., 2001). A high interlaboratory 
heterogeneity has, however, been reported for the Caco-2 cells (Hidalgo, 2001). Therefore, 
the substrate transport at regular time intervals, demonstrating linearity, A-B and B-A 
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differences and effect of positive inhibitor control were performed to facilitate comparisons 
with other laboratories, and to show cell compatibility (Hidalgo, 2001). 
 
Verapamil, a first generation P-gp inhibitor, was used as an inhibitory control although the 
Caco-2 cells also express other ABC-transporters inhibited by verapamil, and thus makes the 
result interpretation more inaccurate (Taipalensuu et al., 2001). Scientists all over the world 
are searching for selective P-gp inhibitors, but have not yet quite succeeded (Szakacs et al., 
2006; Lee et al., 2013). Until then, verapamil is still used in Caco-2 cell methodology to 
inhibit P-gp and makes it easier to compare with other studies.  
 
The RNA expression of multiple ABC-transporters (e.g. multidrug resistance associated 
protein 2 (MRP2), multidrug resistance protein1 (MDR1)) are similar to the RNA expression 
of the transporters in biopsies from human jejunum (Taipalensuu et al., 2001). In addition, 
CYP3A4 is also expressed by the Caco-2 cells, having an interrelationship in substrates and 
inhibitors with P-gp (Kim et al., 1999; Taipalensuu et al., 2001). In light of this and the fact 
that the P-gp receptor has low selectivity, finding a selective substrate for P-gp is important 
for the interpretation of the results of the Caco-2 assay. Digoxin is the most known selective 
P-gp substrate used in Caco-2 cell assays, not metabolized by CYP3A4 (Kim et al., 1999; 
Mease et al., 2012). However, organic anion transporting polypeptides (OATP, SLCO1A2) 
has been discussed to take part in the digoxin transport, but this has been falsified by a more 
recent report (Taub et al., 2011). Thus, digoxin has still the dominating role as substrate in P-
gp inhibition assays in Caco-2 cells (Zhou, 2008; Mease et al., 2012).  
 
4.2.2 CYP inhibition assays 
The CYP assays were performed using recombinant human CYP enzymes (Supersomes™). 
These are commonly used models for in vitro single enzyme investigation, allowing 
investigation of the inhibitory effect on a single enzyme without any other enzymes 
interfering. Furthermore, are supersomes easy to use and are cost effective (Kim et al., 2006; 
Hellum and Nilsen, 2007). Liver microsomes and cell cultures are other in vitro models. They 
include multiple liver enzymes and co-factors and enable both induction and inhibition studies 
in contrast to the supersomes. Liver microsomal preparations are routinely used to predict 
drug interactions that can occur in vivo as a result of inhibition of CYP-mediated metabolism. 
However, the concentration of free drug (substrate and inhibitor) at its intrahepatic site of 
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action, a variable that cannot be directly measured, may be significantly different from that in 
microsomal incubation systems (Di Marco et al., 2003). Microsomes have traditionally been 
viewed as a more flexible system with which to study oxidative biotransformations in terms 
of ease of preparation from many species, long-term storage and availability. Although 
storage of liver prior to microsomal preparation and the nature of the preparation itself can 
lead to a loss in CYP activity (H.C. Rawden, 2005). Cell cultures can consist of primary 
human hepatocytes or immortalised cell lines e.g. HepG2 (Yoshitomi et al., 2001) or BC2 
(Gomez-Lechon et al., 2001) cell lines. Primary human hepatocyte cultures are the 
recommended model to study both induction and inhibition of CYP enzymes in vitro 
(LeCluyse, 2001). Hepatocytes provide the most physiologically relevant model when 
measuring qualitative and quantitative aspects of hepatic metabolism since they contain most 
of the enzymes a compound is likely to encounter in the liver. Additionally, interactions with 
transporter proteins present in hepatocyte membranes can be key determinants of hepatic 
clearance (Soars et al., 2007). However, the limited accessibility on human liver tissue favours 
the other models like recombinant CYP enzymes.  
 
4.2.3 Validation of HPLC methodologies 
Figure 9 show typical HPLC chromatograms after incubation with CYP3A4 (A) and CYP2D6 
(B). The blank (top) contained no metabolite peaks neither for CYP3A4 nor CYP2D6 assays. 
The metabolite peaks were not interfered by the AVJ compounds (bottom) or other 
compounds in the assay (middle and top). Thus there was no need to extract the metabolites 
before the HPLC analysis.  
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CYP3A4 
All points in the calibration curve correlated significantly to the curve (r2 ≥0.99). In pre-
validation, the LLOQ was estimated to be 62.5 nM (CV 14.4%) and CVs of intra-day assays 
were all below 2.2% at low (75.0 nM), medium (3.0 μM) and high (6.0 μM) concentrations of 
6-β-OH-testosterone (n=5). In addition, the inter-day CVs were all below 5.2%, for the same 
QCs analysed in three parallels for five days (n=15). The overall inaccuracy for all QCs was 
less than 10.0%. Furthermore, QCs were analysed for each HPLC run and the CVs of intra-
day assays were all below 3.6% at low, medium and high concentrations of 6-β-OH-
testosterone (n=2), while inter-day CVs were all <5.9%for all three concentrations (n= 6). 
Since the LLOQ had a precision <20%, overall accuracy of 80-120%, >5 times blank 
response and all QCs had a precision <15% our HPLC series were accepted.  
 
CYP2D6 
All points in the calibration curve correlated significantly to the curve (r2 ≥0.99). In pre-
validation, the LLOQ was estimated to be 50 nM (CV 2.3%) and CVs of intra-day assays 
 
Figure 9. HPLC chromatograms for solutions incubated with CYP3A4 (A) or CYP2D6 (B) showing from the top 
blanks (no CYP enzymes), controls (middle) and AVJ (0.1 mg/ml) inhibitions (bottom), respectively.  
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were all below 2.6% at low (50.0 nM), medium (800 nM) and high (6000 nM) concentrations 
of dextrorphan (n=5). In addition, the inter-day CVs were all below 3.1%, for the same QCs 
analysed in three parallels for five days (n=15). The overall inaccuracy for all QCs was less 
than 14.0%. Furthermore, QCs were analysed for each HPLC run and the CVs of intra-day 
assays were all below 6.5% at low, medium and high concentrations of dextrorphan (n=2), 
while inter-day CVs were all below 9.5% for all three concentrations (n= 6). The lowest QC 
concentration should have been within 3 times of the LLOQ. The calibration curve contained 
both 10 nM and 50 nM, almost accepting the 10 nM as LLOQ. Presumably is 30 nM the 
correct LLOQ in our analytical runs. However, since the LLOQ had a precision <20%, overall 
accuracy of 80-120%, >5 times blank response and all QCs had a precision <15% our HPLC 
series were accepted.  
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5 Results and discussion 
5.1 Co-use of herbal remedies and conventional drugs among GP 
patients.  
A cross-sectional questionnaire was distributed to 402 patients in a GP office and 381 were 
returned (Paper I).  
 
5.1.1 Prevalence of herbal use among patients in GP office 
In addition to the likely difference between the prevalence in a GP population and the general 
population, the prevalence may also vary between countries and ethnic groups (Kuo et al., 
2004; Raji et al., 2005) and makes comparison difficult. In addition, the prevalence in some 
studies may include all types of CAM (herbs, homeopathy, prayer etc.) or fish oil/vitamins 
and minerals, and not herbs alone (Kennedy, 2005; Barnes et al., 2008; Elolemy and Albedah, 
2012) .  
 
A total of 167 (44%) patients were currently using herbs, and nearly half of the patients used 
multivitamins or supplements. The prevalence of herb use is somewhat higher compared to 
other findings from general practice (36%) or primary care  (22%) (Giveon et al., 2004; Kuo 
et al., 2004) and surprisingly close to the findings from a Norwegian cancer outpatient clinic 
where a similar questionnaire was used (46%) (Engdal et al., 2008). It is also in range of the 
prevalence of studies of the general population from other countries. The 2007 National 
Health Interview Survey (NHIS), USA, reported of herbal use in the general population of 
nearly 20% (Barnes et al., 2008). However, both the Czech and Saudi-Arabian population 
reports of higher herbal use (50-57%) compared to the US population (Elolemy and Albedah, 
2012; Knotek et al., 2012). Due to the differences mentioned above, the variability in 
prevalence reported here and the lack of studies on herb use in GP practices, it is difficult to 
conclude whether or not the prevalence found in Paper I is high or low compared to other 
populations. However, the findings in Paper I lends support to the numerous other studies 
documenting a general high use of herbal remedies. 
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Elderly is a well-represented patient group in the GP office in addition to women, tending to 
go more frequently to the GP than young men (NDH, 2012). These groups are reported to be 
more prone to herbal use than younger patients or men and might explain our high prevalence 
(Barnes et al., 2008; Loya et al., 2009).  
 
A significantly higher proportion of women were using herbs compared to men (51% herb 
user among women vs 29%, Table 1). In addition, polyherbacy were more frequent among 
women than men (80% of polyherbacy patients were women, p=0.009) and tended to be more 
frequent in the age group 50-59 years (31%, p= 0.059) (data not shown). For the other 
demographic variables there were no significant differences with regard to herb use. Multiple 
studies support the same tendency of higher prevalence of herb use among women compared 
to men (Barnes et al., 2008; Elolemy and Albedah, 2012; Knotek et al., 2012). Thus, although 
the prevalence seems to vary between countries it seems consistent that women use more 
herbal remedies than men.  
 
Table1. Demographics of all respondents according to current herb use and co-use of conventional 
drugs (co-use). 
    n (%) Current herbal user p-valueA Co-user p-valueB 
Gender Male 124 (33%) 29% <0.001C 18% 0.001 C 
Female 249 (67%) 51% 34% 
Age grouped <30 50 (13%) 40% 0.869 20% 0.008 C 
30-39 58 (16%) 45% 24% 
40-49 52 (14%) 40% 12% 
50-59 65 (17%) 51% 34% 
60-69 71 (19%) 44% 38% 
>70 76 (20%) 43% 37% 
Education Compulsory 71 (19%) 42% 0.943 32% 0.611 
Middle level 170 (46%) 44% 28% 
University 129 (35%) 44% 26% 
Employment Employed/Off sick 233 (61%) 41% 0.195 21% <0.001 C 
Pension 129 (34%) 46% 40% 
Unemployed/Home 12 (3%) 33% 58% 
Herbal use Never 147 (40%) 
Earlier 60 (16%) 
Present  165 (44%)     66%  <0.001 C 
A P-value for comparison of current herb users with those not using herbs.  Analysed with Pearson Chi-Square or 
Fisher exact test. 
B P-value for comparison of co-users with non-co-users.  Analysed with Pearson Chi-Square or Fisher exact test. 
C p<0.05 
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5.1.1.1 Types of herbs used 
A total of 28 different herbal remedies were registered used (Table 2). Bilberry (Vacciunum 
myrtillus, 41%), green tea (Camelia sinensis, 31%), garlic (Allium sativum, 27%), Aloe vera 
(Aloe barbadensis, 26%) and Echinacea (Echinacea purpurea, 18%) were the most 
commonly used herbs (Table 2). Except from bilberry, all other herbs are frequently reported 
by others (Bent and Ko, 2004; Barnes et al., 2008; Moussally et al., 2009; Cohen and Ernst, 
2010). Bilberry is abounded of antioxidants and claimed to have anti-inflammatory activity 
(Karlsen et al., 2010). A sub-analysis of the reason for using bilberry revealed that it was used 
largely to strengthen the immune system (84% of bilberry user gave this as the reason). The 
use of bilberry might have been influenced by heavy marketing as a “superfood” (Renee, 
2011).  
 
Table 2 All the different herbal remedies used by the herbal user patients (n=214). 
Herb No.of users   Herb No.of users 
Bilberry 70 Ginkgo Biloba 4 
Green tea 52 Soya extract 4 
Garlic 46 Valeriana 4 
Aloe vera 42 Nattokinase 2 
Echinacea 29 Saw Palmetto 2 
Cranberries 26 Broccoli extract 1 
Ginger 19 Cinnamon 1 
Ginseng 15 Essiac 1 
Grapefruit 13 Healthy chocolate 1 
Apple vinegar 11 Kan Jang 1 
Golden root 10 Melissa 1 
Evening Primrose oil/GLA 8 Misteltoe 1 
Noni juice 5 Psyllium husk 1 
Anthocyanin from 
bilberries 4   Rosehip 1 
 
5.1.2 Communication about herb use 
Friends or family (68%), followed by magazines or internet (32%) were common sources for 
recommendation or information regarding herb use (Table 3). This is in line with other studies 
(Martin et al., 2002; Molassiotis et al., 2005). Few patients got herbal use recommended by 
the pharmacy or a physician. This might be a reflection of the attitudes towards herbal 
remedies and CAM to be something “private”, and patients trusting experiences from friends 
and family or anecdotes in magazines rather than scientific evidence (Verhoef et al., 2007). 
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Table 3: Communication with health care professionals about herbal use among current herb users 
and proportion of co-users of conventional drugs and herbs. 
 Total n (%) 
Proportion of 
co-users   
p-
valueA 
Recommended to use herbs by (n=110) D: Friends or family 75 (68 %) 61 %  1.000  
 The Physician 5 (5 %) 80 %  0.647 
 The shop or pharmacy 32 (29 %) 59 %  0.830 
 Read about it in Magazines or internet 35 (32 %) 69 % 
 0.401 
Communication about herb use with 
(n=146) C: Physician
D 27 (18%) 74 %  0.269 
 Other 10 (7%) 80 %  0.324 
 Never discussed 113 (77%) 59 %  0.104 
Reasons for never discussing herb use 
with health care professionals (n= 110): I was never asked 50 (45%) 56 % 
 0.723 
 Afraid of the response
F 23 (21%) 65 %   
 
Only my own concern/ 
confidential 34 (31%) 62 % 
 
 
 
Uncertain of the herbal 
effect 3 (3%) 33 % 
 
 
Reasons for herb use (n=111) C: 
  
 
Better life 
expectancies 47 (42%) 62 % 
 1.000 
Strengthen the 
immune system 79 (71 %) 58 % 
 0.391 
 Defeat an illness 18 (16%) 89 % 
 0.008B  
 Better than nothing 7 (6%) 29 % 
 0.106 
 Pain relief 4 (4%) 50 % 
 1.000 
A P-value for comparison of communication, motives for herbal use, adverse effects and costs between co-users 
of drugs and herbs and not co-users. Analysed with Pearson Chi-Square or Fisher’s exact test given the number 
of total users were below five. B Significantly different with p<0.05. C Multiple answers were possible. D Includes 
GP, regular GP (family doctor) and hospital physicians. 
E A merge of the responses «warned about the risk” and “discouraged use”. F A merge of the responses “I was 
afraid of not getting acknowledgement for my choice”, “I was afraid they got dissatisfied” and “I was afraid of being 
rejected”.  
 
 
Considering the literature, it was not surprising that the majority of herb users (80%) did not 
discuss their use of herbs with any health care professional (Table 3). The low degree of 
disclosure to health care professionals are similar to other studies where the most common 
reason for no communication about herbal use with a health care provider is; “I was never 
asked” (Eisenberg et al., 2001; Giveon et al., 2004). This indicates that the patients want the 
physician to take the initiative to disclose herbal use and this is also reported for other 
countries and continents (Giveon et al., 2004; Wheaton et al., 2005). One explanation why 
GPs do not ask about herb use might be that many GPs have a lack of knowledge about herbal 
remedies, adverse effects and potential interactions with conventional drugs and thus may find 
it difficult to give advice in such matters (Giveon et al., 2003). This might cause insecurity 
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among the health care providers, which seem to neither recommend nor discourage herbal 
use, thus a neutral response is more common as found in Paper I.  
 
Even though the GPs might find themselves in shortage in knowledge of herb-drug 
interactions (Suchard et al., 2004), information about the patients herb use should be 
considered as “Good practise” and integrated as part of the general medical journal to 
promote good and safe medical treatment. The GPs needs be enabled to give advice about 
herb safety. Good and thorough guidelines in regard to this subject are also lacking, although 
some work has been initiated (EMA, 2012) more research is needed. 
 
5.1.3 Prevalence and characteristics of co-users 
Almost every third (29%) patient in this study co-used conventional drugs and herbal 
remedies, giving 45% co-use among those using conventional drugs regularly and 66% co-use 
among herbal users (Table 1). Reported co-use from GP offices in Israel in 2004 was lower 
(12%) (Giveon et al., 2004), however, up-to-date numbers from GP practice are lacking. Still, 
the co-use is in line with the co-use reported for patients groups like pregnant women (34%) 
(Nordeng et al., 2011) and somewhat lower than reported for the cancer patients (30-55%) 
(Molassiotis et al., 2005; Johansen and Toverud, 2006). Thus, our findings are in line with 
earlier reported co-use for patients groups. 
 
Significant differences were seen between the gender, age and occupation groups in regard to 
co-use of drugs and herbs (Table 1). As earlier reported in other papers females were far more 
into herbal use than men (Ben-Arye et al., 2009) and were, not surprisingly, co-using herbal 
remedies and conventional drugs in a significant higher degree than men (Table 1). More than 
one of every three patients older than 50 years were co-users and this was significantly more 
than for younger patients (p<0.001). Those on disability or retirement pension (40%) co-used 
significantly more than those not receiving pension (p<0.001). The co-users also intended to 
defeat an illness in a significant stronger degree than non-co-users (89% vs 11%, p=0.008).  
 
Based on multivariable analysis (Paper I, Table 6), the co-users had statistically significant 
increased odds to be female (adjOR 2.0), increasing age above 50 years (adjOR 1.3-3.3), 
using herbs to defeat an illness (adjOR 4.2), using two or more herbs (polyherbacy, adjOR 
12.1), using analgesics or dermatological drugs (adjOR 5.1 and 7.9 respectively), and 
54 
 
experience adverse effects from herbs (adjOR 37.5). Being between 40 and 49 years old 
decreased the odds of being a co-user (adjOR 0.2).  
 
The association between high co-use and increasing age above 50 years compared to the 
younger patients in our study (nearly 40% of those >70 years old were co-users), was not 
unexpected. Earlier studies report of co-use among elderly from 32-42% (Yoon and Horne, 
2004; Shahrokh et al., 2005; Loya et al., 2009). Cohen et al. found co-use of 24% among 
geriatric patients, and 52% of them co-using with anticoagulants (Cohen et al., 2002). Elderly 
is an exposed group because of increasing poly-pharmacy, reduced general health and altered 
drug metabolism (Canter and Ernst, 2004; Loya et al., 2009). They have a lower tolerance for 
alterations in the pharmacokinetics or pharmacodynamics, which might have serious 
consequences (Gurley et al., 2005; Ulbricht et al., 2008; Yang et al., 2010; van den Berg et al., 
2011). The strong association for co-use with increasing age, polyherbacy and having one or 
more medical condition, calls for concern. These patients are at high risk for clinically 
relevant herb-drug interactions (Abebe, 2003; Yang et al., 2010).  
 
5.1.4 Adverse effects of herb use 
Although the numbers were low, all of 
those who had experienced adverse effects 
of herbs were co-users (8 patients (7%), 
p=0.026). Figure 10 shows the herbs 
reported used by patients experiencing 
adverse effects. Among the co-users 
experiencing adverse effects, three of them 
were using anticoagulants, three used 
sedatives and two used antihypertensives. 
Abdominal symptoms (pain, diarrhea, 
emesis, 33%) or dizziness (22%) were the 
most common reported adverse effects. In 
a recent paper from Beirut as much as 60% 
of the co-users reported some sort of 
adverse effects (Efferth and Kaina, 2011; 
Alaaeddine et al., 2012). Although our reported prevalence is low, those reporting adverse 
Figure 10. Relative percentage of the frequency herbs 
reported used among those patients experiencing adverse 
effects (n= 8). Garlic (19%), bilberry (15%) and green tea 
(15%) had the highest frequency of a total number of 26 
(100%) herbal adverse effects reports.  
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effects were co-using herbs with reported additive effects (e.g. anticoagulants and garlic) 
which might cause excessive bleedings (Cohen and Ernst, 2010). Thus, the GP should 
consider herbal co-use with conventional drugs when patients describe adverse effects, at least 
when they are unexpected.  
  
5.1.5 Herb-drug combinations used by GP patients 
5.1.5.1 Herbs combined with drugs 
For nearly all the types of herbs used, there were no significant difference between the types 
of herbs used when comparing those who co-used conventional drugs and those who did not 
use conventional drug (Paper I, Table 2). Bilberry (43%), green tea (31%), garlic (25%), Aloe 
vera (21%) and cranberry (19%) were the most frequently used herbs among the co-users in 
this study. In addition, the co-users tended to use more Aloe vera than not conventional drug 
users (p=0.091), and almost two of three (63%) of the polyherbacy patients were using 
conventional drugs concomitantly (p<0.001).  
 
Except from a recent case report indicating an interaction between bilberry and warfarin, 
inducing rectal bleeding, few interaction data are published on bilberry (Aktas C, 2011). Thus, 
attention should be paid to the intake of bilberry in patients taking antiplatelet or 
anticoagulant drugs. Green tea has shown antioxidant properties which are mainly attributed 
to its polyphenolic catechins (Schonthal, 2011). Green tea and it`s compounds have also been 
reported to alter the pharmacokinetics of several drugs as warfarin and codeine, and may be 
hepatotoxic in large doses (Schonthal, 2011). Garlic might have antiplatelet activity and 
should thus, be used with care together with antiplatelet drugs like warfarin (Shord et al., 
2009; Cohen and Ernst, 2010). Excessive bleeding has been reported in patients co-using 
warfarin and garlic, a patient group frequently using garlic (Chan et al., 2011). Aloe vera 
might cause potassium depletion or affect cardiac glycosides and is advised not to be used 
together with heart medication (Cohen and Ernst, 2010). However, no in vitro or in vivo 
clinical relevant pharmacological interactions have yet been established (Djuv and Nilsen, 
2008; Cohen and Ernst, 2010; Djuv and Nilsen, 2012). Cranberry is reported to interact with 
warfarin, increasing International Normalized ratio (INR) values by 30% (Mohammed Abdul 
et al., 2008), but a randomized controlled trial concluded with minor risks for significant 
interactions in humans (Ansell et al., 2009). In addition, some reports state that garlic, green 
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tea, Aloe vera and cranberry in general seem to have a low drug interaction risk in humans 
(Ansell et al., 2009; Gurley et al., 2012).  
 
5.1.5.2 Drugs combined with herbs 
It was identified 255 different drug-group and herb combinations (Table 4). Of these, 18 were 
identified of being at risk of clinically relevant interactions (Table 4, in bold) on the basis of 
clinical trials, case reports or theoretical interactions extrapolated from clinical data (Cvijovic, 
2009; Gurley et al., 2012). A significant higher herbal use were reported by patients using 
analgesics (60%, p=0.031) or anticoagulants (36%, p=0.043) among the drug users (Paper I, 
Table 3).  
 
Anticoagulants (i.e. warfarin) were co-used with garlic (Allium sativum), cranberry 
(Vaccinium oxycoccos), ginger (Zingiber officinale), ginseng (Panax ginseng), grape fruit 
juice (Citrus paradisi) and saw palmetto (Serenoa repens) (Table 4), all interacting with 
anticoagulants increasing the risk of adverse effects (e.g. increased haemorrhage) (Izzo, 2005; 
Mohammed Abdul et al., 2008; Ulbricht et al., 2008; Smith et al., 2010; Chan et al., 2011; van 
den Berg et al., 2011). Anticoagulants have a high potential of causing harmful adverse 
effects when co-used with herbs (Smith et al., 2010; Chan et al., 2011) and , thus, the 
Norwegian Medicines Agency (NoMA) has warned against interactions between certain types 
of herbs and warfarin (NoMA, 2013). In general co-use of these herbs with anticoagulants or 
other cardiovascular drugs should be discouraged or closely monitored for adverse effects / 
INR (Cohen and Ernst, 2010; Chan et al., 2011). Co-use should especially be closely 
monitored or even discouraged among the elderly (Gurley et al., 2005). 
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Table 4. Concomitantly use of herbs and conventional drug-groups. 
  
A
ga
in
st
 g
as
tro
in
te
st
in
al
 
co
nd
iti
on
s 
A
na
lg
es
ic
s 
A
nt
ib
ac
te
ria
l. 
an
tif
un
ga
l a
nd
 
an
tiv
ira
l 
A
nt
ic
oa
gu
la
nt
s 
A
nt
id
ep
re
ss
an
ts
 
A
nt
id
ia
be
tic
s 
A
nt
ih
is
ta
m
in
es
 
A
nt
ih
yp
er
lip
id
em
ic
 a
ge
nt
s 
A
nt
ih
yp
er
te
ns
iv
es
 a
nd
 
di
ur
et
ic
s 
A
nt
i-m
en
op
au
sa
l a
nd
 
an
tic
on
ce
pt
iv
es
 
A
nt
irh
eu
m
at
ic
 
A
nt
is
ei
zu
re
. t
rip
ta
ne
s 
an
d 
ce
nt
ra
l s
tim
ul
at
in
g 
dr
ug
s 
C
he
m
ot
he
ra
pe
ut
ic
 d
ru
gs
 
D
er
m
al
 d
ru
gs
 
D
ru
gs
 u
se
d 
ag
ai
ns
t b
la
dd
er
. 
pr
os
ta
te
 d
is
or
de
rs
 a
nd
 
im
po
te
nc
e 
O
cu
la
r d
ru
gs
 
R
es
pi
ra
to
ry
 d
ru
gs
 
S
ed
at
iv
es
 a
nd
 A
nt
ip
sy
ch
ot
ic
s 
S
tro
ng
 a
na
lg
es
ic
s 
Th
yr
oi
ds
 a
nd
 a
nt
ith
yr
oi
ds
 
V
as
od
ila
to
rs
 a
nd
 c
ar
di
ac
 
gl
yc
os
id
es
 
O
th
er
 d
ru
gs
  
N
um
be
r o
f c
om
bi
na
tio
ns
 
Aloe vera 3A 6  1 2 2 5 5 7 3 2 2  2 2 2 4 1  4 1 2 19 
Anthocyanin 2    1 1 2 2 1 1 2        1   9 
Apple vinegar 1 3 1  1 1 1 1 3   1    1 1   2  2 13 
Bilberry 4 15 1 18 5 5 4 2 24 1 5 4 2 3 1 2 4 8  6 2 4 21 
Cinnamon  1    1 1 1 1  1         1   7 
Cranberry 2 9 1 1 2 1 2 2 5 1 1 3  1 3 1 4 4 1 3  1 20 
Echinacea 2 4 1 1 3 1 3 5 5 2 1 1  1  1 1   4  2 17 
Garlic 2 8 1 9 3 4 3 7 11 2 3 3  2  1 3 6  2  2 18 
Ginger 1 2  1 3  2 1 3 1 1     1 2 1  2  1 14 
Gingko Biloba 2 1     2    1     1 2   2  1 8 
Ginseng 1 1 1 1 2 1 1 3 2  2 1     1 1  2  1 15 
Evening Primrose oil/ GLA 1 1  1  1 1 1  1 1        1   9 
Golden root  2 4 1 1 2 1 1 2 3  2 1    1 1 2  2  2 16 
Grapefruit 1 3 1 1  2 1  2   1    1 2 1  1  2 13 
Green tea 4 11 1 7 5 5 5 8 11 4 5 3 2 2 1 1 3 6  4  6 20 
Healthy chocolate                   1   1 
Kan Jang        1 1 1  1           4 
Nattokinase 1        1             2 
Noni juice      1  1 1              3 
Rosehip    1    1 1 1        1     5 
Saw Palmetto 1 1  2    2 1      1 1       7 
Soya extract  1  1 1 1 1 2 2  1         1   9 
Valeriana  1   2   1 2     1         5 
Number of combinations 13 19 10 13 13 14 16 19 20 11 14 13 2 7 5 12 12 10 1 17 2 12 255 
A Bold numbers: Clinical relevant interactions documented in clinical trials, case reports or theoretical interactions 
extrapolated from clinical data. 
 
 
Antihypertensives and diuretics were the largest drug categories in regard to number of 
combinations with different herbal remedies in Paper I (Table 4), having interaction potential 
with ginseng or grapefruit juice (Ulbricht et al., 2008). Ginseng is also reported to interact 
with antidiabetics, cardiac glycosides, antidiarrheal agents and antidepressants (Ulbricht et al., 
2008; Cvijovic, 2009). Anti-constipation drugs or antidiabetic agents should not be consumed 
with Aloe vera because of additive effects and the same has been shown for valeriana 
(Valeriana officinalis) co-used with antidepressants (Carrasco et al., 2009; Cvijovic, 2009). 
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Co-use of garlic with NSAIDs (e.g. acetylsalicylic acid (Aspirin™), ibuprofen (Ibux™) etc.), 
anti-retroviral therapy or antidepressants have also been reported to give clinically relevant 
interactions (Ulbricht et al., 2008; Cvijovic, 2009). In addition to garlic, NSAIDs is known to 
interact with many herbs (i.e. ginkgo, ginger, bilberries, and ginseng). Another analgesics, 
paracetamol, showed decreased in vitro metabolism when co-used with Coriolus versicolor 
used in traditional Chinese herbal medicine (Abebe, 2002; Ulbricht et al., 2008; Yeung and 
Or, 2012). Keeping in mind that nearly half (44%) of the co-users used two or more herbs 
(polyherbacy), the risk of interactions or additive effects are present.  
 
5.1.6 Clinical consequences’ 
Although there are some characteristics of the co-users (female, elderly etc.) no specific 
variables can unfortunately be used by the GP to pin-point co-users. This is also the case for 
the comparable study (Giveon et al., 2004). The large portion of elderly patients and patients 
on anticoagulants co-using herbs is alarming since these groups are vulnerable to interactions 
(Loya et al., 2009). In addition the strong association for co-use with increasing age, 
polyherbacy and having one or more medical condition, calls for concern. These patients are 
at high risk for clinically relevant herb-drug interactions. Given the under-communication 
with GPs about co-use, it is difficult to prevent unwanted adverse effects and interactions. In 
order to monitor co-use, all GPs should ask their patients routinely to disclose their use of 
herbs. 
 
5.2 In vitro studies 
5.2.1 Herb selected 
AVJ is an old and a well-known herb and is approved by Norwegian Medicines Agency as 
herbal medicine against constipation (NoMA, 1999). In contrast to some other studies 
extracting an assumed active component from the herb (Ohta et al., 2002; Girennavar et al., 
2006), a “whole herb” extract from the AVJ was made to resemble the in vivo situation as 
much as possible. The AVJ was kept cold and dark to avoid any harmful degradation of the 
juice components during storage and was centrifuged to avoid aloe fibres. The supernatants 
were freeze dried to avoid degradation, and redissolved in water and a small amount of 
DMSO or ethanol as possible to solute the AVJ compounds. Ethanol were used in the CYP 
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assays because DMSO may inhibit CYP3A4 and CYP2D6 metabolism even at low 
concentrations (Busby et al., 1999). 
 
In Paper II two different AVJs were investigated because of the unlike compositions of the 
juice components depending on soil, harvest season, processing etc. The two juices, juice ‘A’ 
and ‘B’, and some of their compounds are illustrated in figure 11. It should be notice that the 
concentration of the presumed active components was different in the two commercially 
available products.  
 
5.2.2 CYP inhibition 
In Paper II we investigated the inhibition potential of two different AVJs, AVJ ‘A’ and AVJ 
‘B’, towards recombinant CYP3A4 or CYP2D6 metabolism of testosterone or 
dextromethorphan, respectively. KTZ or quinidine was used as positive inhibitor controls, 
respectively (McLaughlin et al., 2005; Zhou et al., 2005). The potential of AVJ to participate 
in a mechanistic based inhibition of CYP3A4 or CYP2D6 metabolism was explored. 
 
Apart from an Swedish report finding an small induction of CYP3A4 in vitro (Brandin et al., 
2007) and a publication of one single component in AV, rhein, inhibiting both CYP3A4 and 
CYP2D6 in vitro (Tang et al., 2009) no inhibition data have been published neither of other 
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Figure 11. Concentrations of some components in AVJ ’A’ and ’B’. Data from The Norwegian 
National Food authorities (Falch JB, 2000).  
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single constituents or of more complex AVJ extracts on CYP3A4 or CYP2D6 activities. Still, 
rhein is just one of several compounds in AVJ and whole herb AVJ extracts were investigated 
further for other inhibition patterns.  
 
Both AVJ ‘A’ and AVJ ‘B’ inhibited the CYP3A4 metabolism of testosterone with IC50 
values of 8.35±0.72 and 22.4±5.4 mg/ml, respectively. The IC50 values were, however, high 
and the AVJ ‘B’´s IC50 value was approximately 2-fold higher than for AVJ ‘A’. The 
difference was considered significant as no overlap was found in their 95% confidence 
intervals. This might be due to different levels of inhibitory compound(s) in the two AVJ 
extracts. The assumed main active constituent in AVJ, acemannan, is however, present in 1.5 
as high concentration in AVJ ‘B’ as in AVJ ‘A’, 2.98 and 2.03 mg/ml (Falch and Lorås, 
2000). Thus acemannan is probably not involved significantly in the CYP3A4 inhibition 
observed. The levels of rhein in AVJ ‘A’ or AVJ’ B’ are not known.  
 
Furthermore, the AVJs IC75/IC50 ratios were much lower than compared to the inhibitor 
controls` IC75/IC50 ratios indicating a steeper decrease in the AVJ inhibition curve witch 
might suggest a different inhibition mechanism of AVJ on CYP3A4 or CYP2D6 than by KTZ 
or quinidine, which are reversible CYP3A4 or CYP2D6 inhibitors (Bertelsen et al., 2003; 
Zhou et al., 2005).  
 
5.2.2.1 Mechanism-based inhibition  
To reveal if the AVJ inhibition of CYP3A4 and CYP2D6 is mechanism-based, NADPH-, and 
time-dependent characteristics must be fulfilled (Zhou et al., 2005). As AVJ ‘A’ was 
identified as the most potent inhibitor of both CYP3A4 and CYP2D6 activities, this product 
was used in the mechanism-based inhibition assays. 
 
AVJ caused a time-dependent decrease of both CYP3A4 and CYP2D6 activities when pre- 
incubated in the incubation mixture for increasing time intervals before substrate was added. 
A strong increase in CYP3A4 inhibition was seen after 15 min. of pre-incubation which gives 
a high initial inhibition velocity with a decline thereafter (exponential curve). The CYP2D6 
showed however a linear decline in activity when preincubated with AVJ. This might 
implicate different affinities of a reactive metabolite or constituent from AVJ for the two 
different enzymes (CYP apoprotein and/or haem) or different reactive metabolite/constituent 
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inhibiting either CYP3A4 or CYP2D6. The drug ethynylestradiol has been documented to 
modify both the haem and the apoprotein of CYP3A4 (Lin et al., 2002). Thus this might be 
the explanation of the rapid decline (90% inhibition) in CYP3A4 activity after 15 min 
preincubation with AVJ.  
 
Pre-incubation with NADPH gave a significant decrease in both CYP3A4 and CYP2D6 
activities. The conversion of the inhibitor, AVJ, to a reactive metabolite thus requires 
NADPH. Irreversible inhibitors require at least one CYP catalytic cycle to form a reactive 
metabolite which results in irreversible modification of the haem, the apoprotein or both, and 
thereby decreasing the amount of working CYP enzymes (Zhou et al., 2005). Hence, AVJ 
pattern of inhibition is consistent with mechanism-based inhibition (irreversible) for both 
CY3A4 and CYP2D6. In addition, significant reductions in CYP activity were also seen for 
both CY3A4 and CYP2D6 without the presence of NADPH. These might result from CYP 
degradation or inhibition of some other components formed in the incubation solution during 
the pre-incubation not requiring NADPH. 
 
5.2.3  P-gp inhibition 
In paper III, AVJ was evaluated for its inhibition potential on the efflux of digoxin (30 nM) 
by P-gp. As mentioned previously, an alteration in P-gp expression or efflux rate may change 
the drug bioavailability (Kannan et al., 2009). Another perspective to the inhibition studies is 
the increasing trend to optimize pharmacokinetics and drug delivery by identification of P-gp 
inhibitors as part in the identification of new effective cancer treatment (Varma et al., 2006). 
Such an inhibitor might be important in future chemotherapy and might as well as a drug, be 
an herbal remedy. 
 
AVJ did neither influence the A-B nor the B-A transport of digoxin at 90 min., thus no IC50 
value was achieved on P-gp transport of digoxin for this herb (Paper III). The Papp values for 
digoxin (control) at 90 min for the B-A transport was 6.5 x 10-6 cm/s and A-B transport 1.5 x 
10-6 cm/s corresponding earlier reported values (Xu et al., 2003). Digoxin is claimed to be a 
specific P-gp substrate (Fromm et al., 1999; Kim et al., 1999). However, organic anion 
transporting polypeptides (OATP, SLCO1A2) has lately been discussed to take part in the 
digoxin transport, but this has been falsified by a more recent report (Taub et al., 2011). Thus, 
digoxin has still the dominating role as substrate in P-gp inhibition assays on Caco-2 cells 
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(Zhou, 2008; Mease et al., 2012). Furthermore, was the digoxin transport inhibited by 80-90% 
by verapamil, the positive inhibition control, which was in agreement with most of the earlier 
reported values (Keogh and Kunta, 2006). Our Caco-2 cell system thus fulfilled the demands 
made by Hildalgo et al. (Hidalgo, 2001) and should hence make interlaboratory comparisons 
feasible. 
 
In addition, cell viability, integrity and toxicity screening were tested by TEER 
measurements, mannitol transport experiments and MTT-assay. Thorough quality screening 
of the Caco-2 cells as such has been emphasized by several authors (Artursson, 1991; 
Hidalgo, 2001; Shah et al., 2006). TEER was measured also immediately after ended transport 
assay and 88 % of the wells had TEER values > 200 Ω/cm2 also after the termination of the 
transport assay. These wells were included in the analysis. Although there are some 
interlaboratory variations in TEER measurements, our measurements were in line with other 
measurements preformed under similar conditions (Hidalgo et al., 1989; Markowska et al., 
2001). TEER measurements after the assay in addition to pre-incubation measurements 
secures a better quality control of the assay, and should be implemented as a standard control 
in all Caco-2 cell assays.  
 
Surprisingly, a statistically significant linear reduction in lactatdehydrogenase (LDH) 
activities was seen for digoxin concentrations ≥3 μM. Thus, a concentration of 30 nM could 
safely be applied on these cells. This has not to our knowledge been described previously. In 
addition gave AVJ a statistically significant decrease (38%) in LDH activity at 10.0 mg/ml 
compared to control, resulting in exclusion of AVJ concentrations above 1 mg/ml in the 
transport assay.  
 
5.2.4 Clinical consequences’ 
The in vitro AVJ ‘A’ or AVJ ’B’ IC50 values on CYP2D6 or CYP3A4 metabolism are 
presumably too high to imply any clinical drug metabolic interactions in vivo. However, 
intracellular inhibitor accumulations are shown (Di Marco et al., 2003), making an in vivo 
interpretation somewhat difficult. Since the most potent juice, AVJ ‘A’, had an IC25 value of 
4.7 mg/ml towards the CYP3A4 activity this might imply a possible in vivo metabolic 
interaction potential in the small intestines as the daily recommended intake of AVJ is as high 
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as 50 ml (Appiah-Opong et al., 2008). This can have implications on drug metabolism of 
CYP3A4 substrates like methadone (analgesics) or clopidogrel (anti-platelet agent).  
Clinical significant inhibition of CYP2D6 metabolism might occur in CYP2D6 poor 
metabolisers at high AVJ concentrations (> 10.0 mg/ml), leading to in vivo interactions, 
especially with drugs that have narrow therapeutic index e.g. tricyclic antidepressants (TCAs). 
However, these hypothetical interactions require a very high AVJ consumption and are not 
likely to take place in vivo.  
 
Our findings from a validated Caco-2 cell system showed no statistically significant inhibitory 
effects of AVJ on the P-gp mediated transport of digoxin, even though a wide range of 
anticipated relevant physiological concentrations of AVJ were tested. This might indicate that 
AVJ in clinically relevant concentrations, do not possess any significant inhibitory potency 
towards the P-gp mediated efflux transport of digoxin and similar P-gp substrates. 
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6 Summary of the results  
The questions in aims (Chapter 2) can now be answered.  
 
6.1 Co-use among GP patients 
The following questions were asked in regard to the study among GP patients in Norway:  
1. Do Norwegian GP patients use herbal remedies and if so, to what extent? 
 Yes, 44% of the GP patients used herbal remedies at the time.  
2. Are some herbs more commonly used than others? 
 Yes, bilberry, green tea, garlic, Aloe vera and Echinacea were the most 
commonly used herbs.  
3. Which motives do they have for use? 
 Over 70% did report to use herbs to improve the immune system.  
4. Do the patients disclose their herbal use to the GP or other health care providers? 
 No, few (25%) reported to use herbal remedies to their physician or other 
health care providers.  
5. Do any of the herb users also use conventional drugs on a regular basis; if so was there 
any difference between the drugs?  
 Yes, two of three herb users also used regularly conventional drugs (co-users). 
 Yes, a significant higher herbal use was reported by patients using analgesics 
(60%) or anticoagulants (36%).  
6. Which herbs and conventional drug combination can be identified, and are any of 
those at risk of being harmful to the patient? 
 Yes, 255 herb-drug-group combinations were identified and 18 these were 
considered to be clinically relevant in regard to interactions. Co-use of herbs 
like garlic, cranberry, ginseng, grapefruit and saw palmetto with anticoagulants 
or other cardiovascular drugs should be discouraged or closely monitored for 
adverse effects/INR. 
7. Do they experience any adverse effects of herbal use? 
 The 8 patients (7%) who reported adverse effects of herbs were all co-users 
(p=0.026). Abdominal symptoms (pain, diarrhea, emesis, 33%) or dizziness 
(22%) were the most common reported effects.  
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8. Is there any common characteristics of those who co-use herbs and conventional, 
regular drugs and can the GP use them to pin-point those at risk? 
 Yes, there were statistically significant increased odds for co-users to be 
female, increasing age above 50 years, using herbs to defeat an illness, 
polyherbacy, experience adverse effects of herb use and use of analgesics or 
dermatological drugs. 
 No, high co-use were also seen for other groups, and thus, the GPs are advised 
to ask all patients about herbal use.  
 
6.2 AVJ in vitro studies 
The questions addressed in the aims section for in vitro studies can now be answered:  
1 Is the Caco-2 cell model functioning in our laboratory as a reliable and reproducible 
system for evaluating P-gp transport and interactions? 
 Yes, our Caco-2 cells are in line with other laboratories with regards to 
transport linearity and cell integrity (mannitol and TEER). 
2 Is Aloe vera toxic to the Caco-2 cells? 
 No, AVJ is not toxic to the Caco-2 cells unless in extreme doses (>10 mg/ml). 
 Interesting finding was digoxin toxicity ≥3 μM. 
3 Does Aloe vera inhibit P-gp, if so to what extent? 
 No, P-gp was not inhibited by AVJ in the range investigated in vitro. 
4 Does Aloe vera inhibit CYP3A4, if so to what extent? 
 Yes, the AVJ inhibited CYP3A4. The IC50 values were, however, too high to 
imply any clinical AVJ-drug interactions in humans.  
5 Does Aloe vera inhibit CYP2D6, if so to what extent? 
 Yes, the AVJ inhibited CYP2D6. The IC50 values were, however, too high to 
imply any clinical AVJ-drug interactions in humans. 
6 Does Aloe vera inhibit CYP3A4 and CYP2D6 by mechanistic inhibition? 
 Yes, AVJ inhibited both CYP enzymes mechanistically. 
7 Is there a difference between different commercial Aloe vera juice products in their 
ability to inhibit CYP3A4 and CYP2D6 mediated metabolism? 
 Yes, the AVJ’A’ and AVJ ‘B’ showed statistically significant different 
inhibition potential towards both CYP3A4 and CYP2D6.  
8 Does Aloe vera possess a clinical relevant interaction potential towards other drugs? 
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 No, the AVJ must be considered as a weak inhibitor of both CYP3A4 and 
CYP2D6 because of the high IC50 values. AVJ co-use with drugs metabolised 
of both CYP3A4 and CYP2D6 with narrow therapeutic window (e.g. 
antidepressants) or a high AVJ consumption in CYP2D6 PMs may, however, 
have clinical implications. Even so, such extrapolations should be made with 
reservations.  
 
7 Conclusions 
It can be concluded that GP patients co-using drugs and herbs and that this use can give 
clinical relevant interactions (e.g. excessive haemorrhage when co-using garlic and warfarin). 
Elderly patients are most vulnerable for co-use. One of the common used herbs among GP 
patients, Aloe vera, was investigated for in vitro pharmacokinetic interactions on the enzymes 
P-gp, CYP3A4, CYP2D6. Although it was concluded with low possibility of clinical relevant 
pharmacokinetic interactions co-using Aloe vera and drugs, patients with poor CYP2D6 
activity might risk interactions when co-using large quantities of Aloe vera with conventional 
drugs which is metabolized of CYP2D6 (e.g. codeine). Clinical in vivo studies are needed to 
reveal any interactions in humans for Aloe vera and other herbs at risk of herb-drug 
interactions. Until then, the GPs and other health care professionals are advised to ask all 
patients about herbal use. 
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8 Further perspectives 
One of the outcomes of this thesis could have been advices to GPs about how they could 
identify co-users in a simple way. In paper I it was concluded that this was difficult because 
of  a general high co-use in all groups, and although women and elderly were more associated 
with co-use than others, these groups are to indistinct to be of any practical value. Because of 
the high prevalence of herb use and co-use of herbs and conventional drugs, the GP needs to 
ask all patients about herbal use.  
The number of included patients in paper I was too low to conclude with regard to any 
harmful herb-drug combinations. A larger multicentre cross-sectional questionnaire based 
study is thus needed to identify the most problematic herb-drug combinations as well as 
identify patient groups prone to co-use. The herb-drug combinations should again be 
investigated further both in vitro and in vivo for clinically relevant herb-drug interactions.  
As more and more of herbal remedies are investigated for in vitro drug interaction, the urge 
for in vivo studies is still present. Few clinical trials have been performed on herb-drug 
interactions in humans and most of them are of poor scientific value (small and not 
randomized). Aloe vera seems overall safe in regard to in vitro drug interaction from Paper II 
and III, although few other interaction studies have been made. The result of this thesis thus 
support that Aloe vera can be classified as possibly safe for oral administration for a brief 
period of use. However, a clinical trial with Aloe vera juice and conventional drugs (e.g. 
warfarin) should be performed to exclude any human clinically relevant pharmacodynamic or 
pharmacokinetic interactions. 
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10 Appendix 
 
 
 
 
 
 
 
1Senter: 0 2 Pasient nr:     
Bruk av naturmidler blant pasienter på et 
allmennlegekontor.
Praktisk om spørreskjemaet. 
Spørreskjemaet består av tre deler. I første del ønsker vi å få vite noe bakgrunnsinformasjon om 
deg. I del to spør vi om du bruker eller har brukt naturmidler. I siste del ønsker vi å vite litt om 
hvordan du og legen din forholder dere til naturmidler og hvorfor du bruker eller ikke bruker 
naturmidler. 
Spørreskjemaet du har fått utdelt kan du enten fylle ut med en gang eller hjemme hvis det passer 
deg bedre. Skjemaet behandles konfidensielt, men er spørsmålene vanskelige å forstå vil vi være 
behjelpelige med en forklaring. 
Når du er ferdig med skjemaet leverer du det i luka eller til legen. Vil du fylle ut skjemaet hjemme, 
kan du få med deg ferdig frankert konvolutt.  Spørreskjemaet ditt vil bli bearbeidet av Ane Djuv ved 
Det medisinske fakultet i Trondheim. 
Vennlig hilsen  
Ane Djuv 
2DEL 1: 
Bakgrunnsinformasjon om deg: 
Skjemaet ble utfylt:       
1. Kjønn: 
1  Mann 
2  Kvinne 
2. Hvor gammel er du?   
  År 
3.   Hvilken utdanning er den høyeste du har fullført? (Bare ett kryss)  
1  Grunnskole 7-10 år, framhaldsskole, folkehøgskole 
2  Realskole, middelskole, yrkesskole, 1-2 årig videregående skole 
3  Artium, gymnas, allmennfaglig retning i videregående skole 
4  Høgskole/universitet, mindre enn 4 år 
5  Høgskole/universitet, 4 år eller mer 
4. Hva slags arbeidssituasjon har du nå? (Bare ett kryss) 
1  I arbeid
2 Sykemeldt
3  Alderspensjon
4  Uførepensjon
5  Arbeidsledig, permittert 
6  Hjemmearbeidende/værende
Dato Måned År 
35.  Bruker du faste medisiner (eks. tabletter, stikkpiller, salver, plaster etc.)?
1  Ja 
2  Nei 
3  Vet ikke 
6.  Hvis du svarte ja i spørsmålet over (nr 5) bruker du noen av følgende medisiner 
nå (krysse av en eller flere):  
 Astma og/eller KOLS medisiner (eks. Seretide, Serevent, Symbicort, Atrovent, Ventolin) 
 Allergimedisiner (eks. Cetrizin, Livostin, Eurax, Flutide, hydrokortison, Locoid)  
 Blodtrykksenkende (eks. Selo-Zok, Metoprolol, Captopril, Amlodipin, Emconcor) 
 Blodfortynnende (eks. Marevan, Albyl-E, Plavix) 
 Mot høyt blodsukker (eks. Insulatard, Glucophage, Humalog, Actrapid, Metformin) 
 For stoffskifte (eks. Levaxin, Euthyrox, Liothyronin)  
 For reumatiske og/eller autoimmune plager (eks. Confortid, Prednison, Metotrexat) 
 Mot mage-tarm sykdommer (eks. Somac, Duphalac, Lactulose, Afipran) 
 Mot migrene, epilepsi, ADHD (eks. Imigran, Anervan, Zomig, Ritalin) 
 Medisin mot kreftsykdom (eks cellegift, Herceptin, Megace, Zoladex, Casodex)  
 Kolesterolsenkende (eks Simvastatin) 
 Hjertekramper/ angina (eks Nitroglycerin, Monoket)  
 Smerter (eks. Ibux, Paracet, Paralgin Forte, Voltaren, Napren-E, Nobligan, Tramadol) 
 Sterke smerter (Kodein, Dolcontin, Temgesic, Norspan plaster) 
 Overgangsalder (eks. Ovesterin, Activelle, Trisekvens, Eviana, Novofem) 
 Hudsykdom/plager (eks Betnovat, Daivonex, Neotigason, Diprosalic, Skinoren, Epiduo)  
 Øyedråper mot øyesykdom (eks. Pilokarpin, Betoptic, Spersallerg) 
 Antibakteriell-, antiviral-, antifungal behandling (eks. Indinavir, antibiotika, Canesten) 
 Beroligende og søvndyssende (eks. Vival, Valium, Sobril, Stesolid, Imovane, Stilnoct)  
 Anti-depressiva (eks. Cipramil, Cipralex, Seroxat)  
 Anti-psykotika (eks.Haldol, Risperdal, Nozinan, Clozapine, Trilafon, Cisordinol) 
 Antikonsepsjon (eks. P-piller (Yasmin, Microgynon), minipiller (Cerazette), p-ring) 
 Urinveis- og eller blæreplager (eks Proscar, Hiprex, Detrusitol, Vesicare) 
 Impotens (eks Viagra, Sildenafil) 
 Vanndrivende/ diuretika (eks. Furix, Centyl, Cozaar, Diovan) 
 Annet:_______________________________________________________________________
4DEL 2: 
7. Bruker du eller har du tidligere brukt noen naturmidler, generelt eller i 
forbindelse med sykdom?  
Kryss av for om du bruker naturmidlene nå (siste 7 dager), om du har brukt naturmidler tidligere 
(ved sykdom) eller om du ikke bruker. Før på flere hvis det er nødvendig. Bruk gjerne baksiden 
hvis det er nødvendig. 
*(eks.VitaePro, AvantGarden, Immunoplex, B17)
Jeg bruker nå 
(siste 7 dager)
Jeg bruker ikke nå, 
men har brukt 
tidligere  
Jeg bruker ikke nå, 
men har brukt 
tidligere (ved 
sykdom)  
Jeg bruker 
ikke 
    1  2  3  4 
Natto K2 
Agaricus 
Misteltein  
Noni juice 
Rosenrot 
Johannesurt 
Valeriana 
Haibrusk 
Aloe vera 
Grønn te 
Essiac 
Ginseng 
Ginko biloba 
Ingefær  
Solhatt 
Hvitløk 
Soyaekstrakt   
Tranebær 
Blåbær 
Epleeddik 
Q10 
GLA/nattlysolje 
Grapefrukt 
Multikosttilskudd/vitaminer * 
Annet:  
58. Om du bruker naturmidler nå, hvor ofte tar du naturmidlene? 
Kryss av for hvor ofte du bruker naturmidlene fra spørsmål 6: daglig, flere ganger i uken, ukentlig, ikke hver 
uke, men minst hver 14.dag, ikke hver 14. dag, men minst en gang i måneden, sjeldnere enn en gang i 
måneden eller periodevis. 
Naturmiddel: D
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  1  2  3  4  5  6  7 
Natto K2 
Agaricus 
Misteltein  
Noni juice 
Rosenrot 
Johannesurt 
Valeriana 
Haibrusk 
Aloe vera 
Grønn te 
Essiac 
Ginseng 
Ginko biloba 
Ingefær  
Solhatt
Hvitløk
Soyaekstrakt
Tranebær
Blåbærkapsler
Epleeddik
Q10
GLA/nattlysolje 
Grapefrukt  
Multikosttilskudd/vitaminer * 
Annet: 
*(eks.VitaePro, AvantGarden, Immunoplex, B17)
6DEL 3: 
Vi ønsker også å vite om du har snakket med legen eller annet helsepersonell om 
naturmidler.  Deretter ønsker vi å vite hvorfor du bruker/ikke bruker naturmidler og 
grunnen til at du begynte med disse. 
Er det liten plass under kategorien annet kan du fylle ut mer på baksiden av arket. 
9. Har du snakket med noe helsepersonell om å bruke naturmidler, i så tilfelle, 
hvem? (Sett kryss ved det eller de utsagn som passer best) 
1  Fastlegen  
2  Annen allmennpraktiserende lege 
3  Lege på sykehus eller annen helseinstitusjon 
4  Sykepleier 
5  Fysioterapeut/kiropraktor 
6  Tannlegen 
7  Annet helsepersonell:                                               .    
8  Jeg diskuterte det ikke med noen 
10. Hvordan var responsen fra helsepersonalet? (Bare ett kryss):
1  Oppmuntret meg til å bruke naturmidler 
2  Rådet meg mot å bruke naturmidler 
3  Advarte meg mot risikoen ved bruken av naturmidler 
4  Var nøytral/likegyldig 
5  Annet:                                                                .
6  Ikke aktuelt da jeg ikke har diskutert dette med noen 
11. Hvis du ikke snakket med noe helsepersonell om å bruke naturmidler, hva var 
årsaken? (Bare ett kryss) 
1  Jeg ble aldri spurt 
2  Jeg var redd for ikke å få forståelse for mitt valg 
3  Jeg var redd for at de kom til å bli misfornøyd 
4  Det er mitt valg, ingen andre trenger å vite noe 
5  Jeg var redd for å bli avvist 
6  Jeg vet ikke om naturmidlene har noen effekt 
7  Annet:                                                                .
712. Hvorfor bruker du ikke naturmidler (Sett kryss for det eller de utsagn som 
passer best.) 
1  Jeg har aldri vurdert det 
2  Jeg tror ikke det fungerer 
3  Legen min har sagt det ikke fungerer 
4  Jeg er fornøyd med den behandlingen jeg får 
5  Annet:                                                                .
Hvis du ikke bruker naturmidler kan du nå avslutte spørreskjemaet og levere det som 
beskrevet på første side. 
Bruker du naturmidler kan du fylle ut resten av spørreskjemaet. 
13. Hvorfor valgte du å begynne med naturmidler? (Sett kryss ved det eller de 
utsagn som passer best) 
1  Jeg fikk det anbefalt av venner/familie 
2  Jeg fikk det anbefalt av lege 
3  Jeg fikk det anbefalt i helsekostbutikk 
4  Jeg fikk det anbefalt i apotek 
5  Jeg leste om det i ukeblad/presse 
6  Jeg leste om det på internett 
7  Jeg fikk det forskrevet av en alternativ behandler 
8  Annet:                                                                .
14. Diskuterte du bruken av naturmidler med den/de du krysset av for under 
spørsmål 12? (Bare ett kryss) 
1  Ja 
2  Nei 
3  Ikke aktuelt 
815. Hva ønsker du å oppnå med å bruke naturmidler? (Sett kryss ved det eller de    
     utsagn som passer best.) 
1  Jeg håper det skal gi bedre leveutsikter 
2  Jeg prøver å bedre immunforsvaret 
3  Jeg har sykdom jeg ønsker å behandle 
4  Bedre enn ingenting 
5  Det hjelper mot smertene 
6  Det hjelper mot depresjon 
7  Annet:                                                                .
16. Har du opplevd ubehag som du tror kan skyldes naturmidlene du bruker? (Bare 
ett kryss) 
1  Ja 
2  Nei 
3  Ikke det jeg har lagt merke til 
17. Hvis du svarte ja på spørsmål 16, kan du beskrive det ubehaget du har 
opplevd? 
18.  Omtrent hvor store utgifter har du på naturmidler? 
 I løpet av siste måned:                                         Kr
 Gjennomsnitt pr måned:                _________       Kr
Du er nå ferdig med å svare på spørreskjemaet og kan levere det som beskrevet på 
første side. Tusen takk for hjelpen!
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Abstract 
Background 
Different patient groups are known to use herbal remedies and conventional drugs 
concomitantly (co-use). This poses a potential risk of herb-drug interaction through altering 
the drugs pharmacokinetics or pharmacodynamics. Little is known about co-use among 
patients in general practice. The primary aim of this study was to compare patients in general 
practise that co-use herbal remedies and conventional drugs with those who do not. The 
secondary aim was to register the herb-drug combinations with potential clinical relevant 
interactions among the co-users. 
Method 
A questionnaire based cross-sectional study conducted in the autumn 2011 in a general 
practice office with four general practitioners (GPs) and one intern in Western Norway. 
Adults >18 years who came for an office visit were invited. The questionnaire asked about 
demographics, herbal use, conventional drug use and communication about herbal use. 
Multivariable logistic regression was used to compare co-users to the other patients. 
Results 
Of the 381 patients who completed the questionnaire, the prevalence of herbal use was 43%, 
with bilberry (41%), green tea (31%), garlic (27%), Aloe vera (26%) and purple coneflower 
(18%) as the most frequently used. Among those using conventional drugs regularly, 108 
(45%) co-used herbs. Close to 40% of patients on anticoagulants co-used herbs, with garlic 
and bilberry as the most frequent herbs. Compared to all other patients, co-users had 
significantly (p<0.05) increased odds to be female (adjOR 2.0), age above 70 years (adjOR 
3.3), use herbs to treat an illness (adjOR 4.2), use two or more herbs (polyherbacy, adjOR 
3 
12.1) and having experienced adverse effects of herbal use (adjOR 37.5). Co-use was also 
associated with use of analgesics or dermatological drugs (adjOR 5.1 and 7.9 respectively). 
Three out of four patients did not discuss herbal use with any health care professional.   
Conclusion  
A sizable proportion of the GP patients co-used herbs with conventional drugs, also 
combinations with reported interaction potential or additive effects like anticoagulants and 
garlic. The low disclosure of herbal use to their GP, polyherbacy and the risk of interactions 
in vulnerable groups like elderly and chronically ill patients, warrant increased awareness 
among GPs. 
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Background 
In the last two decades there has been a considerable increase in the herbal remedy market [1, 
2]. Interactions between herbal remedies and drugs have been put on the agenda and received 
increased attention [3, 4]. Both serious and less serious adverse interactions have been 
reported e.g. between the drug cyclosporine and St. Johns wort (Hypericum perforatum), and 
between drugs like warfarin or aspirin which are reported to interact with a range of herbs like 
garlic (Allium sativum), cranberry (Vaccinium oxycoccos), Ginkgo Biloba, ginger (Zingiber 
officinale) and grape fruit (Citrus paradisi) [5-9]. Co-use of herbs and drugs might alter the 
drugs pharmacokinetics and/or pharmacodynamics, hence causing unexpected adverse 
effects of the drug [10-13].  
Studies have reported extensive use (40-56%) of herbs in the general population [14-16]. The 
2007 National Health Interview Survey, USA, reported that nearly 20% of the general 
population were using herbs [17]. The typical herb user was female, aged 30 to 69 years, with 
higher education or hospitalized in the last year [17]. Forty-one per cent of USA adults 
reported the use of herbal remedies to self-treat before seeking medical care from a physician 
[14].  
Only 50% of herb users inform their physician about it [14]. In addition, the health care 
professionals rarely ask the patients about the use of herbs or other types of complementary 
and alternative medicine [18]. The doctor did not ask is the common phrase explaining the 
lack of communication [19]. The general practitioners (GPs) also tend to underestimate the 
use [18]. It is therefore important to have knowledge about the characteristics of herb users in 
general and co-users in particular to make health professionals more aware. 
5 
It is reported that up to 40% in various patient groups co-administrate herbal remedies and 
drugs [20-22]. One study found that 40% of pregnant women used herbal remedies and about 
85% of these co-used conventional drugs [21]. The use of herbal remedies among adults with 
cancer is reported to be between 30-55% [15, 23] and one study found that almost 40% co-use 
herbal remedies and chemotherapy [24]. Elderly patients have more poly-pharmacy problems 
and are more vulnerable to interactions because of altered pharmacokinetics and decreased 
health in general [25]. Considering that 13-47% of elderly patients report to consume herbs 
[26, 27] and 31- 75% of these co-use herbs and prescribed conventional drugs [28, 29], the 
risk of adverse interactions might be high. About 50% of the general population have one or 
more chronic conditions and as the elderly, they have a high care rate and poly-pharmacy 
(50%) [30]. They also tend to use more herbal remedies, which increase the possibility of 
herb-drug interactions [31]. 
Despite the large reported use of herbs and co-use of herbs and conventional drugs in the 
general population and in various patient groups, few studies have been performed among 
patients in primary care and general practice in particular. About 40% of the patients in 
primary care clinics in USA believed that taking prescription medications and herbal remedies 
together was more effective than taking either alone and nearly 50% of the herb users co-used 
drugs [32]. An Israeli study on co-use among patients in general practitioners offices, 
reported 36% of herbal use and approximately 30 % were co-users [33]. GPs are the first 
medical contact within the health care system, dealing with all health problems both acute and 
chronic [34]. Given the nature of general practice, the few studies are somewhat surprising.  
6 
The primary aim of this study was to compare patients in a general practice in Norway that 
co-use herbal remedies and drugs with those who do not, with regards to demographics, types 
of drugs and herbs used, reason for use and communication with health care professionals 
about this use. The second aim was to register the herb-drug combinations with potential 
clinical relevant interactions among the co-users. 
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Materials and Methods 
This was a questionnaire based cross-sectional study. The survey took place in a general 
practitioners office with four GPs and one intern physician situated in the city centre of a 
middle sized town with nearly 70 000 inhabitants on the west coast of Norway. About 6000 
patients were on the GPs list at the time of the data collection. The data collection took place 
during 5 weeks in the autumn 2011 (2011.07.11-2011.12.15). The study was approved by the 
Regional Committee for Research Ethics in South-eastern Norway.  
Participants and recruitment  
The inclusion criteria were patients 18 years old or older, having an office consultation with a 
GP and who were able to read and understand the questionnaire.  
The questionnaire was first made available to the patients in the waiting area for self-
inclusion, but after a short time the recruitment was done by the staff in the reception. The 
reception staff was instructed to consecutively ask the patients who contacted them when they 
prior or after the GP consultation whether they would be interested in taking part in the survey 
and gave the questionnaire to those who said yes. It was not systematically registered how 
many said no, but according to the staff this was about half of the patients. The first page of 
the questionnaire informed the patient about the project, its objectives and the handling of 
their information. In addition, information was given on wall posters in the waiting area. The 
reception staff assisted the participants with the questionnaire whenever needed. The patients 
were asked to return the questionnaire to the reception or by mail in pre-addressed and pre-
paid envelopes. Their answers were anonymous. A completed questionnaire was interpreted 
as informed consent.  
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Questionnaire 
The questionnaire included questions about herbal use, drug use and communication about 
herbal use and was based on a questionnaire previously used among cancer patients in an 
outpatient clinic in Central Norway [24].  
The questionnaire was divided into three parts. The first part contained questions about 
demographic data (Table 1) and about conventional drugs used regularly from a predefined 
list of 25 drug-categories with possibilities to add other drugs (Table 3). The drug categories 
covered most of the regularly prescribed drugs based on data from the Norwegian Institute of 
Public Health and were exemplified with common Norwegian sales name to make them 
recognizable for the patients [35].  
The second part asked about herbal use from a predefined list of the 24 most common herbs 
sold in Norway and the frequency of use [36] (Table 2). In addition, supplements (i.e. 
multivitamins) and an extra space for other herbs were also included. Only those products 
defined as herbs (herbal substances, herbal preparations or herbal medicinal products) were 
included in the analysis [37]. Herb users were defined as those answering that they used herbs 
daily, weekly, monthly, less than monthly or periodically. Non-users were defined as those 
answering that they used herbs earlier or never used.  
In the last part of the questionnaire the communication between the patient and health care 
professionals, motives for use or no use and who recommended use of herbs were obtained 
(Tables 1 and 5). In addition, they were asked about any side effects of their herbal use and 
approximately monthly costs.  
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Statistics 
To find the total number of consultations in the GP practice during the 5 weeks data collection 
period, and the age and gender distribution of these patients, a report module of the electronic 
health record system was used (WinMed 2.12r Statistics, CompuGroup Medical Norway AS, 
Lysaker, Norway).
Pearsons Chi-square was used for bivariable analyses of categorical data, like the differences 
between users and non-users of conventional drugs. In analyses that included less than 5 cases 
in a cell, the Fisher exact test was used. For multivariable analysis to disclose any associations 
between co-users and other variables, binary logistic regression analysis (adjusted odds ratio, 
adjOR) was used. All variables with p-values <0.2 in bivariable analysis were included in the 
regression analysis. In addition a separate multivariable logistic regression model were used 
to compare co-users with drug only users including variables with a p-value <0.2 in the 
bivariable analyses of variables that both co-users and drug only users answered (from table 1 
and 3). P-values < 0.05 were considered as statistically significant. Tendencies were ascribed 
for p-values between 0.05 and 0.10. The statistics analysis was done using SPSS 19.0 (SPSS, 
Chicago, IL, USA).  
10 
Results 
The total number of patients having consultation in the GP office during the five weeks of 
data collection was 1652. Fifty-seven per cent of these were females. The average age was 
54.5 years, with 25% being 70 years old or above. The other age groups, grouped as shown in 
table 1, were evenly distributed in the range 13-17% of the total number patients.  
Four-hundred and two questionnaires were distributed and 381 were returned. Of the 381 
respondents, 67% were females, the average age was 52.5 years (SD=18.11, range 18-92) and 
20% were 70 years old or above (Table 1). About 35% had higher education and 61% were 
employed or on sick leave (off sick). Nearly two out of three (63%) used conventional drugs 
regularly. 
Nearly half of the patients used multivitamins or supplements (data not shown). A total of 164 
(43%) patients were currently using herbs, and there was a significantly higher proportion of 
women using herbs compared to men (51% of all female patients vs. 29% of all male patients, 
p<0.001). Elderly above 70 years old, had a  significant higher herbal use with 91% using 
herbs alone or co-using with drugs compared to the youngest patients (p<0.001). A total of 74 
(20%) of the patients were using two or more herbs (polyherbacy) and about 80% of those 
were women (p<0.001, data not shown). For the other demographic variables there was no 
significant differences with regard to herb use (data not shown).  
Among those using conventional drugs, 108 (45%) also used herbs (co-users). Significant 
differences were seen between the genders, age and occupational groups in regard to co-use of 
drugs and herbs (Table 1). Compared to men, females co-used significantly more drugs and 
herbs (18% vs. 34%, p=0.001). More than one of every three patients older than 50 years were 
11 
co-users and this was significantly more than for younger patients (p=0.008). Those employed 
co-used significantly less than those not employed (p<0.001).  
Friends or family were those most frequently recommending herbal use (68%), followed by 
magazines or internet (32%), the shop or pharmacy (29%, Table 1.). Significantly more of the 
co-users than non-co-users, used herbs with the intention to treat an illness (89% vs 11%, 
p=0.008). The most common reasons for no use were Never considered it (39%) and Do 
not believe in it/ Seems unsafe (32%). 
«TABLE 1 APROX HERE» 
Among those who used herbs, bilberry (Vacciunum myrtillus, 41%), green tea (Camelia 
sinensis, 31%), garlic (Allium sativum, 27%), Aloe vera (Aloe barbadensis, 26%) and 
Echinacea (Echinacea purpurea, 18%) were the most commonly used herbs (Table 2). For 
nearly all the types of herbs used, there were no significant difference between the types of 
herbs used when comparing those who co-used conventional drugs and those who did not use 
conventional drug. Among the five most commonly used herbs (18% or more of the users), 
those who co-used conventional drugs tended to use more Aloe vera than not conventional 
drug users (p=0.091). In addition, almost two of three (63%) of the polyherbacy patients were 
also using conventional drugs (p<0.001).  
«TABLE 2 APROX HERE»
For nearly all types of conventional drugs used there were no significant differences between 
herb users and non-users (Table 3). The only significant difference was higher use of herbs 
12 
among those using analgesics (60% used herbs vs 40% did not, p=0.031) or anticoagulants 
(36% used herbs vs 64% did not, p=0.043). 
«TABLE 3 APROX HERE»
A total of 256 different herb-drug combinations were registered (Table 4). Of these, 18 were 
identified of being at risk of clinical relevant interactions (in bold, Table 4.). 
Antihypertensives and diuretics were the largest drug categories in regard to number of 
combinations with different herbs (n=21) followed by analgesics (n=19), antihyperlipidemic 
agents (n=19) and thyroid- or antithyroid hormones (n=17) (Table 4.). Bilberry (n=21), green 
tea (n=20) and cranberry (n=20) were the herbs with the highest number of combinations with 
drugs. The most common combinations were seen between bilberry and antihypertensives 
(n=24), anticoagulants (n=18) or analgesics (n=15) (Table 4). Green tea and garlic had also 
high number of co-use for these drugs.  
«TABLE 4 APROX HERE»
Nearly 80% of the herb users did not discuss herbal use with any health care professional. The 
majority (80%) of those were co-users (p=0.104) (Table 5.). The most common health care 
professional the patients discussed their herbal use with was the GP (15%, data not shown). 
Of those discussing herbal use with their GP, about 80% were co-using conventional drugs 
(p=0.156). The response from the GP on disclosure of co-use differed from encouraging 
continued use (32%), neutral response (32%) and discouraged (14%) herbal use (p=0.815, 
data not shown).  
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Only non-co-users had been warned about risks with herb use (data not shown), while 83% of 
those being encouraged to continued use were co-users (p=0.463). The most common reason 
for no communication was I was never asked (45%, p=0.723).  
All of those who had experienced adverse effects of herbs were co-users (7%, n=8, p=0.020). 
The herbs most frequently used by those experiencing adverse effects were garlic (n=5), 
bilberry (n=4), green tea (n=4) and ginger (n=3). The most common drugs co-used with herbs 
of this group were anticoagulants (33%) sedatives (33%) and antihypertensives (22%). 
Abdominal pain, diarrhea and emesis (33%) or dizziness (22%) was the most common 
reported effects.  
«TABLE 5 APROX HERE»
Multivariable analysis 
A total of 17 variables were included in the binary logistic regression analysis comparing co-
users to all other patients. Of these, seven variables were significantly (p<0.05) associated 
with co-use of herbs and conventional drugs (Table 6), with an increased odds for co-users to 
be female (adjOR 2.0), above 70 years (adjOR 3.3), wanting to treat an illness (adjOR 4.2), 
using several herbs (polyherbacy, adjOR 12.1) and experience adverse effects (adjOR 37.5). 
Increased levels of co-use were also associated with use of analgesics or dermatological drugs 
(adjOR 5.1 and 7.9 respectively). Being between 40 and 49 years old decreased the odds of 
being a co-user (adjOR 0.2).  
«TABLE 6 APROX HERE» 
In the sub-analysis of co-user vs. drug only users, the model included gender, and use of 
anticoagulants, analgesics and dermal drugs (data not shown). Those who co-used drugs and 
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herbs tended (p<0.100) to be female (adjOR 1.9) and use analgesics (adjOR 1.7) compared to 
only drug users. 
Discussion 
A total of 29% of GP patients in this study co-used herbs and conventional drugs. The co-use 
was associated with female gender, increasing age above 50 years, using herbs to treat an 
illness, polyherbacy, use of analgesics or dermatological drugs and having experienced 
adverse effects from herbs. 
Strengths and limitations  
One of the limitations of this study was that it is a cross sectional study, meaning that no 
causal relationship can be identified. In addition, the study took place in one GP clinic in a 
middle sized town on the west coast of Norway. It thus might not be representative for other 
populations, but the patients visiting the practice are similar to other GP patients in Norway 
[38]. Although those taking part in this study were representative for all patients visiting the 
GP practice during the period of the survey, those using herbs might also be more positive to 
contribute to such a study than non-herb users. This would give an overestimation in the 
prevalence of herb users. However, this would also be the same for other studies investigating 
herbal use, and would not hamper the comparison with these. All data are self-reported and 
inaccuracies in the reported use of herbs and drugs must be taken into consideration. Still, the 
latter was minimized by handing out lists of the most common drugs in familiar groups with 
examples of the most common sales name of the different drugs.  
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Herbal use 
The prevalence of herbal use of 44% is somewhat higher compared to other findings from 
general practice/family doctors (22-36%) [32, 33]. Our prevalence is surprisingly close to the 
findings from a Norwegian cancer patient clinic where a similar questionnaire was used 
(46%) [24]. It is also in range of the prevalence of studies of the general population from 
other countries. The 2007 National Health Interview Survey, USA, reported of nearly 20% 
herbal use in the general population [17]. However, both the Czech and Saudi-Arabian 
population reports of higher herbal use (50-57%) compared to the USA population [29, 39]. 
Thus, the prevalence might vary between countries and ethnic groups [27].  
Few patients were recommended herbal use by the pharmacy or a physician. As reported by 
other papers, friends or family are the common sources for herbal recommendation or 
information [14, 23]. 
Bilberry, green tea, Aloe vera, garlic and Echinacea were the most commonly used herbs 
among the patients. Except from bilberry, all other herbs are also frequently reported by 
others [11, 17, 40, 41]. A sub-analysis of the reason for using bilberry revealed that it was 
used largely to strengthen the immune system (84% of bilberry user gave this as the reason). 
The use of bilberry might have been influenced by heavy marketing as a super-food [42].  
Overall, every third patient in this study co-used drugs and herbal remedies. Reported co-use 
from GPs offices in Israel in 2004 was lower (12%) [33], however, up-to-date numbers from 
GP practice are lacking. The co-use is in line with the co-use reported for patient groups like 
pregnant women (34%) and somewhat lower than reported for the cancer patients (30-55%) 
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[15, 21, 23]. Thus, our findings are in line with earlier reported co-use for patient groups, and 
the prevalence of co-use seems to be similar across different populations.  
Characteristics of co-users 
Based on the high co-use of drugs and herbs, drug users are at high risk of clinically relevant 
interactions [3, 43]. As expected, increasing age above 50 years was associated with a higher 
co-use compared to the younger patients in our study (nearly 40% of those >70 years old were 
co-users). Earlier studies report of co-use among elderly from 32-42% [25, 44, 45]. Cohen et 
al. found co-use of 24% among geriatric patients, and 52% of them co-using with 
anticoagulants [46]. Elderly patients are an exposed group because of increasing poly-
pharmacy, reduced general health and altered drug metabolism [25, 47]. They have a lower 
tolerance for alterations in the pharmacokinetics or pharmacodynamics, which might have 
serious consequences [3, 4, 8]. In addition, females, or those taking two or more herbs, were 
both significantly associated with co-use in this study. Females are reported in several other 
papers as the most common user of herbal remedies, thus not in particular as co-users [48].  
The most frequent co-use of drugs in this study was with bilberry, green tea, garlic, Aloe vera 
and cranberry. Bilberry is abounded of antioxidants and has been reported to have anti-
inflammatory activity [49]. A recent case report indicates an interaction between bilberry and 
warfarin that induces rectal bleeding[50], however, few interaction data are published on this 
herb. Thus, attention should be paid to the intake of bilberry in patients taking antiplatelet or 
anticoagulant drugs. Garlic might have antiplatelet activity and should thus, be used with care 
together with antiplatelet drugs like warfarin [11, 51]. Excessive bleeding has been reported 
in patients co-using warfarin and garlic, a patient group frequently using garlic [52]. Aloe 
vera might cause potassium depletion or affect cardiac glycosides and is advised not to be 
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used together with heart medication [11]. However, no in vitro or in vivo pharmacological 
interactions have yet been established [11, 53, 54]. Cranberry is reported to interact with 
warfarin, increasing International Normalized ratio (INR) values by 30% [9], but an 
randomized controlled trial concluded with minor risks for significant interactions in humans 
[55]. Some reports state, however, that garlic, green tea, Aloe vera and cranberry in general 
seem to have a low drug interaction risk [12, 55].  
Those on regular analgesics or dermal drugs were significantly associated with co-use. 
NSAIDs (i.e. Aspirin) is known to interact with many herbs (i.e. ginkgo, garlic, ginger, 
bilberry, ginseng) and a recent study shows decreased in vitro metabolism of paracetamol 
when co-used with Coriolus versicolor used in traditional Chinese herbal medicine [8, 56, 
57]. Keeping in mind that nearly all of the co-users used two or more herbs, the risk of 
interactions or additive effects are present.  
In the present study, herbal adverse effects were only reported by co-users (7%). In a recent 
paper from Beirut as much as 60% of the co-users reported some sort of adverse effects [58, 
59]. Although our reported prevalence is low, those reporting adverse effects were using 
herbs with reported additive effects (i.e. anticoagulants and garlic) [11]. Still, the numbers are 
too low to draw any firm conclusions.  
Herb-drug interactions at risk 
There were identified 256 different drug-group and herb combinations (Table 4). Of these, 18 
were identified of being at risk of clinically relevant interactions (in bold, Table 4.) on the 
basis of clinical trials, case reports or theoretical interactions extrapolated from clinical data 
[12, 60]. Anticoagulants (i.e. warfarin) were co-used with garlic (Allium sativum), cranberry 
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(Vaccinium oxycoccos), ginger (Zingiber officinale), ginseng (Panax ginseng), grape fruit  
juice (Citrus paradisi) and saw palmetto (Serenoa repens), all interacting with anticoagulants 
increasing the risk of adverse effects (i.e. increased haemorrhage) [6, 8, 9, 13, 20, 52]. 
Antihypertensives and diuretics were the largest drug categories in regard to number of 
combinations with different herbal remedies in the present study, having interaction potential 
with ginseng or grapefruit juice [8]. Ginseng is also reported to interact with antidiabetics, 
cardiac glycosides, antidiarrheal agents and antidepressants [8, 60]. Co-use of garlic with 
NSAIDs, anti-retroviral therapy or antidepressants have also been reported to give clinically 
relevant interactions [8, 60]. In general co-use of these herbs with anticoagulants or other 
cardiovascular drugs should be discouraged or closely monitored for adverse effects / INR 
[11, 52]. Co-use should especially be closely monitored or even discouraged among the 
elderly [61]. Anti-constipation drugs or antidiabetic agents should not be consumed with Aloe 
vera (Aloe barbadensis) because of additive effects and the same has been shown for 
valeriana (Valeriana officinalis) co-used with antidepressants [60, 62].  
The duration or amount of herb use and the way of administration of the herb (i.e. oral, 
topical) was not covered in this study and would have given us more information whether the 
herb-drug interaction was clinically relevant. Aloe vera used as juice ingested orally in large 
daily doses has a much higher interaction potential contra Aloe vera used topically against 
skin burns, although dermal absorption cannot be excluded. Some of the herbs are ingested as 
foods like garlic and grapefruit and will in general not be a problem, unless used in excessive 
amounts.  
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GPs needs to ask all patients 
The majority of herb users did not discuss their use of herbs with any health care professional 
and only 15% discussed herbal use with their GP. For those on conventional drugs, having a 
chronic illness and thus having a closer relationship to their GP, one should expect a higher 
willingness to share information about their herbal use. As the most common reason for not 
communicating about the subject is I was never asked, there are strong indications that 
patients are waiting for the GPs to be the one to take initiative in these matters. Although 
there are some characteristics of the co-users (female, elderly, use of certain drug groups etc.), 
there are unfortunately no specific variable that in our opinion can be used by the GP to pin-
point co-users. The GP should therefore routinely ask all their patients about use of herbal 
remedies in order to identify potential harmful co-use. 
Conclusion 
The high percentage of herbal co-use among patients using conventional drugs in general 
practice, and the relation between increasing co-use with increasing age and comorbidity, 
makes general practice an arena where co-use should be discovered. Given the under-
communication with GPs about co-use, it is difficult to prevent unwanted adverse effects and 
interactions. In order to monitor co-use, all GPs should ask their patients routinely to disclose 
their use of herbs.  
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Table1. Demographics of all respondents according to herb and drug use; comparison of conventional 
and non-conventional drug users among herbal users and non-herbal-users, and comparison of co-
users with non-co-users (N=381). 
Yes No 
Co-user 
Regular drug user Regular drug user 
n (%) 
Yes  No 
p-valueA
Yes  No  
p-valueA p-valueC(Co-
user) 
(Only 
herb 
user)
(Only 
drug 
user)
(Non-
user) 
Gender Male 124 (33) 18 % 11 % 0.551 39 % 32 % 0.085 0.001 B
Female 249 (65) 34 % 16 % 33 % 16 %
Age grouped <30 50 (13) 20 % 20 % <0.001B 18 % 42 % <0.001 B 0.008 B
30-39 58 (15) 24 % 21 % 24 % 31 % 
40-49 52 (14) 12 % 29 % 37 % 23 % 
50-59 65 (17) 34 % 15 % 34 % 17 % 
60-69 71 (19) 38 % 4 % 35 % 23 % 
>70 76 (20) 37 % 7 % 54 % 3 % 
Education
Compulsory 71 (19) 32 % 8 % 0.178 46 % 13 % 0.010 B 0.611 
Middle level 170 (45) 28 % 15 % 29 % 27 % 
University 129 (34) 26 % 18 % 36 % 20 %
Employment Employed/Off 
sick 233 (61) 21 % 20 % <0.001
 B 30 % 29 % <0.001 B <0.001 B
Disability or 
retirement 
pension 
129 (34) 40 % 5 % 47 % 9 % 
Unemployed/H
ome 12 (3) 58 % 17 % 8 % 17 % 
Herbal use Never 152 (40) 63 % 37 % 0.533 
Earlier 60 (16) 58 % 42 % 
Present  164 (43) 66 % 34 % 0.450 
Recommended to use 
herbs by (n=110)  D: 
Friends or 
family 75 (68) 61 % 39 % 1.000  
The Physician 5 (5) 80 % 20 % 0.647 
The shop or 
pharmacy 32 (24) 59 % 41 % 0.830 
Read about it in 
Magazines or 
internet 
35 (6) 69 % 31 % 0.401 
The alternative 
therapist 7 (32) 43 % 57 % 0.424 
Other 3 (6) 33 % 67 % 0.152 
Reasons for herb use 
(n=111) D: Better life 
expectancies 47 (3) 62 % 38 % 1.000 
Strengthen the 
immune system 79 (42) 58 % 42 % 0.391 
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Defeat an 
illness 18 (71) 89 % 11 % 0.008
B
Better than 
nothing 7 (16) 29 % 71 % 0.106 
Pain relief 4 (6) 50 % 50 % 1.000 
Other 3 (4) 100 % 0 % 0.280 
Reasons for not using 
herbs (n=177): Never 
considered it 69 (3) 51 % 49 % 0.002
 B
No 
need/satisfied 
with the 
treatment I get 
52 (39) 58 % 42 % 
Do not believe 
in it/ Seems 
unsafe 
56 (29) 80 % 20 % 
A P-value for comparison of conventional drug user with not conventional drug user. Analysed with Pearson Chi-Square or 
Fisher exact test. 
B p<0.05. 
C P-value for comparison of co-users with non-co-users. Analysed with Pearson Chi-Square or Fisher exact test. 
D Multiple answers were possible.
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Table 2. Types of herbs used and proportion of co-users of conventional drugs and herbs (N=164).  
Total use
Proportion of co-
users 
Herbs E n (%) p-valueA
Aloe veraF 42 (26) 55% 0.091 
Apple vinegar 10 (6) 70% 1.000 
BilberryG 68 (41) 68% 0.740 
Cranberry 26 (16) 77% 0.261 
Echinacea 29 (18) 55% 0.200 
Essiac 1 (1) 0% 0.341 
Garlic 44 (27) 61% 0.578 
Ginger 18 (11) 50% 0.186 
Ginkgo Biloba 4 (2) 100% 0.300 
Ginseng 15 (9) 67% 1.000 
GLA/Evening Primrose oil 8 (5) 50% 0.447 
Golden root 10 (6) 80% 0.497 
Grapefruit 13 (8) 46% 0.135 
Green tea 51 (31) 65% 0.860 
Misteltoe 1 (1) 0% 0.341 
Nattokinase 2 (1) 100% 0.548 
Noni juice 5 (3) 20% 0.047B
Soy 4 (2) 75% 1.000 
Valeriana 4 (2) 75% 1.000 
Others in totalC 15 (9) 67% 0.480
- Other: AnthocyaninD 4 (2) 75% 1.000
- Other: Saw Palmetto 2 (1) 100% 0.548
A P-value for comparison of co- users with herb users alone.  Analysed with Pearson Chi-Square or Fisher exact 
test. 
B Significantly different with p<0.05 
C Herbs added by the respondent to the open question about other herbs they used 
D Anthocyanin extracted from outer layers of bilberry and blackcurrant.  
E Herbs included in the questionnaire with no users: Shark cartilage and St. Johns wort. 
F May include either topical or oral Aloe vera use.  
G May include both bilberry (V. myrtillus) and/or blueberry (V.cyanococcus) due to confused with one another.  
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Table 3. Total number and proportion of herb users for the different drug categories (N= 239). 
Drugs (ATC group) Total n (%) Proportion of co-users p-valueA
Against gastrointestinal conditions (A01-09) 15 (6) 60% 0.288 
Analgesics (M01A, N02B) 55 (23) 58% 0.031B
Antibacterial, antifungal and antiviral (G01, J01-05) 2 (1) 50% 1.000 
Anticoagulants (B01) 88 (37) 36% 0.043B
Antidepressants (N06) 20 (8) 50% 0.815 
Antidiabetics (A10) 23 (10) 52% 0.515 
Antihistamines (R06) 25 (10) 32% 0.204 
Antihyperlipidemic agents (C10) 81 (34) 47% 0.784 
Antihypertensives and diuretics (C02-C03, C07-09) 107 (45) 45% 1.000 
Anti-menopausal and anticonceptives (G01-03) 21 (9) 48% 0.823 
Antirheumatic (L01, L04, M01-04) 28 (12) 39% 0.550 
Antiseizure, triptanes and central stimulating drugs 
(N02C, N03, N06B) 20 (8) 45% 1.000 
Chemotherapeutic drugs (L01-04) 5 (2) 60% 0.660 
Dermal drugs (D01-11, C05) 14 (6) 64% 0.171 
Drugs used against bladder and prostate disorders 
and impotence (G04) 11 (5) 55% 0.551 
Ocular drugs (S01) 9 (4) 44% 1.000 
Respiratory drugs (R01-05, 07, H02) 20 (8) 45% 1.000 
Sedatives and  Antipsychotics (N05) 39 (16) 49% 0.726 
Strong analgesics (N02A, N07BC) 3 (1) 33% 1.000 
Thyroids and antithyroids (H03) 26 (11) 54% 0.406 
Vasodilators and cardiac glycosides (C01) 5 (2) 60% 0.660 
Other drugs total 14 (6) 57% 0.413 
A P-value for comparison of herbal user or non-user for each drug category, analysed with Pearson Chi-Square or 
Fishers exact test if the number of total users was below five. 
B Significantly different with p<0.05 
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Table 4. Concomitantly use of herbs and conventional drugs. 
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Aloe vera 3A 6 1 2 2 5 5 7 3 2 2 2 2 2 4 1 4 1 2 19
Apple vinegar 1 3 1 1 1 1 1 3 1 1 1 2 2 13
Bilberry 4 15 1 18 5 5 4 2 24 1 5 4 2 3 1 2 4 8 6 2 4 21
Cinnamon 1 1 1 1 1 1 1 7
Cranberry 2 9 1 1 2 1 2 2 5 1 1 3 1 3 1 4 4 1 3 1 20
Echinacea 2 4 1 1 3 1 3 5 5 2 1 1 1 1 1 4 2 17
Garlic 2 8 1 9 3 4 3 7 11 2 3 3 2 1 3 6 2 2 18
Ginger 1 2 1 3 2 1 3 1 1 1 2 1 2 1 14
Gingko Biloba 2 1 2 1 1 2 2 1 8
Ginseng 1 1 1 1 2 1 1 3 2 2 1 1 1 2 1 15
GLA/Evening Primrose oil 1 1 1 1 1 1 1 1 1 9
Glucosamin 1 1
Golden root  2 4 1 1 2 1 1 2 3 2 1 1 1 2 2 2 16
Grapefruit 1 3 1 1 2 1 2 1 1 2 1 1 2 13
Green tea 4 11 1 7 5 5 5 8 11 4 5 3 2 2 1 1 3 6 4 6 20
Kan Jang 1 1 1 1 4
Medox 2 1 1 2 2 1 1 2 1 9
Nattokinase 1 1 2
Noni juice 1 1 1 3
Rosehip 1 1 1 1 1 5
Saw Palmetto 1 1 2 2 1 1 1 7
Soy 1 1 1 1 1 2 2 1 1 9
Valeriana 1 2 1 2 1 5
Xocai chocolate 1 1
Number of 
combinations 
13 19 10 13 13 14 16 19 21 11 14 13 2 7 5 12 12 10 1 17 2 12 256
A Bold numbers: Clinical relevant interactions documented in clinical trials, case reports or theoretical interactions 
extrapolated from clinical data. 
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Table 5: Communication with health care professionals, adverse effects and monthly costs of 
herbs among current herb users and proportion of co-users of conventional drugs and herbs. 
Total n (%) Proportion of co-users p-valueA
Communication about herb use with
(n=146):  C Physician
D 27 (18) 74% 0.269 
Other 10 (7) 80% 0.324 
Never discussed 113 (77) 59% 0.104 
The health care providers response to 
herb use (n=167): Not discussed 
134 (80) 63% 0.463 
Encouraged use 12 (7) 83% 
Discouraged useE 7 (4) 57% 
Neutral/indifferent 14 (8) 71% 
Reasons for never discussing herb 
use with health care professionals (n= 
110):
I was never asked 
50
(45) 56% 
0.723
Afraid of the responseF 23 (21) 65% 
Only my own concern/ 
confidential
34 (31) 62% 
Uncertain of the herbal 
effect
3 (3) 33% 
Experienced adverse effects of herbs? 
(n=120) 
Yes 8 (7) 100% 0.026B
No 112 (93) 61% 
 Costs of herb use per month (EuroG) Mean (SD, range) 36.6 (29.0, 0.4-205) 40.4 (34.8, 0.4-205) 0.337 
Cost range, NOK (Euro)  (n=88) 
1-199 (0.1-27.2) 24 (27) 71% 0.330 
200-399 (27.3-54.5) 47 (53) 57% 
400-599 (54.6-81.8) 9 (10) 56% 
>600 (>82.0) 8  (9) 88% 
A P-value for comparison of communication, motives for herbal use, adverse effects and costs between co-users 
of drugs and herbs and not co-users. Analysed with Pearson Chi-Square or Fishers exact test given the number 
of total users were below five. 
B Significantly different with p<0.05.
C Multiple answers were possible. 
D Includes GP, regular GP (family doctor) and hospital physicians. 
E A merge of the responses «warned about the risk and discouraged use. 
F A merge of the responses I was afraid of not getting acknowledgement for my choice, I was afraid they got 
dissatisfied and I was afraid of being rejected.  
G Converted from NOK to Euro. Exchange rate retrieved 23.11.2012 at 09.12 AM (1 Euro= 7.32 NOK).  
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Table 6. Adjusted odds ratio (adjOR) with 95% confidence intervals (95%C.l.) from 
multivariate regression models for co-use of herbal remedies and conventional drugs.
adjOR
95% C.I.
p-value ALower Upper
Gender Female vs male 2.0 1.0 4.0 0.043 B
Age grouped Age<30 vs: 0.000 B
- 30-39 0.8 0.3 2.6 0.715
- 40-49 0.2 0.0 0.9 0.034 B
- 50-59 1.3 0.4 3.8 0.665
- 60-69 2.8 1.0 8.3 0.058
- >70 3.3 1.2 9.3 0.023 B
Reasons for herb use Treat an illness 4.2 1.3 13.4 0.015 B
Drugs Analgesics 5.1 2.4 10.7 0.000 B
Dermatological drugs 7.9 2.0 30.8 0.003 B
Adverse effects of the herbal 
remedy
Yes vs No: 37.5 2.8 503.4 0.006 B
Polyherbacy None or one herb vs >2 
herbs:
12.1 5.8 25.4 0.000 B
A P-value for multivariable logistic regression with co-use as the dependent variable. Analyzed with regression 
analysis and Forward method in SPSS. 
B Significantly different with p<0.05.
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Aloe Vera Juice: IC50 and Dual Mechanistic
Inhibition of CYP3A4 and CYP2D6
Ane Djuv* and Odd Georg Nilsen
Norwegian University of Science and Technology – Cancer Research and Molecular Medicine, Trondheim, Norway
The aim of this study was to evaluate the inhibitory potency (IC50 values) of ethanol extracts of two commer-
cially available aloe vera juice (AVJ) products, on CYP3A4 and CYP2D6 activities in vitro and to determine if
such inhibitions could be mechanism-based. Recombinant human CYP3A4 and CYP2D6 enzymes were used
and the activities were expressed by the metabolism of testosterone and dextromethorphan with ketoconazole
and quinidine as positive inhibitor controls, respectively. The formed metabolites were quantiﬁed by validated
HPLC techniques. Time- and NADPH- dependent inhibition assays were performed to evaluate a possible
mechanism-based inhibition. One of the AVJ extracts showed about twice the inhibitory potency towards both
CYP enzymes over the other with IC50 values of 8.350.72 and 12.52.1mg/mL for CYP3A4 and CYP2D6,
respectively. The AVJ was found to exert both CYP mediated and non-CYP mediated inhibition of both
CYP3A4 and CYP2D6. This dual mechanistic inhibition, however, seems to be governed by different mecha-
nisms for CYP3A4 and CYP2D6. Estimated IC50 inhibition values indicate no major interference of AVJ with
drug metabolism in man, but the dual mechanistic inhibition of both enzymes might be of clinical signiﬁcance.
Copyright © 2011 John Wiley & Sons, Ltd.
Keywords: aloe vera juice; CYP3A4; CYP2D6; interaction; in vitro; IC50.
INTRODUCTION
The use of natural health products have increasing
popularity in the population and are often considered
safe and natural. In general about 30–40% of the popu-
lation is using alternative medicine at any time and the
large majority (50–90%) does not report their herbal
use to their physician (Bruno and Ellis, 2005; Giveon
et al., 2003). As many patients co-administrate pre-
scribed drugs and natural health products (Bruno and
Ellis, 2005) drug–herb interactions must be considered
a challenge, especially as several metabolic interactions
between drugs and common herbs are reported
(Ulbricht et al., 2008).
Aloe barbadensis (Miller), Aloe vera (AV), is an old
and common medicine plant used as a topical or oral
therapeutic agent against a variety of diseases as well
as a constituent in cosmetic products (Boudreau and
Beland, 2006). The majority of AV products are pro-
duced from the inner leaf gel of AV and purchased as
tablets (dried aloe gel), juices (AVJ) and puriﬁed gels.
It is claimed to have medical effects such as immunosti-
mulating, antitumor, antiinﬂammatory and antidiabetic
(Vogler and Ernst, 1999). The inner gel of AV consists
mainly of water and the remaining solid material
consists of polysaccharides, vitamins and minerals
(Boudreau and Beland, 2006). Acemannan, one of the
most abundant polysaccharides (>60% of solid matter),
is believed to be important for the immunostimulating
activity attributed to AV (Zhang and Tizard, 1996). In
addition, several other constituents ofAVhave been iden-
tiﬁed and claimed to have healing effects, i.e. Aloe emo-
din and rhein (Boudreau and Beland, 2006: Tang et al.,
2009). Quantitative variations, however, are found for
these constituents due to differences in harvest seasons
and growth location (Boudreau and Beland, 2006). Such
inter-herbal differences are also demonstrated for
Echinacea purpurea (Hansen and Nilsen, 2008; Modarai
et al., 2007) and Rhodeola rosea (Hellum et al., 2010).
Thus, more than one AV extract from different produ-
cers should be included in drug interaction studies.
According to a report (FY 2006/2007) from The Na-
tional Centre for Toxicological Research (NCTR) in
the U.S. Food and Drug Administration (FDA),
increased attention is needed to the escalating use of
AV both in cosmetics, dietary supplements and natural
medicines (Slikker, 2007). The International Aloe Sci-
ence Council (IASC) reports a multi-million dollar in-
dustry in growth (Rodriguez, 2004), and the potential
market is estimated to be around 10billion dollars.
Thus, a heavily growing market is assumed for this herb.
Apart from a Swedish report showing a small induc-
tion of CYP3A4 in vitro (Brandin et al., 2007) and a pub-
lication of one single isolated constituent of AV, rhein,
inhibiting both CYP3A4 and CYP2D6 in vitro (Tang
et al., 2009), no inhibition data have been published on
CYP3A4 or CYP2D6 activities either for other single
constituents or for more complex AVJ extracts. Data
from isolated herbal constituents, however, are often
not relevant for the inhibition potential of a more com-
plex extract from the whole herb as shown, for instance,
for grapefruit juice (Guengerich and Kim, 1990).
Cytochrome P450 (CYP) enzymes are predominantly
expressed in the liver, but also in the intestines, lungs,
placenta and kidneys. Although this class has more than
50 enzymes, six of them metabolize about 90% of all
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drugs, the two most signiﬁcant enzymes being
CYP3A4 and CYP2D6 (Lynch and Price, 2007) con-
tributing to about 40–45% or 20–30% of all phase-I drug
reactions, respectively (Ingelman-Sundberg, 2005; Lynch
and Price, 2007). Large variations in the CYP2D6-
metabolism are found, however, due to its genetic
polymorphism (Ingelman-Sundberg, 2005).
CYP enzymes can be inhibited or induced by drugs,
resulting in clinically signiﬁcant drug–drug metabolic
interactions that can cause adverse reactions or thera-
peutic failures (Pal and Mitra, 2006). The intake of
herbs during drug treatment has also been shown signiﬁ-
cantly to modulate drug metabolism and pharma-
cokinetics (Lynch and Price, 2007). However, our
knowledge in this area is still insufﬁcient.
Inhibition of CYP3A4 and CYP2D6 can both be re-
versible or irreversible (mechanism-based) in nature
(Zhou et al., 2005). A mechanism-based inactivation is
anticipated to be due to a formation of reactive metabo-
lites that bind covalently to the enzyme causing irrevers-
ible CYP inactivation (Zhou et al., 2005). Some herbal
products have been reported as mechanism-based
CYP inhibitors, e.g. grapefruit juice and medical plants
such as cinnamon (Cinnamomum burmani), fennel
(Foeniculum vulgare), true ginger (Zingiber cassumunar)
and a few isolated herb constituents such as bergamottin
and glabridin (Kent et al., 2002a) of CYP3A4; Greater
galangal/Thai ginger (Alpinia galangal), black pepper
(Piper nigrum) (Subehan et al., 2006) and Madagascar
Periwinkle (Catharanthus roseus) (Usia et al., 2005) of
CYP2D6. Thus CYP3A4 and CYP2D6 enzymes seem
to be vulnerable to irreversible inhibition by herbal
products and special interest should be paid to herbs
with high sale volumes.
The aim of this study was to evaluate the inhibitory
potency of ethanol extracts of two different AVJ pro-
ducts on CYP3A4 or CYP2D6 activities in vitro and to
compare IC50 inhibition values with those reported for
potent drug inhibitors. Furthermore, to determine if a
possible AVJ inhibition of these two CYP enzymes
could be mechanism-based.
MATERIALS AND METHODS
Chemicals and enzymes. CYP2D6 supersomesTM
(cat. no. 456217, lot no. 73755), CYP3A4 supersomes TM
(cat. no. 456202, lot no. 66311), NADPH-regenerating
system including Solution A [31mM NADP+, 66mM
glucose-6-phosphate and 66mM MgCl2 in H2O]
(cat. no. 451220, lot no. 71909/85424) and Solution B
[40U/mL glucose-6-phosphate dehydrogenase in 5mM
sodium citrate] (cat. no. 451200, lot no. 73022/85423)
were obtained from BD Biosciences (Woburn, MA
01801, USA). 6b-OH-Testosterone (purity≥97%, cat.
no. H2898, lot no. 22406011), ketoconazole (purity
98%, cat. no. K-1003, lot no. 121H0524), testosterone
(purity≥98%, cat. no. T-1500, lot no. 1166233
22406011), dextromethorphan (purity≥99%, cat. no.
D2531-10G, lot no. 044KI020), dextrorphan (purity≥
99%, cat. no. UC205-10G, lot no. 065K3257) and quini-
dine (purity≥98%, cat. no. 22600, lot no. 1295350) were
obtained from Sigma-Aldrich (St Louis, MO63178,
USA). 0.1M Potassium phosphate buffer (KPO-buffer,
pH 7.4) was made from KH2PO4 and K2HPO4 (Jansen
Chimica B-2440).
Herbal products. The Aloe vera juice (AVJ) ‘A’ (99%
pure Aloe vera containing ascorbic acid and potassium
sorbate. Batch no. 805) was a gift from Lusitania,
Primavida LDA (8501–915 Portimão, Portugal). AVJ‘B’
(99.5% Aloe vera juice made from the concentrate of
freeze-dried AVJ containing erythorbic acid, citric
acid, sodium benzoate, potassium sorbate. Batch no.
7863) was manufactured by American quality Aloe TM
(Missouri 65757, USA) and purchased in a local shop.
Herbal preparation. Tubes containing 30mL AVJ‘A’ or
AVJ‘B’ were centrifuged (3000rpm/805g) for 10min.
The supernatants were freeze-dried (70C), weighed
and resuspended in appropriate volumes (2.314mL or
3.589mL, respectively) of 1.9% ethanol solution to
make stock solutions (SS) of 270mg/mL. The ethanol
concentration used for dissolving AVJ was kept to a
minimum and the pH was adjusted by potassium hy-
droxide (KOH) to minimize a potential source of incu-
bation error from the low juice pH. Eight working
solutions (WS) [0.04, 0.40, 4.00, 20.00, 40.0, 80.0, 160.0
and 240.0mg/mL] were made from each SS by further
dissolving in 1.9% ethanol.
CYP3A4 assay. The CYP3A4 assay was performed as
described earlier by Engdal and Nilsen with some mod-
iﬁcations (Engdal and Nilsen, 2009). Incubations were
performed in KPO-buffer (pH 7.4, 0.1mM), to which
was added CYP3A4 enzyme (160mL, 50nM), testoster-
one (50mL, 0.8mM), solution B (20mL, 8U/mL) and
herb solutions (100mL AVJ extracts in six different con-
centrations). Incubations were performed at 37C and
initiated by adding 20mL solution A after a pre-incubation
period of 5min. All incubation solutions contained 0.4%
ethanol and 0.98% acetonitrile (for dissolution of testos-
terone) and a total incubation volume of 400mL (pH
7.4). Ketoconazole (KTZ) (100mL, 0.64mM/0.34mg/mL)
was used as a positive inhibitor control. After 10min
incubation, ice cold methanol (200mL) was used to stop
the reaction and the solutions were placed directly on
ice. All solutions were centrifuged at 3000rpm/805g
for 10min and the supernatants were transferred to
HPLC vials for analyses.
CYP2D6 assay. The CYP2D6 assay was performed as
described earlier by Hellum and Nilsen (2007). Incuba-
tions were performed in KPO-buffer (pH 7.4, 0.1mM),
to which was added CYP2D6 (80mL, 50nM), dextro-
methorphan (32mL, 0.1mM), solution B (20mL, 8U/
mL) and herb solutions (100mL AVJ extracts in six dif-
ferent concentrations). Incubations were performed at
37C and initiated with solution A after a pre-incuba-
tion period of 5min. All incubation solutions contained
0.4% ethanol with a total incubation volume of 400mL
(pH 7.4). Quinidine (100mL, 0.96mM/0.31mg/mL) was
used as a positive inhibitor control. After 25min incuba-
tion, ice cold acetonitrile (200mL) was used to stop the
reaction and the solutions were placed directly on ice.
All solutions were centrifuged at 3000rpm/805g for
10min and the supernatants were transferred to HPLC
vials for analyses.
HPLC analyses.Aliquots of 40mL were analysed for the
metabolite 6b-OH-testosterone by high pressure liquid
A. DJUVAND O. G. NILSEN
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chromatograph (HPLC) (Agilent Technologies, 1200
Series, column; Eclipse XDB-C18, 5mm, 4.6150mm)
using 40% methanol as the mobile phase. The ﬂow rate
was 1mL/min and the total run time was 25min. Detec-
tion of 6b-OH-testosterone was performed by UV at
240nm. The retention time was 21min.
Aliquots of 30mL were analysed for the metabolite,
dextrorphan, by HPLC as above, using 20% acetonitrile
and 80% 0.01M KPO-buffer (pH 3.4) as the mobile
phase. The ﬂow rate was 1mL/min and the total run
time 25min. Detection of dextrorphan was performed
using a ﬂuorescence detector with excitation and emission
wavelengths of 230 and 330nm, respectively. The reten-
tion time for the metabolite was approximately 4.3min
and for dextromethorphan approximately 21min.
The peak areas were used for quantitation of
metabolites.
Mechanistic inhibition. Time- and NADPH-dependent
inhibition assays were performed for AVJ‘A’ with a
method described previously by Hellum and Nilsen
(2007). In short, the time-dependent inhibition assay
was done by pre-incubating the incubation mixtures at
37C for 0, 15, 30 and 45min. The pre-incubation mix-
tures contained all the metabolic incubation constituents
and IC50 concentrations of AVJ‘A’ for CYP3A4 or
CYP2D6, respectively, but without substrates added.
After the pre-incubation period, the speciﬁc substrates
were added: testosterone (50mL, 0.8mM) or dextro-
methorphan (32mL, 0.1mM) to initiate the metabolic re-
action, and all incubation mixtures were incubated for
10 or 25min, respectively. The reactions were termi-
nated on ice by adding 200mL ice-cold methanol or
200mL acetonitrile, respectively.
The NADPH-dependent assay was performed by pre-
incubating as above with and without the presence of
the NADPH regenerating system for 0, 30 or 45min.
After pre-incubation, the NADPH regeneration system
was added to the tubes without NADPH. Substrate (tes-
tosterone or dextromethorphan) was added to all tubes
and incubated for another 10 or 25min. The reaction
was terminated on ice by adding 200mL ice-cold metha-
nol or 200mL acetonitrile, respectively.
Analytical validation. Calibration curves for 6b-OH-
testosterone consisted of seven calibration standards
(62.5–10000nM). The lower limit of quantiﬁcation
(LLOQ) was 62.5nM (CV 14.4%). The CVs of intra-
day assay precision were 1.5%, 2.2% and 1.3% at low
[75.0nM], medium [3.0mM] and high [6.0mM] concentra-
tions of 6-b-OH-testosterone, respectively (n=5), while
inter-day CVs were 5.2%, 4.3% and 3.1%, respectively
(n=15). The overall inaccuracy was less than 10.0%.
Calibration curves for dextrorphan consisted of seven
calibration standards (50–10000nM). The LLOQ was 50
nM (CV 2.3%). The CVs of intra-day assays precision
were 2.3%, 2.6% and 1.9% at low [50.0nM], medium
[800nM] and high [6000nM] concentrations of dextror-
phan respectively (n=5), while inter-day CVs were
2.3%, 3.1% and 3.1%, respectively (n=15). The overall
inaccuracy was less than 14.0%.
The calibration standards and QCs contained no CYP
enzyme as no extractions were necessary and no
disturbing peaks appeared from the incubated and
centrifuged AVJ samples.
Calculation of CYP activity. The basic (control) activ-
ities of CYP3A4 and CYP2D6 were determined on the
basis of the amount of metabolite (6b-OH-testosterone
or dextrorphan) that was formed after the 10min or 25
min incubation of substrate (testosterone or dextro-
methorphan) without the presence of inhibitor. Activity
was expressed in general as the amount of metabolite
formed (pmol) per pmol CYP enzyme and incubation
time (min) (pmolpmol1min1) or as a percentage
of the basic activity when an inhibitor was added.
Statistics.Data are presented as meanSD of three par-
allels. A two-sample t-test was used to test the effect of
herbal preparations and inhibitor controls on CYP3A4
or CYP2D6 enzyme activities and regression analyses
were used to estimate IC50 and IC75 inhibition values
from inhibition plots. The IC75/IC50 ratios were calcu-
lated. Conﬁdence intervals (95%) for all IC50 values
were estimated. A value of p<0.05 or non-overlapping
conﬁdence intervals were considered to be statistically
signiﬁcant. Statistical analyses were performed in
SigmaPlot 2004 version 11.0 (Systat Software, Inc. 225
W Washington Street, Suite 425, Chicago, IL 60606)
and Microsoft Excel 2003 (Microsoft Cooperation,
Redmond, WA, USA).
RESULTS
The basic (control) activities of CYP3A4 and CYP2D6
were 672.546.0 and 15.51.8 pmolpmol1min1,
respectively. Inhibitory plots of the positive inhibitor
controls KTZ and quinidine on CYP3A4 and CYP2D6
activities can be seen in Fig. 1 and the respective IC50
IC75/IC50 inhibition values are summarized in Table 1.
Both inhibition plots had signiﬁcant ﬁts (p<0.05) to all
experimental points, KTZ concentrations in the range
0.0064–2.0mM [0.0034–1.06mg/mL] and quinidine
0.0001–1mM [3.2105–0.32mg/mL].The IC50 inhibition
values for KTZ and quinidine were calculated with
95% conﬁdence intervals of [0.17, 0.40] and [0.025,
0.033] mM, respectively
Figure 2 shows the inhibition of CYP3A4 activity in
the presence of AVJ‘A’ or AVJ‘B’. Both preparations
inhibited the CYP3A4 activity at concentrations above
1mg/mL. The IC50 value for CYP3A4 inhibition by
AVJ‘A’ was calculated to 8.350.72mg/mL with a
95% conﬁdence interval of [6.94, 9.76] mg/mL. The
IC75/IC50 ratio was estimated to be 1.8. The IC50 value
for CYP3A4 inhibition by AVJ‘B’ was calculated to be
22.45.4mg/mL with a conﬁdence interval of [11.8,
32.9] mg/mL. The IC75/IC50 ratio was estimated to be
1.5. The 95% conﬁdence intervals for juice ‘A’ and ‘B’
did not overlap and the IC50 values were considered sig-
niﬁcantly different.
Figure 3 shows a reduction of CYP2D6 activity in the
presence of AVJ‘A’ or AVJ‘B’. The IC50 value for
AVJ‘A’ was calculated to be 12.52.1mg/mL. The
95% conﬁdence interval was [8.4, 16.6] mg/mL. The
IC75/IC50 ratio was calculated to be 2.1. An IC50 value
for AVJ‘B’ of 43.02.0mg/mL was found with a 95%
conﬁdence interval of [39.1, 46.9] mg/mL. The IC75/
IC50 ratio was calculated to be 1.2. The 95% conﬁdence
intervals for juice ‘A’ and ‘B’ did not overlap and the
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IC50 values were considered signiﬁcantly different also
for CYP2D6.
Figure 4A shows a time-dependent inhibition of both
CYP3A4 and CYP2D6 when pre-incubated with
AVJ‘A’. CYP3A4 showed an exponential decrease
(y=38.507x1.33, r2=0.953) in activity with increasing
pre-incubation time, while CYP2D6 showed a linear
reduction (y=0.7878x+35.9, r2=0.989) in activity. A
signiﬁcant (p<0.01) decrease in enzyme activity was
seen already after a pre-incubation time of 15min for
both enzymes. This reduction in activity was most
profound for CYP3A4 initially, switching to CYP2D6
at 45min where almost no activity was observed.
Figure 4B shows a decreased CYP3A4 activity when
AVJ was pre-incubated both in the absence and pres-
ence of NADPH. However, the inhibition was higher
in the presence of NADPH than without. The same
pattern can be seen in Fig. 4C for the pre-inhibition of
CYP2D6.
DISCUSSION
This study investigated the in vitro inhibitory potential
of crude ethanol extracts from two different commercial
types of AVJs towards CYP3A4 or CYP2D6 activities.
Also the potential of AVJ to participate in a mechanistic
based inhibition of CYP3A4 or CYP2D6 was explored.
The basic activities of CYP3A4 and CYP2D6 and the
inhibition of the added positive inhibitor controls,
KTZ and quinidine, showed a variation during the study
within 15%, which was in agreement with our pre-set
limits of variation. All analytical series were accepted
by simultaneously run QCs in duplicates at three differ-
ent concentrations.
One isolated constituent of AV, rhein, was shown
earlier to inhibit both CYP3A4 and CYP2D6 in vitro
(Tang et al., 2009). The reported rhein inhibition con-
stants (Ki) calculated for CYP3A4 and CYP2D6 were
30 and 74mM, respectively. The levels of rhein in our
AVJ‘A’ or AVJ‘B’ products, however, are not known.
Still, rhein cannot be excluded as a contributing factor
to some of the differences found between the two juices
in their inhibition potential of the two CYP enzymes.
Both AVJ‘A’ and AVJ‘B’ inhibited the CYP3A4 me-
tabolism of testosterone with IC50 values of 8.350.72
and 22.45.4mg/mL, respectively. The IC50 value of
AVJ‘B’ was more than 2-fold higher that of AVJ‘A’.
The difference was considered signiﬁcant as no overlap
was found in their 95% conﬁdence intervals. These dif-
ferences might be due to different levels of inhibitory
compound(s) in the two AVJ extracts different from
rhein. Although the assumed main active constituent
in AVJ, acemannan, is present in 1.5 times higher con-
centration in AVJ‘B’ compared with AVJ‘A’, 2.98 and
2.03mg/mL (Falch and Lorås, 2000), acemannan can
not be excluded as an inhibitory compound, because of
growth season variation.
Even AVJ‘A’ must be considered a weak inhibitor of
CYP3A4 when compared with similar extracts from other
herbs such as horse chestnut (Aesculus hippocastanum)
and Gingko biloba with IC50 values of 1.173 and 0.756
mg/mL, respectively (Hellum and Nilsen, 2008; McConn
et al., 2004). AVJ‘A’ and AVJ‘B’ exhibit IC50 values in
line with other weak CYP3A4 inhibitors as noni juice
and mistletoe (Engdal and Nilsen, 2009).
Both AVJ‘A’ and AVJ‘B’ inhibited the CYP2D6
metabolism of dextromethorphan with IC50 values of
12.5 and 43.0mg/mL, respectively. When compared with
IC50 inhibition values from similar extracts of other
herbs as St John’s wort at 67mg/mL or A. Grey (Heliopsis
longipes) at 9.9mg/mL (Hellum and Nilsen, 2007;
Rodeiro et al., 2009), the inhibition of AVJ is marginal.
Our knowledge on herb–drug interactions with regard
to CYP2D6 is limited. However, extracts from Candle
Figure 1. Inhibition of CYP3A4 (A) and CYP2D6 (B) by the positive
control inhibitor ketoconazole [0.0064–2.0mM] or quinidine
[0.001–1.0mM], respectively. All values are presented as meanSD
of three parallels. Curve fits, r2=0.995 or 0.998, respectively.
Table 1. Inhibition parameters of CYP3A4 and CYP2D6 activ-
ities for two different commercially available AVJ preparations
CYP3A4 CYP2D6
IC50
mg/mL)
IC75/IC50
ratio
IC50
(mg/mL)
IC75/IC50
ratio
AVJ‘A’ 8.350.72 1.8 12.52.1 2.1
AVJ‘B’ 22.45.4 1.5 43.02.0 1.2
Ketoconazolea 0.150.03c 2.0
Quinidineb 0.0090.0006d 2.9
Mean valuesSD are given for three parallels.
aPositive control inhibitor of CYP3A4.
bPositive control inhibitor of CYP2D6.
cCorresponding to 0.290.06mM.
dCorresponding to 0.0290.002mM.
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Bush (Cassia alata) leaves, Stonebreaker (Phyllanthus
amarus) leaves or common valerian (Valeriana ofﬁ cina-
lis) showed IC50 values of 165.57.50, 182.04.81 or
1660155mg/mL, respectively (Appiah-Opong et al.,
2008; Hellum and Nilsen, 2007). Thus the in vitro inhi-
bition potential of AVJ on CYP2D6 activity seems minor
when compared with that reported for other herbs.
The AVJs IC75/IC50 ratios were 1.8 or 1.5 for
CYP3A4 and lower than that of KTZ with an IC75/
IC50 ratio of 2.0. The same pattern was seen for the
IC75/IC50 ratios for CYP2D6. This demonstrates a
somewhat steeper decrease in the AVJ inhibition curves
with increasing concentrations of AVJ than by KTZ or
quinidine. This might indicate a different inhibition
mechanism of AVJ on CYP3A4 or CYP2D6 than by
KTZ and quinidine, respectively, which both are revers-
ible CYP3A4 or CYP2D6 inhibitors (Bertelsen et al.,
2003; Zhou et al., 2005). In addition, the IC75/IC50 ratios
of AVJ-A and AVJ-B are also different for CYP2D6,
which also might suggest different inhibition proﬁles.
Several herbs have been identiﬁed as mechanism-
based inhibitors of CYP3A4 or CYP2D6. To reveal if the
AVJ inhibition of CYP3A4 and CYP2D6 is mechanism-
based, NADPH- and time-dependent characteristics must
be fulﬁlled (Zhou et al., 2005). As AVJ‘A’ was identiﬁed
as the most potent inhibitor of both CYP3A4 and
CYP2D6 activities this product was used as an AVJ
model in the mechanism-based inhibition assays.
As shown in Fig. 4A, AVJ caused a time-dependent
decrease of both CYP3A4 and CYP2D6 activities when
pre-incubated in the incubation mixture for increasing
time intervals before the substrate was added. An expo-
nential time-dependent inhibition pattern of CYP3A4
was also found for the medical plant fennel, Foeniculum
vulgare (Subehan et al., 2006), and for grapefruit juice
(Chan et al., 1998). On the other hand, CYP2D6 had a
linear increase in inhibition as also found for melaleuca
(Melaleuca leucadendron) (Subehan et al., 2006) and
common valerian (Valeriana ofﬁcinalis) (Hellum and
Nilsen, 2007). This might implicate different afﬁnities
of reactive metabolite(s) or constituent(s) from AVJ
for CYP3A4 and CYP2D6 (CYP apoprotein and/or
haem) or different reactive metabolite(s)/constituent(s)
inhibiting either CYP3A4 or CYP2D6. Ethynylestradiol
has been documented to modify both the haem and the
apoprotein of CYP3A4, showing a linear inhibition
curve for CYP3A4 (Lin et al., 2002). In addition, ethyny-
lestradiol has demonstrated differences in its binding
to haem or apoprotein for different CYP enzymes (Kent
et al., 2002b). Thus the inhibition pattern for one com-
pound might vary between the CYP enzymes. The exact
mechanism for the CYP3A4 and CYP2D6 inhibition by
AVJ remains unclear, but it is probably different
mechanisms or inhibition patterns for the two CYP
enzymes.
As seen in Fig. 4B and C, the pre-incubation of AVJ
in the incubation medium with NADPH gave a signiﬁ-
cant decrease in both CYP3A4 and CYP2D6 activities.
The conversion of the inhibitor, AVJ, to a reactive metab-
olite thus seems to require NADPH as an electron-donor
to the CYP enzyme. Hence, the AVJ pattern of inhibition
is consistent with a mechanism-based inhibition (irrevers-
ible) for both CY3A4 and CYP2D6. However, signiﬁcant
reductions in CYP activities were also seen for both
CY3A4 and CYP2D6 when pre-incubated without the
NADPH regenerating system (Fig. 4B and C). These
inhibitions might come from other components formed
from AVJ during the pre-incubation not requiring
NADPH, thus a non-CYP mediated inhibition. A mech-
anistic AVJ inhibition of both CY3A4 and CYP2D6
might thus be of a dual nature.
Grapefruit juice (GFJ) is a well known mechanism-
based inhibitor of CYP3A4 (Chan et al., 1998). Its fura-
nocoumarin dimers have been found to be extremely
potent inhibitors of CYP3A4 activity (Row et al.,
2006). Bergamotti, another GFJ constituent, inhibits
CYP2D6 and is also identiﬁed as a weak inhibitor of
CYP3A4 (Tassaneeyakul et al., 2000). Thus herbal pro-
ducts are complex and made up of multiple chemical
compounds that might have interaction potential alone
or together. Studies in which pure isolated substances
are used do not include the complex nature of herbs
and make procedures and interpretations for the whole
herb complicated. By including total herb extracts of
AVJ and not isolated single components, a higher re-
semblance to the in vivo situation might have been
achieved.
The in vitro IC50 inhibition values of AVJ‘A’ and
AVJ‘B’ on CYP2D6 and CYP3A4 metabolism are high
and presumably too high to imply per se any clinical drug
metabolic interactions in vivo. However, high intracellular
herbal accumulations are shown (Di Marco et al., 2003),
Figure 2. Inhibition of CYP3A4 by AVJ‘A’ or ‘B’ [0.01–60mg/mL].
Testosterone [0.10mM] was used as a substrate. All values are
presented as meanSD of three parallels. Curve fits, r2=0.998
and 0.991 for AVJ‘A’ and ‘B’, respectively.
Figure 3. Inhibition of CYP2D6 by AVJ‘A’ or ‘B’ [0.01–60mg/mL].
Dextromethorphan [0.008mM] was used as a substrate. All values
are presented as meanSD of three parallels. Curve fits, r2=
0.998 and 0.987 for AVJ‘A’ and ‘B’, respectively.
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making an in vivo interpretation somewhat difﬁcult.
Since the most potent juice, AVJ‘A’, had an IC25 value
of 4.7mg/mL towards the CYP3A4 activity and the daily
recommended intake of AVJ is as high as 50mL (about
1000mg) (Organics Australia Online, 2009), this might
imply a possible in vivo CYP3A4 inhibition potential
in the small intestines. Clinical signiﬁcant AVJ inhib-
ition of CYP2D6 metabolism is not likely to take place
in vivo.
The dual mechanistic inhibition of both CYP3A4 and
CYP2D6 by AVJ might be of clinical importance as se-
vere drug toxicity has been observed as a result of irre-
versible inactivation of CYP3A4 or CYP2D6. This is
found for CYP3A4 inactivators such as erythromycin
or clarithromycin when they are co-administered with
terfenadine or astemizole (CYP3A4 substrates), causing
torsades de pointes (Zhou et al., 2005) or when quini-
dine or paroxetine is co-administered with codeine,
causing lack of analgesic effects. One case report is,
however, published on similar AVJ interactions between
sevoﬂurane and Aloe vera (Lee et al., 2004). According
to the paper, the interaction was most likely a pharma-
cological rather than pharmacokinetic interaction. Still,
another paper concludes that CYP1E1 is the key metab-
olizing enzyme of sevoﬂurane (Restrepo et al., 2009).
An interaction between CYP and AV can thus not be
excluded, and further investigation is needed.
Grapefruit juice is a more potent inhibitor of both
CYP3A4 andCYP2D6 thanAVJ, both enzymes probably
being irreversibly inhibited (Tassaneeyakul et al., 2000).
Grapefruit juice shows signiﬁcant clinical interactions
in humans with, for instance, cardiovascular medica-
tions, e.g. calcium-channel blockers (Ulbricht et al.,
2008). The combined mechanistic or dual mechanistic
inhibition of both CYP3A4 and CYP2D6 by AVJ
in vitro may thus also have some clinical relevance.
It is concluded that both the investigated AVJ products
are capable of inhibiting the metabolic activities of
CYP3A4 and CYP2D6, but to a different degree and
probably by different inhibition mechanisms. Further-
more, AVJ is involved in a dual mechanistic inhibition
of both CYP enzymes. Estimated IC50 inhibition values
indicate no major interference of AVJ with drug metab-
olism in man, but the dual mechanistic inhibition of both
enzymes might be of clinical signiﬁcance.
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The aims of this study were to carry out a thorough quality control setup for essential Caco-2 cell characteristics
in P-glycoprotein (P-gp) inhibition studies and to explore if Aloe vera juice (AVJ) inhibits the bidirectional
transport of the P-gp substrate digoxin (30 nM). Seven AVJ concentrations (0.00001-1.0 mg/mL), anticipated
to cover a clinically relevant range, were tested and digoxin apparent permeability coefﬁcients (Papp),
net Papp values (PappNet) and net ﬂux values (JNet) were calculated. Relevant validation parameters for P-gp
inhibition studies in Caco-2 cells are suggested to include, as a minimum, an assay linearity test with and
without a known P-gp inhibitor, cell cytotoxicity testing (MTT-test) for substrates and inhibitors, and cell
integrity testing by TEER and mannitol transport measurements. The question is also raised whether a
minimum effect of a reference P-gp inhibitor as verapamil should be demanded. Cell cytotoxicity was seen for
digoxin at concentrations ≥3 μM and for AVJ at 10 mg/mL. AVJ did not inhibit the P-gp transport of digoxin
in any of the concentrations tested. This indicates that AVJ is no inhibitor of the P-gp mediated transport of
digoxin in vitro if AVJ is present in clinically relevant concentrations. Copyright © 2008 John Wiley & Sons, Ltd.
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INTRODUCTION
Drug–herb interactions are an issue taken more and more
seriously. About 30% of the American adult population
is reported to use complementary medicine in general
and herbal remedies in particular. Herbs are frequently
taken together with conventional drugs by patients (28%),
and physicians often underestimate their patients’ use
of herbal remedies (Giveon et al., 2003). This is a chal-
lenge as adverse pharmacokinetic interactions between
drugs and common herbs are being discovered (Xu et al.,
2003; Pal and Mitra, 2006). Fortunately there are several
in vitro methodologies available for the evaluation of
such interactions.
Caco-2 cells derived from human colon carcinoma cells,
constitute a promising model for bi-directional transport
and interaction studies of P-glycoprotein (P-gp) drug sub-
strates (Artursson, 1991). This model seems suitable for
in vitro assays and has been shown to correlate with
in vivo controls (Artursson and Karlsson, 1991; Collett
et al., 2004). Despite this, Caco-2 cells form a heterogen-
eous cell population that is exposed to different growth
conditions which cause inter-laboratory variability (Shah
et al., 2006). A thorough quality control of the Caco-2
cells will, however, facilitate the possibility of comparing
data between laboratories (Hidalgo, 2001). An evaluation
of speciﬁc cell characteristics should thus be mandatory
for the use of Caco-2 cells in general and for P-gp
inhibition studies (Artursson, 1991; Hidalgo, 2001; Shah
et al., 2006).
Aloe barbadensis (Aloe capensis), Aloe vera (AV), is
an old medicine plant used as a topical or oral thera-
peutic agent against different skin diseases and illnesses,
and as a constituent in a myriad of cosmetic products
(Boudreau and Beland, 2006). Most AV products are
made from its ﬂeshy leaves containing aloe latex and
aloe gel. They are purchased as tablets (dried aloe gel),
juices and puriﬁed gels. The National Centre for Toxi-
cological Research (NCTR) in the U.S. Food and Drug
Administration (FDA) in their report (FY 2006/2007)
called attention to the increasing use of AV in cosmet-
ics, dietary supplements and natural medicine (Slikker,
2007). According to The International Aloe Science
Council (IASC), AV products are today converted for
over 125 million dollars per year, and the potential
market is estimated to be approximately 10 billion dol-
lars (Rodriguez, 2004). Thus, a heavily growing market
is assumed for this herb.
Apart from a case report suggesting a possible phar-
macodynamic interaction between AV and sevoﬂuorane
(Lee et al., 2004) and a very recent publication (Brandin
et al., 2007) indicating a minor induction of CYP1A2,
CYP3A4 and MDR1 in LS 180 cells, no data are available
on the drug interaction potential of AV. As 50% of all
marketed drugs are reported to be P-gp substrates (Keogh
and Kunta, 2006), and it is assumed that AV will become
widespread in the international market, the P-gp inter-
action potential of AV should be thoroughly evaluated.
The aims of this study were to carry out a thorough
quality control setup for essential Caco-2 cell charac-
teristics in P-gp inhibition studies and to explore whether
Aloe vera juice (AVJ) possesses any inhibitory effect on
the bidirectional transport of the P-gp substrate digoxin.
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MATERIALS AND METHODS
Cells and chemicals. Caco-2 cells were obtained from
the American Type Culture Collection (ATCC, Rockville,
MD, USA, cat.nr.HTB-37). L-Glutamine and fetal bovine
serum were obtained from Sigma-Aldrich (St Louis, MO,
USA). All tissue culture consumables were purchased
from Gibco BRL Life Technology (NY, USA) with
the exception of the trypsin/EDTA solution (PAA
Laboratories GmbH, Linz, Austria). Tetrasodium salt
(3-(4.5-dimethylthiazol-3yl)-2.5-difenyltetrazolium
bromide) (MTT) (cat. no: M-2128, lot nr: 044K5305),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), non-labelled digoxin (053K1529), phosphate
buffered saline (PBS) (lot no. 066K8205), verapamil
(cat no. V-4629) and dimethylsulphoxide (DMSO) (cat.
no. D-8418) were bought from Sigma-Aldrich (D-8418,
St Louis, MO, USA). Isopropanol was purchased from
Arcus Norway (L003133). Non-labelled mannitol was
obtained from Merck KGaA (Darmstadt, Germany).
Hank’s balanced salt solution (HBSS) was acquired from
Gibco BRL Life Technology (NY, USA). The following
radiolabelled compounds were used: 3H-digoxin (23.5 Ci/
mmol, 1 mCi/mL) (PerkinElmer cat. no. NET222; lot
no. 3559-502) (Wellesley, USA) and 14C-mannitol (54.9 μM;
1.20 μCi/mL) (American Radiolabeled Chemicals, St
Louis, MO, USA; cat. no: ARC 127A). The Optiphase
Supermix scintillation cocktail (PerkinElmer, Wellesley,
USA) was used for counting. Aloe vera juice (batch
no: 510, 2005) made from Aloe barbadensis, Asphodela-
ceae family, was a gift from Lusitania, Primavida LDA
(Portugal).
Cell culture. The human colon carcinoma cell line,
Caco-2, was cultured in DMEM (Dulbecco’s modiﬁed
Eagle’s medium) supplemented with 25% fetal bovine
serum, 1% nonessential amino acids, 2 mM glutamine,
10 μg/mL insulin and 1% penicillin/streptomycin. The
cells were seeded onto 24-well 6.5 mm Transwell plates
with 0.4 μm Pore Polycarbonate Membrane Inserts
(Corning Inc.) at a density of 0.4– 0.5 × 106/cm2 and for
transport studies. The culture medium was replaced
every 2 days. To prevent phenotypic drift only passage
35–40 were used.
Herbal speciﬁcations. AV has a high water content of
99–99.5%. The remaining solid material consists mostly
of polysaccharides, vitamins and minerals (Boudreau
and Boland, 2006). More and more of the components
in the AV are known. AV contains 75 potentially active
constituents: anthraquinones, saccharides, vitamins, amino
acids and enzymes (Vogler and Ernst, 1999). Acemannan
is one of the most abundant (>60% of solid matter)
and well known of the polysaccharides and is believed
to be important for the immunostimulating activity
attributed to AV (Zhang and Tizard, 1996). The con-
tent of acemannan in our native AVJ was 2.06 mg/mL.
Dissolution of AVJ and digoxin. A 30 mL daily dose of
AVJ was centrifuged (3000 rpm for 10 min) and the
supernatant was decanted and evaporated to dryness
(591 mg). The dried AVJ was then dissolved in a 0.8%
DMSO/water solution and sonicated for 10 min at room
temperature to make a stock solution of 197.10 mg/mL.
A dilution sequence was made of the stock solution
with 0.8% DMSO/water and equal volumes were added
to the HBSS buffer to achieve seven different AVJ
concentrations in the range from 0.97 mg/mL to 0.97 ×
10−5 mg/mL or approximately 1.0 mg/mL to 1.0 × 10−5 mg/
mL. The concentration of DMSO in all ﬁnal study solu-
tions was 0.04% (v/v). The addition of AVJ caused the
HBSS/HEPES buffer pH to decrease from pH 7.4 to
pH < 5.0. To minimize the confounding effects of the
low juice pH, the solutions were pH adjusted (Neuhoff
et al., 2005).
To achieve a satisfactory dissolution of non-labelled
digoxin in the cytotoxicity assay (30 nM–5 μM) and of
3H-labelled digoxin in the transport assays (30 nM),
the two ﬁnal study solutions contained 7.0% and 0.6%
(v/v) of ethanol, respectively.
Cell viability. In vitro cytotoxicity of AVJ and digoxin
were determined by the tetrasodium salt colorimetric
assay (MTT). MTT is converted to formazan crystals
by mitochondrial lactate dehydrogenases (LDH) in
living cells. The measured absorbance of formazan at
570 nm, is thus proportional to the number of living
cells (Mosmann, 1983). Caco-2 cells (passage 39) were
seeded onto two 24-well plates at a seeding density of
0.06 × 106/cm2 and incubated with 500 μL of DMEM
culture medium in 5% CO2/95% air at 37 °C for 72 h.
The culture medium was exchanged by 500 μL of AVJ
or digoxin ﬁnal study solutions and the cells were in-
cubated for 90 min at 37 °C. The 500 μL ﬁnal study
solutions were replaced by 250 μL MTT (5 mg/mL)
and incubated for 40 min at 37 °C. After removal of
the MTT solutions, the cells were washed twice with
500 μL cold PBS (4 °C). DMSO (>99.9%) (150 μL)
was added to each well for extraction of the formazan
product. The 24-well plates were placed on a shaker
for 30 min at 37 °C to dissolve the formazan crystals.
One hundred microlitres of extract was added to 10 μL
isopropanol to avoid bubbles, and the optical density
was measured at 570 nm in a Titrek Multiscan Plus
MK II spectrophotometer.
Cell integrity. The cells were cultured for 21–22 days
before the medium was replaced with HBSS/HEPES
buffer (pH 7.4, 37 °C). TEER (transepithelial electrical
resistance) values were measured (Fluke 83 Multimeter)
before and after the transport assay. Only Caco-2 mono-
layers with TEER ≥200 Ω/cm2 were included in the re-
sults (Artursson, 1991). 14C-mannitol (55 μM) was added
to the apical side (250 μL) during the transport assay to
measure cell integrity (Artursson et al., 1994). Mannitol
Papp A–B values <1.0 × 10−6 cm/s were accepted.
Bidirectional transport studies of digoxin. 3H-digoxin
dissolved in HBSS/HEPES buffer (30 nM, 23.5 Ci/mmol)
was added to the donor side (250 μL on apical side and
500 μL on basolateral side) of the Caco-2 cell monolayer in
the presence of test compounds under sink conditions.
The digoxin transport was measured up to 180 min in
apical to basolateral (A–B) and basolateral to apical
(B–A) directions. Verapamil (100 μM) dissolved in HBSS/
HEPES buffer was used as a positive inhibitor control
(Lin, 2003) also under sink conditions. Seven different
AVJ solutions were added bilaterally. Samples of 100 μL
were collected from the receiver chambers and analysed
by scintillation counting (Beckman LS6500 Multi-Purpose
Scintillation Counter). The differences in volumes on
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the apical (250 μL) and basolateral (500 μL) sides were
corrected for in the calculations.
Scintillation counting. Analysis of 3H-digoxin was per-
formed by liquid scintillation counting (10 min, Beckman
LS6500 Multi-Purpose Scintillation Counter) with a count-
ing efﬁciency (CE) of 26%. Counts per minute (cpm)
were converted to amount (mol) of digoxin by Equation
(1), where Bq is the background count, SA (dpm/mol)
is the speciﬁc activity of the labelled digoxin, CE (cpm/
dpm) is the counting efﬁciency and Vr/Vs is the volume
correction for the volume in the receiver (Vr) chamber
and the sample volume (Vs):
Amount (mol)
of digoxin
(   )
=
−
× ×
CPM Bq
CE SA
V
V
r
s
1
(1)
Transport parameters. Apparent permeability coefﬁcients
(Papp) of digoxin were determined according to:
Papp
Q
t A C
     ( )= ×
⋅
d
d
cm/s
1
0
, (2)
where dQ/dt is the transport rate of digoxin (nmol/s),
C0 the initial concentration of substrate in the donor
chamber (nmol/cm3) and A is the surface area of the
monolayer (cm2) (Artursson, 1991).
Papp ratio for digoxin was calculated as:
R
Papp
Papp
B A A B
B A
A B
− −
−
−
=/ (3)
and the net digoxin Papp as:
PappNet = PappB–A − PappA–B (4)
The net digoxin ﬂux (JNet) was calculated according to:
JNet = JB–A − JA–B (nmol/h/cm
2), (5)
where the digoxin ﬂux, J, is equal to 
d
d
Q
t A
×
1
 (nmol/h/
cm2).
Statistics. Statistical analysis was calculated by Microsoft
Ofﬁce Excel 2003. All data are given as mean ± stand-
ard deviation (SD) of 3– 4 replicates. Differences be-
tween groups were analysed by a two-sample Student’s
t-test. Values of p < 0.05 were considered statistically
signiﬁcant. Least square regression lines were considered
to ﬁt linearity at p values <0.05.
RESULTS
The basic transport characteristics of digoxin (30 nM) in
the Caco-2 cell system are shown in Fig. 1, with or without
the presence of the P-gp inhibitor verapamil. A linear
accumulation (0.966 < r2 < 0.998, p < 0.05) of digoxin
with time was obtained in the receiver chamber up to
180 min in all cases. Mean experimental Papp values
of 1.40 ± 0.06 × 10−6 and 5.82 ± 0.51 × 10−6 cm/s were
obtained for digoxin alone in the A–B and B–A
directions, respectively. Furthermore, a mean Papp ratio,
RB–A/A–B, a mean net Papp, PappNet, and a mean net ﬂux,
JNet of 4.15 ± 0.24, 4.42 ± 0.46 × 10−6 cm/s and 0.65 ± 0.06
× 10−3 nmol/h/cm2, respectively, were calculated. The
introduction of verapamil (100 μM) increased (p < 0.001)
the digoxin mean Papp (A–B) by 33% and decreased
Figure 1. Transepithelial transport of digoxin (30 nM) across the
Caco-2 cell monolayer measured in the apical to basolateral
(A–B) and basolateral to apical (B–A) directions as a function
of time, with or without the presence of the P-gp inhibitor
verapamil (100 μM). Data are presented as mean ± SD of three
to four replicates.
(p < 0.001) the digoxin mean Papp (B–A), mean RB–A/A–B,
mean PappNet and mean JNet by 61%, 70%, 90% and
89%, respectively, as expected from a strong experi-
mental P-gp inhibitor. The inhibiting effect of verapamil
on digoxin transport was constant over a range of
50– 400 μM (data not shown). Based on these results,
a 90 min transport time and a 100 μM concentration
of the P-gp inhibitor verapamil were selected for the
remaining part of the study.
TEER values were measured for the B–A direction
before and after the transport assay. All cells included
in the transport assay calculations had TEER values
≥200 Ω/cm2. About 88% of the wells had TEER values
≥200 Ω/cm2 after the termination of the transport assay.
The mean values for digoxin alone (control, 30 nM), in
the presence of the P-gp inhibitor (verapamil, 100 μM)
or in the presence of AVJ (0.00001 to 1.0 mg/mL) were
291, 286 and 230 Ω/cm2, respectively. Mannitol trans-
port (Papp) ranged from 2.0 × 10−8 to 3.0 × 10−10 cm/s
for cells with TEER values ≥200 Ω/cm2.
In Fig. 2a, the LDH activity showed a statistically signi-
ﬁcant linear decrease (y = −0.252x + 1.466, r2 = 0.994,
p < 0.05) with increasing concentrations of digoxin. At
5 μM a 61% decrease in LDH activity was found com-
pared with the control. However, no effect on the LDH
activity was observed at 30 nM. Figure 2b shows that
the LDH activity in the Caco-2 cells was not affected
by any of the AVJ concentrations added, with the
exception of the highest (10.0 mg/mL). The reduction
in LDH activity at this concentration compared with
the control was 38%. Solvents present in the incuba-
tion medium (7.0% ethanol or 0.04% DMSO) did not
inﬂuence LDH activity (data not shown).
The effects of different concentrations of AVJ on
the bidirectional 90 min transport of digoxin, expressed
as Papp values, are shown in Table 1 and Fig. 3a. AVJ
caused no statistically signiﬁcant change in the Papp
values of digoxin in either direction in the investigated
range, while the positive inhibitor control conﬁrmed
cell functionality. The mean digoxin Papp ratio (RB–A/A–B)
for all AVJ concentrations was calculated as 4.01 ± 0.20
compared with 3.82 ± 0.30 for the digoxin control and
1.33 ± 0.10 for verapamil.
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Figure 2. LDH activity in Caco-2 cells after addition of different
concentrations of (a) digoxin (30.0 nM–5.0 μM) or (b) AVJ
(0.00001–10.0 mg/mL). LDH activity is measured after a 90 min
incubation period. Data are presented as mean ± SD of three to
four replicates. * p < 0.05.
Figure 3b shows the corresponding net digoxin ﬂux
(JNet) and net digoxin Papp (PappNet) values after addi-
tion of the different AVJ test solutions. None of these
digoxin transport parameters were affected statistically
signiﬁcantly by any of the AVJ concentrations applied,
Table 1. Bidirectional transport of digoxin across the Caco-2
monolayer in the presence of AVJ
Papp (cm/s) × 10−6
Test compound A–B B–A
Controla 4.69 ± 0.23 17.85 ± 1.39
AVJ 0.00001 mg/mL 3.73 ± 0.38 16.66 ± 0.25
AVJ 0.0005 mg/mL 4.88 ± 0.26 19.50 ± 0.57
AVJ 0.0001 mg/mL 4.79 ± 0.38 18.76 ± 0.57
AVJ 0.001 mg/mL 4.89 ± 0.54 19.42 ± 1.31
AVJ 0.010 mg/mL 5.06 ± 0.23 19.77 ± 2.84
AVJ 0.100 mg/mL 5.14 ± 0.29 19.91 ± 0.46
AVJ 1.000 mg/mL 5.04 ± 0.60 19.98 ± 1.32
Verapamilb (0.049 mg/mL) 8.03 ± 0.30 10.57 ± 0.41
a Digoxin alone
b Verapamil (100 μM) is added as a positive inhibitor control of
P-gp. * p < 0.05.
Figure 3. Effects of AVJ (0.00001–1.00 mg/mL) on the transe-
pithelial transport of digoxin (30 nM) in Caco-2 cells expressed
as (a) Papp values and (b) JNet (left y-axis) and PappNet (right
y-axis). Control: digoxin alone. Verapamil (100 μM): is added as
a positive P-gp inhibitor control. Data are presented as mean ±
SD of three to four replicates.
while verapamil reduced (p < 0.001) both parameters
by 89% and 81%, respectively, when compared with the
control. The mean net digoxin ﬂux, JNet, was 1.58 ± 0.12
× 10−3 nmol/h/cm2 when co-incubated with AVJ, while the
control (digoxin alone) was 1.43 ± 0.14 × 10−3 nmol/h/cm2.
The digoxin JNet in the presence of verapamil was 0.29
± 0.07 × 10−3 nmol/h/cm2. The mean digoxin Papp value,
PappNet, was 14.60 ± 1.09 × 10−6 cm/s, when co-incubated
with AVJ, while the control and verapamil showed values
of 13.18 ± 1.34 × 10−6 cm/s and 2.62 ± 0.66 × 10−6 cm/s,
respectively.
DISCUSSION
A high inter-laboratory heterogeneity has been reported
for Caco-2 cells since the discovery (1975) that these
cells are a good P-gp screening model for drug–drug
interactions (Hidalgo, 2001; Markowska et al., 2001).
According to Hildalgo et al. investigations of the substrate
transport at regular time intervals, demonstrating lin-
earity, A–B and B–A differences and positive inhibitor
effects as shown in Fig. 1, can be one way to facilitate
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comparisons with other laboratories, and to show cell
compatibility. The Papp values for digoxin were ob-
tained at 90 min for the B–A transport as 6.5 × 10−6 cm/s
and A–B transport as 1.5 × 10−6 cm/s. This corresponds
to earlier studies (Xu et al., 2003). The positive inhibi-
tion control, verapamil, inhibited the digoxin net ﬂux
(JNet) by 80–90%. This is in agreement with most of
the earlier reported values (Keogh and Kunta, 2006).
Our Caco-2 cell system thus fulﬁls the demands made
by Hildalgo (2001) and should hence make inter-
laboratory comparisons feasible.
The reported range for verapamil inhibition of P-gp
in the literature is, however, quite wide from almost
100% inhibition (Collett et al., 2004) down to 37–41%
inhibition (Balimane et al., 2004). These variations be-
tween laboratories might indicate that verapamil is not
a complete inhibitor of P-gp. Or, that this variation is
due to inter-laboratory differences in Caco-2 cell quali-
ties that will inﬂuence also the inhibition potency of
other P-gp inhibitors. This raises the question whether
a lower limit of verapamil inhibition should be intro-
duced for an acceptance of the inhibition studies per-
formed with Caco-2 cells.
Thorough quality screening of the Caco-2 cells as such
has been emphasized by several authors (Artursson,
1991; Hidalgo, 2001; Shah et al., 2006). Both TEER and
mannitol were included as cell integrity controls, meas-
uring TEER also immediately after the end of the trans-
port assay, and cell cytotoxicity controls (MTT test)
for all substrates and inhibitors used, as an integrated
part of an overall quality assurance system.
TEER was measured before and immediately after
the transport assay. The latter was considered the most
relevant. The exclusion of six of 48 monolayers, even after
the transport assay, seems satisfactory. All wells included
in our calculations showed TEER values ≥200 Ω/cm2.
Although there are some inter-laboratory variations in
TEER measurements, our measurements are in line
with other measurements performed under similar con-
ditions (Markowska et al., 2001). TEER measurements
after the transport assay provide a good quality control
of the cell integrity and thus experimental results, and
should be included in all transport assays on Caco-2 cells.
Mannitol is a large molecule and only crosses the
epithelium by paracellular pathways. Mannitol thus
demonstrates the existence of paracellular transport
pathways and consequently also the integrity of the
Caco-2 monolayer. This is considered to be the best
indicator for tight junctions (Markowska et al., 2001).
Papp values less than 1.0 × 10−6 cm/s, as obtained in our
study, are in agreement with accepted standards (Artursson
et al., 1994). With established tight junctions, no digoxin
will leak paracellularly either way.
The MTT test showed that the AVJ decreased sig-
niﬁcantly the LDH activity at the highest concentration
(10.0 mg/mL). This concentration was omitted in our
further inhibition studies with AVJ. It corresponds
to a daily dose of AVJ of 30 L and is far outside the
physiological range.
Digoxin (30 nM), a concentrations used in all our
transport assays, did not affect the Caco-2 cells LDH
activity. When higher concentrations of digoxin were
applied, the LDH activity decreased linearly with the
increase in digoxin concentrations (Fig. 3a), which
indicates cytotoxicity to the Caco-2 cells. A signiﬁcant
decrease in LDH activity was observed already at 3 μM.
This should be noted as digoxin is reported to be used
as a P-gp substrate in Caco-2 cell assays in concentra-
tions ranging up to 5 μM (Bhardwaj et al., 2002).
Aloe species are classiﬁed both as a natural remedy
and as a herbal medicinal product according to the re-
gulations of the Norwegian Medicine Agency (2007).
Although several components of AVJ have been iden-
tiﬁed, their potential pharmaceutical mechanisms and
effects are not yet clear (Vogler and Ernst, 1999). An
interaction effect of AV on the P-gp drug transporter
may, however, greatly inﬂuence drug pharmacokinetics
and thus drug efﬁcacy (Lin and Yamazaki, 2003; Keogh
and Kunta, 2006).
The AVJ concentrations used in this study were
selected to cover an anticipated clinically relevant range.
The lowest concentrations (0.01– 0.00001 mg/mL) were
estimated from a daily dose of 30 mL (19.4 mg/mL dried
weight) and AVJ distributed in the total body volume
of 60 L with a 100% uptake down to 0.1% uptake from
the small intestine. The higher concentrations (1.00–
0.10 mg/mL) were considered more relevant for intesti-
nal concentrations. A concentration of 10 mg/mL was
omitted due to the observed effects on intracellular
LDH activity.
A weak induction of the P-gp gene (MDR1) by AVJ
is stated in one report at one concentration (Brandin
et al., 2007). Further information should be added to
this ﬁnding. As P-gp inhibition/induction may occur dif-
ferently at different concentrations in a biphasic man-
ner (Zhou et al., 2004), an evaluation of the inhibition
pattern of AVJ on the P-gp transport of digoxin in
Caco-2 cells were considered relevant, especially if a
wide range of AVJ concentrations was applied. Our
ﬁndings from a validated Caco-2 cell system showed,
however, no statistically signiﬁcant inhibitory effects of
AVJ on the P-gp mediated transport of digoxin, even
though a wide range of anticipated relevant physiologi-
cal concentrations of AVJ were tested. This might indi-
cate that AVJ in clinically relevant concentrations, do
not possess any signiﬁcant inhibitory potency towards
the P-gp mediated efﬂux transport of digoxin and simi-
lar P-gp substrates.
AVJ is a herbal product common in traditional medi-
cine and used against many illnesses such as inﬂammatory
bowel diseases (IBD), cancer, HIV and diabetes (Vogler
and Ernst, 1999; Boudreau and Beland, 2006). Prednisone,
imatinib (STI-571), docetaxel and indinavir are some
drugs used by these patient groups, and are all P-gp sub-
strates. Effects of AVJ on the P-gp drug transport of
these substrates thus might be negligible as far as inhi-
bition is concerned. Care should be taken, however,
when extrapolating to other P-gp substrates as differ-
ent efﬂux sites and binding afﬁnities might be involved.
In conclusion, the Caco-2 cell methodology in our
laboratory is in line with other reference laboratories.
It is recommended that validation parameters for P-gp
inhibition studies should include as a minimum an as-
say linearity test with and without a known P-gp inhibi-
tor, cell cytotoxicity testing for substrates and inhibitors,
and cell integrity testing by TEER and mannitol trans-
port measurements. The question is also raised whether
a minimum effect of a reference P-gp inhibitor such as
verapamil should be demanded. Special attention should
be paid to digoxin as a P-gp substrate in concentrations
≥3 μM and to concentrations of AVJ > 1.0 mg/mL, as
cytotoxic effects are indicated at these concentrations.
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No statistically signiﬁcant inhibitory effects of AVJ
was found on the P-gp mediated transport of digoxin,
even though a wide range of anticipated relevant physi-
ological concentrations of AVJ were tested. This might
indicate that AVJ in clinically relevant concentrations,
do not possess any signiﬁcant inhibitory potency towards
the P-gp mediated efﬂux transport of digoxin and simi-
lar P-gp substrates.
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